{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6n_JgKDA","lastupdate":"2024-10-28T00:00:00.000Z","update_date":"2024-10-28T00:00:00.000Z","lastModified":"Oct 31, 2025","active":1,"confidence_score":90,"confidence_score_reason":"video or image, markets, not claimed","urlname":"UroGen-Pharma","minimal_profile":null,"status":"Public","fullstatus":"Public on NASDAQ on May, 2017<br>","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$wVPjRd4z7vx729DcWE9IfJnzFDmkc5wlJT7WfRUQHHyWjGYsgx5hv2","name":"UroGen Pharma","oneliner":"Urologic Oncology Therapies","registrar":"513537621","website":"https://www.urogen.com","careerspage":"https://www.urogen.com/who-we-are/work-with-us","founded_month":4,"founded_year":2004,"formernames":["Theracoat","TheraCoat"],"sociallinks":{"twitter":"https://twitter.com/urogenpharma","youtube":"https://www.youtube.com/channel/UCfocvR6Si3Awb5beahHHlzg","facebook":"","linkedin":"https://www.linkedin.com/company/11520884","instagram":""},"social":["https://twitter.com/urogenpharma","https://www.youtube.com/channel/UCfocvR6Si3Awb5beahHHlzg","https://www.linkedin.com/company/11520884"],"flattenedsociallinks":"https://twitter.com/urogenpharma|https://www.youtube.com/channel/UCfocvR6Si3Awb5beahHHlzg|https://www.linkedin.com/company/11520884","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"201-500","employees_exact":315,"patent":1,"raised":522200000,"stage":"Public","public_stage":"Public","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":null,"about":"UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated. \n\nThe company has developed RTGel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained-release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option.\n\nUroGen's lead product candidates, UGN-101 (mitomycin urothelial gel, known as MitoGel) and UGN-102 (mitomycin intravesical gel, known as VesiGel), are designed to potentially remove tumors by nonsurgical means and to treat several forms of non-muscle-invasive urothelial cancer, including low-grade upper-tract urothelial carcinoma and bladder cancer, respectively.\n\nIn April 2020, the FDA accepted for filing UroGen's new drug application for UGN-101 (mitomycin gel) for the treatment of low-grade upper-tract urothelial cancer. UGN-101 will be the only drug available for this type of cancer.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+972774171410","country":null,"address":{"israeli":[{"id":"7169d879-a1f3-4140-8992-e0920e3c0b94","city":"Ra'anana","type":null,"address":"Ha-Ta'asiya Street 9, Ra'anana, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":[{"id":"c8a64636-88b1-4722-a4c0-81351441006d","city":"Princeton","address":"400 Alexander Park Drive, Princeton, NJ, USA","country":"United States","placeid":null}]},"headquarter_address":null,"district":"Center District","news":[{"id":"bfSAp1bXwF1jp3F70D2mdF1i0GVEbp3FQDi6MvDpRsewu1LsQZhumc","date":"Oct 30, 2025","link":"https://finance.yahoo.com/news/biogen-inc-biib-q3-earnings-111502569.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"earnings","round":null,"company":"Biogen Inc.","layoffs":null,"summary":"Biogen Inc. reported quarterly earnings of $4.81 per share, surpassing the Zacks Consensus Estimate of $3.89 per share, marking a 23.65% earnings surprise. The company also reported revenues of $2.53 billion, exceeding the consensus estimate by 8.31%. Despite these positive results, Biogen shares have declined by about 3.3% since the start of the year, underperforming the S&P 500s gain of 17.2%. The companys earnings outlook and estimate revisions will be crucial for future stock performance. Currently, Biogen holds a Zacks Rank #3 (Hold), indicating expected market performance alignment in the near term.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["earnings","revenue","stock","estimates","performance"],"date_of_event":"September 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"rmyCs4qLivkCzdGLJzdO19h9pR5lWaP3E3Mm1LN5pf0bfTkCRFEe8Q","news_summary":"Biogen Inc. (BIIB) Q3 Earnings and Revenues Top Estimates","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"GyoNvQNRm1jMON4c07e7kPp1s8aeABnHhvUJoK0v6yI8XrmKj1WVUx","date":"Oct 30, 2025","link":"https://finance.yahoo.com/news/adherex-technologies-inc-fenc-may-140030955.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"earnings report","round":null,"company":"Adherex Technologies Inc. (FENC)","layoffs":null,"summary":"Adherex Technologies Inc. (FENC) is expected to report a year-over-year increase in earnings and revenues for the quarter ending September 2025. The company is anticipated to post a quarterly loss of $0.08 per share, representing a 61.9% improvement from the previous year, with revenues expected to rise by 60.3% to $11.17 million. The consensus EPS estimate has been revised significantly lower over the past 30 days, reflecting a reassessment by analysts. The Zacks Earnings ESP model suggests that a positive earnings surprise is likely, especially if combined with a strong Zacks Rank. This could lead to a positive impact on the companys stock price.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["earnings","revenues","EPS","estimates","stock price"],"date_of_event":"September 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"oq63qvpKhJ9uFqJBdeKib8OLlFi7KKeJ6Wwus8wbsYHDxUu8eS7TA1","news_summary":"Adherex Technologies Inc. (FENC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"YdDa4rtb2QEmLsltcDsFmU3J04vqT6lWf3GR2w0EtJZG90H4N4BuOP","date":"Oct 30, 2025","link":"https://finance.yahoo.com/news/urogen-pharma-report-third-quarter-120000720.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial results","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd., a biotech company focused on developing treatments for urothelial and specialty cancers, announced it will report its third-quarter 2025 financial results on November 6th, 2025. The announcement will be followed by a live webcast and conference call. UroGen has developed RTGel® reverse-thermal hydrogel, a platform technology that enhances the therapeutic profiles of existing drugs. The company has two FDA-approved products for treating low-grade upper tract urothelial cancer and recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The webcast will be accessible on UroGens Investor Relations website, with a replay available for 30 days.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["conference call","financial results","FDA approval","cancer treatment","webcast"],"date_of_event":"November 6, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading"],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"GHxUXjja5cJAKX3QTyOE40QeGLNyjkXD02RNJf5ESV6p1HujZTFyrb","news_summary":"UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"GzLuUagzskEcn9pM4DxzXdFYFD51Hu0LaiGGRusoRdF8GkTpGLRUOm","date":"Oct 29, 2025","link":"https://finance.yahoo.com/news/urogen-pharma-urgn-expected-beat-140026674.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"earnings report","round":null,"company":"Urogen Pharma","layoffs":null,"summary":"Urogen Pharma (URGN) is anticipated to report a year-over-year decline in earnings despite higher revenues for the quarter ending September 2025. The company is expected to post a quarterly loss of $0.72 per share, a 30.9% decrease from the previous year, while revenues are projected to rise by 22.9% to $30.98 million. The consensus EPS estimate has been revised downwards by 5.91% over the last 30 days. The Zacks Earnings ESP model suggests that a positive Earnings ESP, combined with a strong Zacks Rank, could indicate a potential earnings beat. However, the overall outlook remains cautious as the company navigates these financial challenges.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["earnings","revenues","EPS","analysts","estimates"],"date_of_event":"September 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"9x9zATRb4EeKk9bZ8RVLDLCRJDJyVuaqaZbuHsqXXZbg5p6ZdvqU6J","news_summary":"Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"Kw3wxbwySezNEwdpWKSgnmqctlCT2LJlgXqzn2ruStcPBaH8WIg4Y6","date":"Oct 27, 2025","link":"https://finance.yahoo.com/news/centers-medicare-medicaid-services-assigns-120000890.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA approval","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding System (HCPCS) Level II J Code, J9282, for ZUSDURI, an FDA-approved treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). This J Code, effective January 1, 2026, will streamline billing and claims submission, facilitating easier access to the treatment. ZUSDURI, utilizing UroGen’s RTGel® technology, is delivered directly into the bladder, offering a non-surgical treatment option. The assignment of a J Code is a significant milestone for UroGen, simplifying reimbursement processes and reducing administrative barriers for healthcare providers.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["J Code","ZUSDURI","CMS","reimbursement","bladder cancer"],"date_of_event":"October 27, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"r5IK3Kfn3ffoKZPKe3HxMqIeb7OD9vytCyHvHWjyRYZ5WNleBBhBgv","news_summary":"Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"mRmaKFUFdoVq4kM08H2B9yT4wiQDqi8mPT95A4OX3CqirhYNNvq0x8","date":"Oct 22, 2025","link":"https://finance.yahoo.com/news/meiragtx-mgtx-moves-12-4-121800504.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical programs","round":null,"company":"MeiraGTx Holdings PLC","layoffs":null,"summary":"MeiraGTx Holdings PLC experienced a significant 12.4% increase in its stock price, closing at $9.26, driven by heightened investor confidence in its late-stage clinical programs targeting conditions such as Parkinsons disease and AIPL1-associated retinal dystrophy. Despite the positive stock movement, the company is expected to report a quarterly loss of $0.51 per share, with revenues projected to decline by 59.4% compared to the previous year. The stocks recent performance is attributed to the promising potential of its genetic medicine programs, which aim to address severe unmet medical needs. MeiraGTx is part of the Zacks Medical - Biomedical and Genetics industry and currently holds a Zacks Rank #3 (Hold).","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["stock price","clinical programs","investor confidence","earnings estimate","revenue decline"],"date_of_event":null,"product_stage":"late-stage clinical","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"hZrFbeQvIKIRSBSFzUWQ6mWpHpEXVUUTBgTCqRzsboO6cERCnOg2x0","news_summary":"MeiraGTx (MGTX) Moves 12.4% Higher: Will This Strength Last?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"zh9ewXql7pAN05MPT0q9Qf1ybjbNGPAlzys46Xaoxg3srH12ecYBnT","date":"Oct 2, 2025","link":"https://finance.yahoo.com/news/zusduri-clinical-review-published-reviews-120000462.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA approval","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. announced the publication of a comprehensive review of its FDA-approved drug, ZUSDURI™ (mitomycin), for treating recurrent, low-grade, intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC). The review, published in the journal Reviews in Urology™, highlights the drugs high complete response rates and durable disease response, as demonstrated in clinical trials such as OPTIMA II, ATLAS, and ENVISION. ZUSDURI has a manageable safety profile with primarily mild to moderate adverse reactions. The drug is administered in an outpatient setting and does not require general anesthesia, making it a convenient option for patients. The publication underscores ZUSDURIs role as an innovative treatment for LG-IR-NMIBC.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["FDA approval","clinical trials","cancer treatment","safety profile","patient outcomes"],"date_of_event":"October 2, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"hzBO1w7qiOhqMC5DQCAs5RnwIWNaf48xdiC67LkzvUhCdDtvpGeyw3","news_summary":"ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"zuqI4CoXtWHYihNQoGt93IaPH9lEQEZE7NSiyDswGTkqDoa3Bdow53","date":"Sep 8, 2025","link":"https://finance.yahoo.com/news/urogen-pharma-announces-inducement-grants-120000633.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"employee expansion","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd., a biotech company focused on urothelial and specialty cancers, announced the grant of inducement restricted stock units (RSUs) to 40 new employees. These employees will aid in the commercialization of UroGens products, Jelmyto® and ZUSDURI™, and support the development of its pipeline. The RSUs, part of UroGens 2019 Inducement Plan, will vest over three years. UroGens products are FDA-approved and designed to treat cancers non-surgically. The company is headquartered in Princeton, New Jersey, with operations in Israel.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["RSUs","employees","commercialization","cancer","technology"],"date_of_event":"September 8, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Expand"],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"QZgmYE1eH1cwmhVteW2hkAFAboS8wHuqmH7EXXJnfXT6mvaQ7Fr654","news_summary":"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"fXtB40mlLMr2MXE6Jh7mh8c4dUrYCFCFVmO06s27QHBlCZs4SAMH0y","date":"Aug 21, 2025","link":"https://finance.yahoo.com/news/urogen-pharma-present-upcoming-investor-120000002.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"conferences","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd., a biotech company focused on developing treatments for urothelial and specialty cancers, announced its participation in several investor conferences in September 2025. The company will present at the Wells Fargo Healthcare Conference, Cantor Fitzgerald Global Healthcare Conference, and H.C. Wainwright 27th Annual Global Healthcare Conference. UroGen has developed RTGel® reverse-thermal hydrogel, a platform technology aimed at improving drug therapeutic profiles. The company has two FDA-approved products for treating urothelial cancers. These conferences provide UroGen an opportunity to engage with investors and showcase their innovative solutions.","partners":null,"customers":null,"eventType":null,"investors":[],"confidence":10,"key_topics":["biotech","cancer","FDA","conferences","technology"],"date_of_event":"August 21, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"using","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Djd366pDjIwU7zCKDYmhKsAbx6yDyph1cyeSBQx4qjpZX1hM3BO5SS","news_summary":"UroGen Pharma to Present at Upcoming Investor Conferences","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"yAXM1nGaudnVtv3AwoPXpn747L8WEskJtOX7iIraSQ3N3EYhXxBrJ6","date":"Aug 10, 2025","link":"https://finance.yahoo.com/news/urogen-pharma-ltd-nasdaq-urgn-132645588.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"earnings report","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. recently released its quarterly results, which led to an 8.5% drop in its share price. Despite revenues of US$24 million beating expectations by 4.7%, statutory losses increased by 28% to US$1.05 per share, causing concern among investors. Analysts have adjusted their forecasts, predicting revenues of US$122.3 million in 2025, a 30% increase from the past year, but also expecting losses to shrink by 12% to US$2.94 per share. The consensus price target remains at US$34.63, indicating that higher forecast losses are not expected to impact long-term valuation significantly. UroGen Pharmas growth rate is expected to accelerate, with a forecasted 68% annualized revenue growth by 2025, outpacing the industry average of 19%.","partners":null,"customers":null,"eventType":null,"investors":[],"confidence":9,"key_topics":["earnings","revenue","losses","analyst forecasts","stock price"],"date_of_event":"August 10th 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":"developing","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"1TWg06oUBPD11Tm6lgqzCLrVb6S6IjaCewn6ZCyezpxQ87Ybq6DpcO","news_summary":"UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"tflLZJFsyKCkOjSZ6rMPcRFQXiv2lolDyC0W58M6A3zvv1aylqBsko","date":"Aug 8, 2025","link":"https://finance.yahoo.com/news/urogen-pharma-ltd-urgn-q2-072517920.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA approval","round":null,"company":"UroGen Pharma Ltd","layoffs":null,"summary":"UroGen Pharma Ltd has achieved FDA approval for its new drug, Zourri, intended for treating recurrent, low-grade, intermediate-risk, non-muscle invasive bladder cancer. This marks a significant milestone for the company. The company reported a strong second-quarter net product revenue of $24.2 million for Gelmio, an 11% increase from the previous year. UroGen has expanded its sales force to 82 representatives to reach a larger portion of healthcare providers. Despite a net loss of $49.9 million for the quarter, the company is optimistic about Zourris market uptake, especially post-J code assignment in 2026. Challenges remain with reimbursement logistics, but there is strong interest from healthcare providers.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["FDA approval","revenue growth","clinical trials","sales expansion","reimbursement issues"],"date_of_event":"August 07, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Expand"],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"fGCRkIe9w73X2A64uJ1lE8TDsbCtKS64wAwdZpyDh34thMxQQyV8si","news_summary":"UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"PjE4WdEbsnmFvEWhY0u7u9lIsX8fZK7a5XMZjSbdHPpdxdZkRAy5XL","date":"Aug 7, 2025","link":"https://finance.yahoo.com/news/sector-health-care-stocks-decline-200040225.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Not specified","round":"Not specified","company":"Not specified","layoffs":"Not specified","summary":"The article mentions that health care stocks were slipping late Thursday afternoon, with the NYSE Health Care Index down 1%. It suggests that a Silver or Gold subscription plan is required to access premium news articles from MT Newswires. The article does not provide specific details about any particular company, its impact, or any structured issues related to investments, partnerships, or acquisitions.","partners":"Not specified","customers":"Not specified","eventType":"Not specified","investors":"Not specified","confidence":8,"key_topics":["Health care","Stocks","NYSE","Subscription","Premium"],"date_of_event":"August 7, 2025","product_stage":"Not specified","investment_date":"Not specified","acquired_company":"Not specified","valuation_amount":"Not specified","impact_on_company":"Not specified","investment_amount":"Not specified","structured_issues":[],"acquisition_amount":"Not specified","FDA approved/pending approval":"Not specified","AI technology developing/using":"Not specified","entityGrowthIconPath":"none;"},"sentiment":"Not specified","analysisId":"Npcaqh3M0vMVPm0af1vfcP3Lp4G8QBs4rDY7d8qoZmQRo3ZrRJbBGf","news_summary":"Sector Update: Health Care Stocks Decline Late Afternoon","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"pVoEkfC2iSCJTSzr15PBkesC8o4CXaTodA7JzO2UAnJ0QNObTs07BV","date":"Aug 7, 2025","link":"https://finance.yahoo.com/news/urogen-pharma-expands-commercial-portfolio-120000497.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA approval","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. announced the FDA approval of ZUSDURI, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). This approval marks a significant milestone for UroGen, positioning it as a multi-product uro-oncology company. The company reported net product sales of $24.2 million for JELMYTO in Q2 2025, an 11% increase from the previous year. With $161.6 million in cash and securities, UroGen is well-positioned to support the ZUSDURI launch and pursue strategic initiatives. The company is also advancing its pipeline, including next-generation mitomycin formulations and immuno-oncology candidates.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["FDA approval","financial results","product launch","market opportunity","clinical trials"],"date_of_event":"August 07, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"FSASbt5wmDmnVOL3Qn7EHFExZ88JSkSVnxFwtwbSfzTiLYWp6C6P0u","news_summary":"UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"x5xconjyzwOnQgGuQq9Ig4IiCbEsf4ZrO8XVcDVLVkqp2pwNgWbIDD","date":"Aug 7, 2025","link":"https://finance.yahoo.com/news/urogen-pharma-urgn-reports-q2-131505667.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"earnings report","round":null,"company":"Urogen Pharma","layoffs":null,"summary":"Urogen Pharma reported a quarterly loss of $1.05 per share, which was worse than the Zacks Consensus Estimate of a $0.82 loss. This represents an earnings surprise of -28.05%. The company posted revenues of $24.22 million, missing the consensus estimate by 0.96%. Despite these results, Urogen Pharma shares have increased by 87.9% since the beginning of the year, outperforming the S&P 500s gain of 7.9%. The companys earnings outlook and estimate revisions will be crucial for future stock performance. Currently, Urogen Pharma holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["earnings","revenue","stock performance","estimates","Zacks Rank"],"date_of_event":"June 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"N3O0lS06yT7mgV8z7tgdDY3n5hkaEXrA1hrFWHLIVmXAVjx5IVzDeI","news_summary":"Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"3aoONfCQ1uGXqd1vgs0c6F0yR2fgMnKQoJYxuvAxsbMLL4lc1gp8yb","date":"Aug 6, 2025","link":"https://www.clinicaltrialsarena.com/news/urogen-zusduri-phase-iii-readout/","source":"www.clinicaltrialsarena.com","visible":1,"analysis":{"tags":"FDA approval","round":null,"company":"UroGen Pharma","layoffs":null,"summary":"UroGen Pharmas Zusduri (mitomycin) has been approved as the first non-surgical therapy for non-muscular invasive bladder cancer (NMIBC), marking a significant milestone in cancer treatment. The Phase III ENVISION trial demonstrated sustained efficacy, with a two-year duration of response in 72.2% of patients. Approved in June 2025, Zusduri is expected to reach $449 million in sales by 2031. It faces competition from MSDs Keytruda and Ferring Pharmaceuticals Adstiladrin, which are approved for high-risk patients. The approval positions Zusduri as a transformative option for recurrent LG-IR-NMIBC patients, offering a durable treatment alternative.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["FDA approval","clinical trial","non-surgical therapy","NMIBC","market competition"],"date_of_event":"June 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Qqm1XaF2K8j2WezM87qp9A1Ix3cnyceDgl5lKSjO0ETsI4Pv63FrUE","news_summary":"UroGen’s Zusduri benefit maintained in NMIBC Phase III study","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"g3RGOhBt1WaXJ5CT70gAcuSjnMYB1gKcHwp4rjFLyfL2X64nZ0P4mD","date":"Aug 5, 2025","link":"https://finance.yahoo.com/news/urogen-announces-24-month-duration-120000390.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA approval","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. announced a significant milestone with the FDA approval of ZUSDURI™ (mitomycin) for treating recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The Phase 3 ENVISION trial demonstrated a 24-month duration of response (DOR) of 72.2% in patients who achieved a complete response at three months. This approval marks a transformative step in managing this chronic cancer, offering a new outpatient treatment option that can provide a clinically meaningful recurrence-free interval. The approval is expected to positively impact UroGen Pharma by providing a durable treatment option for patients, reducing the need for repeated surgeries.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["FDA approval","clinical trial","cancer treatment","patient response","new therapy"],"date_of_event":"August 5, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"mvG0yZCpsOpUpT0nYGP0Tr1FoV13sHZ9L1TjhYJvvgBjINFyFt5GU9","news_summary":"UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"796jRIx6r1DhP3nwrDsu5MYn6PgGMLk2oPhdRn9gRrmskBgaaESxKb","date":"Jul 30, 2025","link":"https://finance.yahoo.com/news/lenz-therapeutics-inc-lenz-reports-131001363.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"earnings","round":null,"company":"LENZ Therapeutics, Inc.","layoffs":null,"summary":"LENZ Therapeutics, Inc. reported a quarterly loss of $0.53 per share, surpassing the Zacks Consensus Estimate of a $0.58 loss, marking an earnings surprise of +8.62%. The company posted revenues of $5 million for the quarter ended June 2025, compared to zero revenues a year ago. LENZ shares have increased by about 9.7% since the beginning of the year, outperforming the S&P 500s gain of 8.3%. The companys earnings outlook remains favorable, with a Zacks Rank #2 (Buy), indicating expected market outperformance in the near future. The current consensus EPS estimate for the coming quarter is -$0.70 on $5.63 million in revenues.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["earnings","revenue","stock","estimates","market"],"date_of_event":"June 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"jxn4gbAxjkP3O233ALiubOiybFkBmeTqJFtQoB18PHkolpqFmxYir0","news_summary":"LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"X7lj1kPVP0ydTAM49hKYoaRSrtQ1ydcLPyqQfc9tvRR7glTdXsuTsX","date":"Jul 29, 2025","link":"https://finance.yahoo.com/news/urogen-pharma-urgn-presented-real-053100590.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. (NASDAQ:URGN) presented its uTRACT Registry study design at the 2025 American Society of Clinical Oncology, focusing on the real-world study of JELMYTO, a treatment for low-grade upper tract urothelial carcinoma. The study, conducted across 22 sites in the U.S., has enrolled 274 patients as of May 2025, aiming for 400 registries. The study will provide insights into treatment patterns, safety, effectiveness, and outcomes over three years. The treatment is under FDA review, and the study is expected to offer valuable data. UroGen Pharma is a biopharmaceutical company developing cancer and urologic disease treatments.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["JELMYTO","uTRACT Registry","FDA review","cancer treatment","clinical study"],"date_of_event":"June 2, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"zCfLuPG9yNp1gq49jgUe4u8wFnL828QoO1xOUzoURQ9vE5GQVJQfuR","news_summary":"UroGen Pharma (URGN) Presented Real-World Study of JELMYTO at 2025 American Society of Clinical Oncology","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"BAkyCUnsQerOMye8f1ZdcoirMrlMoH5lHMRu5BVVeLWfsDiWbmbbpI","date":"Jul 29, 2025","link":"https://finance.yahoo.com/news/urogen-pharma-report-second-quarter-120000788.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial results","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd., a biotech company focused on developing treatments for urothelial and specialty cancers, will report its second quarter 2025 financial results on August 7th, 2025. The announcement will be followed by a live webcast and conference call. UroGen has developed RTGel, a proprietary hydrogel-based platform technology, and has two FDA-approved products for treating specific types of cancer. The company is headquartered in Princeton, NJ, with operations in Israel. The webcast will be accessible on UroGens Investor Relations website, with a replay available for 30 days.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["financial results","conference call","FDA approval","cancer treatment","webcast"],"date_of_event":"August 7, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":"not mentioned","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"wJjtp8NnDAeAPJEW3R9ypnOlQBQ0ajZDnVqAQ5b8vw7Wc9ahNzc4ns","news_summary":"UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"XJwfah3RKbnLJUhc6tW0KxAZUkhJNvNdSxQO20LMHRs6iQkLOB5Bu9","date":"Jul 28, 2025","link":"https://finance.yahoo.com/news/urogen-announces-publication-phase-3b-120000112.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"home treatment","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. announced positive results from a Phase 3b study on the feasibility of administering ZUSDURI™ (mitomycin) for intravesical solution at home for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The study demonstrated that trained home health professionals can safely and effectively administer the treatment outside of a traditional clinical setting, potentially easing the burden on patients and reducing reliance on hospital resources. The study showed a 75% complete response rate at three months, with no new safety concerns. This approach reflects UroGens commitment to providing effective and convenient treatment options for urologic cancers.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["home treatment","cancer therapy","clinical trial","patient convenience","safety"],"date_of_event":"July 28, 2025","product_stage":"Phase 3b","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"xxCS0UUwbm5obJCDdFQlJ3Hoi7DbW0wwfBqgx73SpZ9kihVgC7E73v","news_summary":"UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"gmW2fdWHshpRpQGZHuzsaXS4bGL5UvkwjhXgTmSTxtfrZMlNnO6kqX","date":"Jul 24, 2025","link":"https://finance.yahoo.com/news/high-growth-tech-stocks-us-173820239.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA approval","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. is a biotechnology company focused on developing treatments for urothelial and specialty cancers. The company has a market cap of $783.57 million and generates revenue primarily from its biotechnology segment. UroGen Pharmas recent advancements include the FDA approval of ZUSDURI and ongoing Phase 3 UTOPIA trial, highlighting its focus on R&D and innovation in non-muscle invasive bladder cancer treatments. The company invests significantly in its proprietary RTGel® technology, which aids in sustained drug release. Despite regulatory challenges, UroGens robust pipeline and strategic R&D spending are crucial for its success in the competitive biotech landscape.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["FDA approval","R&D","biotechnology","cancer treatment","innovation"],"date_of_event":null,"product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"6KCe0rKO2blQaBIUD4qtkqUVL9gEvLvzwZNW3tmNb2nVvNhU8Rv5Uw","news_summary":"High Growth Tech Stocks In The US Market","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"bWYD2BUfBhoixNSrKEW5X3ZMFEu6m5URfD0Rm2ae0IQEYj73F4Fxaz","date":"Jul 24, 2025","link":"https://finance.yahoo.com/news/urogen-pharma-ltd-nasdaq-urgn-105545230.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"profitability","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd., a company focused on developing solutions for urothelial and specialty cancers, is facing financial challenges with a recent loss of US$138 million. Analysts expect the company to reach breakeven by 2027, requiring an average annual growth rate of 67%. Despite the negative equity on its balance sheet, which may be due to accumulated losses, analysts remain optimistic about the companys future profitability. The article highlights the importance of understanding UroGen Pharmas financial fundamentals and the potential risks associated with its current financial position.","partners":[],"customers":[],"eventType":null,"investors":[],"confidence":9,"key_topics":["profitability","growth","losses","analyst expectations","equity"],"date_of_event":"July 24th 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"NFq70CSxxfGEHLkURo5LsEsh69yu0jPRdhem9GsFYU0Ja92YgCveIn","news_summary":"UroGen Pharma Ltd. (NASDAQ:URGN) Is Expected To Breakeven In The Near Future","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"MIt9Wox7JCzHoSEpQ2ELHxTpyYYjGPCsRFpmjNXYHaSVxURk4o470j","date":"Jul 21, 2025","link":"https://finance.yahoo.com/news/urogen-announces-five-long-term-120000473.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. announced positive results from a five-year long-term extension study of their Phase 2b OPTIMA II trial for ZUSDURI (mitomycin) in treating low-grade intermediate-risk non-muscle invasive bladder cancer. The study, published in the Journal of Clinical Genitourinary Cancer, showed that patients who achieved complete response had a median event-free duration of two years, with some extending to 3.5 years. The findings highlight ZUSDURIs potential as a non-surgical treatment option, offering sustained responses and meaningful, lasting event-free periods for recurrent patients. This development underscores UroGens commitment to providing innovative cancer treatments.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["cancer","treatment","study","patients","response"],"date_of_event":"July 21, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"bxszdWQ6OtzZYBBh6ZY8B4Hn7eaEZ1zzLZOFWzWVyPAxrOrquPQPw9","news_summary":"UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"26AiEzsqcGEsZvQnaYhxLXCHt8t96UYHfBIZgBpgsDJhbl8KARXuFM","date":"Jul 8, 2025","link":"https://www.clinicaltrialsarena.com/news/urogen-ugn-103/","source":"www.clinicaltrialsarena.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"UroGen Pharma","layoffs":null,"summary":"UroGen Pharma has completed the enrolment of 99 subjects in its Phase III UTOPIA trial for UGN-103, a therapy for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The trial aims to assess the efficacy and safety of UGN-103, which uses RTGel technology for prolonged bladder exposure and sustained drug release. The primary goal is to achieve a complete response rate at three months, with a follow-up phase to evaluate response durability. UGN-103 is positioned as a next-generation formulation offering improvements over Zusduri. The company has a licensing and supply deal with medac and has secured patent protection for UGN-103 until December 2041.","partners":"medac","customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["Phase III","bladder cancer","RTGel technology","patent protection","licensing deal"],"date_of_event":"July 8, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ibWY7HTH2v6sXHf4jWY8jzzkiUBt8PR4xjFt6exmrP7Eri5FMCv9xV","news_summary":"UroGen concludes enrolment in Phase III trial of UGN-103 for bladder cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"mFl1x3FeNtzGHxteSWOQj9yaLOnWc2vBBc2tXqHvhBRXQJGUMc9nfb","date":"Jul 7, 2025","link":"https://finance.yahoo.com/news/urogen-announces-completion-enrollment-phase-120000918.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. has completed patient enrollment for its Phase 3 UTOPIA clinical trial of UGN-103, a next-generation formulation for treating recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The trial involves 99 patients globally and aims to evaluate the efficacy and safety of UGN-103, which uses UroGen’s RTGel® technology for sustained drug release. The company has a licensing and supply agreement with medac for developing UGN-103, which is expected to offer improvements over the existing ZUSDURI™ formulation. UroGen has received a Notice of Allowance from the U.S. Patent and Trademark Office, ensuring patent protection until December 2041.","partners":"medac","customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["clinical trial","bladder cancer","drug formulation","patent protection","partnership"],"date_of_event":"July 07, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"oMrl8wa7GiH9BmURSFbTb6VYrdRyDEdJNQvvCcuDRmhIDHRhoIkLt1","news_summary":"UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"vTur6sjQvpfawZMjKDrA8Cpxj1mouGyOyFOZ8OWSM1YlupUtw0RMuW","date":"Jul 6, 2025","link":"https://finance.yahoo.com/news/urogen-pharma-receives-fda-approval-080118780.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA approval","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. has received FDA approval for ZUSDURI, a mitomycin-based intravesical solution for treating recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. This marks ZUSDURI as the first FDA-approved medication for this condition, utilizing UroGens proprietary RTGel technology for non-surgical tumor ablation. The approval is backed by positive results from the Phase 3 ENVISION trial, showing a high complete response rate among patients. While UroGen Pharma is recognized as a promising investment, the article suggests that certain AI stocks may offer greater potential. The article was originally published by Insider Monkey.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["FDA approval","bladder cancer","drug formulation","clinical trial","investment potential"],"date_of_event":"mid-June","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cdz7GWN3wz5LDvtd3zCTlKc1xlCUGgTDvIL2KMj6PF03b2DuvCUTh6","news_summary":"UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"TUG6vAgBpJ928ApZzd6PAivP1BtKrhlZ5AUPXIOd6i1YlSDBue1Lc9","date":"Jun 17, 2025","link":"https://finance.yahoo.com/news/h-c-wainwright-sees-billion-173201725.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"regulatory approval","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. (NASDAQ:URGN) has received a significant boost as analysts at H.C. Wainwright upgraded its stock rating to Buy with a price target of $50. This follows the regulatory approval of Zusduri, priced at $21,500 per dose, aimed at treating non-muscle invasive bladder cancer. The companys stock price has surged over 100% in the past five days, with expectations of further growth. UroGen Pharma, a clinical-stage biopharmaceutical company, is set to launch its product, targeting a market of 59,000 patients annually in the U.S. The treatment is projected to generate $1 billion in sales by 2026. Despite potential changes in clinical trial strategies, the financial outlook remains positive.","partners":null,"customers":null,"eventType":null,"investors":"H.C. Wainwright","confidence":9,"key_topics":["regulatory approval","stock rating","product launch","sales projection","clinical trial"],"date_of_event":"Monday","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"TAxy5xXmT8kxKLq6fvgICbMGYjJouAy0gF8AfIpNpArYGrNpijbvru","news_summary":"H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"YOt6a5Z83BIyAGIIeu2I5EaM6jWU97VnDEikbx26TlvRoXva4tiklb","date":"Jun 13, 2025","link":"https://www.biopharmadive.com/news/astrazeneca-ai-deal-china-third-harmonic-liquidation/750601/","source":"www.biopharmadive.com","visible":1,"analysis":{"tags":"collaboration","round":null,"company":"AstraZeneca","layoffs":null,"summary":"AstraZeneca has formed a new collaboration with CSPC Pharmaceutical Group to develop oral medicines using AI technology for immunological diseases and other chronic conditions. The deal involves an upfront payment of $110 million to CSPC and potential additional payments up to $5.2 billion based on development and sales milestones. This partnership builds on AstraZenecas previous investments in China, including a $2.5 billion R&D center in Beijing and collaborations with other Chinese biotechs. The collaboration is part of AstraZenecas strategy to deepen its presence in the Chinese market and leverage AI in drug discovery.","partners":"CSPC Pharmaceutical Group","customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["collaboration","investment","AI technology","drug development","China market"],"date_of_event":"June 13, 2025","product_stage":"R&D","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$110 million upfront, up to $5.2 billion in milestones","structured_issues":["Partners","Investment"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cdmSKRrWbuBtotBvPy2NOMcHMfUyGkVqmAO0VV0HfJyBDUQkQV2fF5","news_summary":"AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"8RlhCGdS2LRR1dNTVT7SQ0ZpjqG2HJtPsxmc19c211uqdygA1yxZgZ","date":"Jun 13, 2025","link":"https://finance.yahoo.com/news/high-growth-tech-stocks-us-173820455.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"biopharmaceutical","round":null,"company":"Soleno Therapeutics, Inc.","layoffs":null,"summary":"Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing treatments for rare diseases. The company is currently in a transformative phase with its VYKAT™ XR for Prader-Willi syndrome, which has received FDA approval and is seeking EU exclusivity. Despite a net loss of $43.77 million in Q1 2025, Soleno is projected to achieve robust annual revenue growth of 53.4% and an earnings surge of 65.09% per year. This positions the company favorably in the market, especially given the significant unmet needs in the Prader-Willi syndrome market.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["biopharmaceutical","rare diseases","FDA approval","market cap","earnings growth"],"date_of_event":"Q1 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":"$3.99 billion","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"kSsI7NROF0C2VdbLYbRhGbSwxLlrxgb3Z3NrmHKkkgA0PtWl2UrKEy","news_summary":"High Growth Tech Stocks in US for June 2025","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"EvzgJBSyMDXMgzs0IqSDQUyW2dUZGYWLwAvOmNTQFFg7LpVYm8DY5m","date":"Jun 12, 2025","link":"https://finance.yahoo.com/news/u-fda-approves-urogen-zusduri-172800294.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA approval","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. has announced that the U.S. FDA has approved ZUSDURI, a medication for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). This approval is based on the successful results of the Phase 3 ENVISION trial, which showed a 78% complete response rate at 3 months, with 79% of responders maintaining this response at 12 months. ZUSDURI, utilizing UroGens RTGel technology, offers a new treatment alternative to the traditional surgical procedure, TURBT. This approval marks a significant milestone for UroGen, providing a new FDA-approved option for the estimated 59,000 U.S. patients with recurrent LG-IR-NMIBC each year.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["FDA approval","bladder cancer","ZUSDURI","RTGel technology","clinical trial"],"date_of_event":"June 12, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"6UJRT8BHG05P7yiv2WnttTfhHk2NAq9p0C0D0bFRcpEVsABCPLlXQ1","news_summary":"U.S. FDA Approves UroGen’s ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9CmNJCBJmSHeNa1EMoWJLtR4GmSdkpMlfTnlJbCUZx2KnJubFuSSvf","date":"Jun 6, 2025","link":"https://www.businesswire.com/news/home/20250606792691/en/","source":"www.businesswire.com","visible":1,"analysis":{"tags":"employee expansion","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd., a biotech company focused on urothelial and specialty cancers, announced the grant of inducement restricted stock units (RSUs) to 27 new employees. These employees will aid in the commercialization of Jelmyto®, UroGens first approved product, and the development of its pipeline. The RSUs, part of UroGens 2019 Inducement Plan, will vest over three years. UroGens proprietary RTGel® technology aims to improve drug therapeutic profiles, offering better treatment options for patients. The company is headquartered in Princeton, New Jersey, with operations in Israel.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["RSUs","Jelmyto","UroGen","employees","commercialization"],"date_of_event":"June 06, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Expand"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"yBqTX41XOxOlVoHCvSUwVcSLKl1g9ih5eWDMS9shAO25kAudneBqOc","news_summary":"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"lpH4tNT3HPf0BSYR7ChPtuHhGu7ugDypybBybUhZ5KIZMET9a6ekXQ","date":"Jun 2, 2025","link":"https://finance.yahoo.com/news/urogen-announces-data-asco-2025-140000006.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. presented new data from its Phase 3 ENVISION and ATLAS clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The studies focus on UGN-102, an investigational therapy for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The data highlights the 18-month duration of response (DOR) and the impact of tumor burden on treatment efficacy. UGN-102 utilizes UroGens RTGel® technology to enhance bladder tissue exposure to mitomycin. The FDA has accepted the new drug application for UGN-102, with a target action date set for June 13, 2025. An FDA advisory committee recently voted on the benefit/risk profile of UGN-102.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["clinical studies","bladder cancer","FDA approval","UGN-102","ASCO meeting"],"date_of_event":"June 02, 2025","product_stage":"Phase 3","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"uPB9kRzXFn2mIKddLDDFpXf8UhGALvqR3iGo4nXSN7rtl7v5SpODyp","news_summary":"UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"bljZLb6mEXOvCqC6HQBUh6YMvzFXyejJfVav6BItZz4iEa1Hrtp5wa","date":"Jun 2, 2025","link":"https://finance.yahoo.com/news/urogen-presents-utract-registry-asco-150000337.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical study","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. presented the uTRACT Registry study design at the 2025 ASCO Annual Meeting, focusing on the real-world use of JELMYTO for treating low-grade upper tract urothelial carcinoma (LG-UTUC). The study aims to enroll 400 patients, with 274 already participating across 22 sites. It will collect comprehensive data over three years to assess clinical outcomes, including disease presence, response duration, and recurrence-free survival. JELMYTO, an FDA-approved mitomycin-containing gel, is used for chemoablative therapy in the urinary tract. The studys insights are expected to inform best practices and support JELMYTOs clinical utility.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["uTRACT Registry","JELMYTO","LG-UTUC","clinical outcomes","ASCO Meeting"],"date_of_event":"June 02, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved"],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #FDA approved","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"fFhH0xzytGGEYuI3PZmiDOy7QBdqzbs1TzZfuiIv7Pvdb3yE3WplGJ","news_summary":"UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Ak9LgLOef8AsIFwO6BmICLKzyOf0cTzX5VsgamUnLVvZHlYgMEQtl9","date":"May 27, 2025","link":"https://www.businesswire.com/news/home/20250527694477/en/","source":"www.businesswire.com","visible":1,"analysis":{"tags":"innovation","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd., a biotech company focused on developing innovative treatments for urothelial and specialty cancers, announced its participation in the TD Cowen: 6th Annual Oncology Innovation Summit. The company has developed RTGel® reverse-thermal hydrogel, a platform technology designed to improve drug therapeutic profiles. UroGens products, including a treatment for LG-UTUC and an investigational treatment UGN-102 for bladder cancer, aim to provide non-surgical tumor ablation options. The summit participation is a positive step for UroGen, showcasing its innovative solutions to a wider audience. The event will be held virtually on May 28, 2025.","partners":null,"customers":null,"eventType":null,"investors":[],"confidence":10,"key_topics":["biotech","cancer","innovation","technology","summit"],"date_of_event":"May 28, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"0nSzdFEd2UBpRU4aqNPYKijlrR4THNKFNLMIjsThvI1XO98VvbRW1y","news_summary":"UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"vOlqaLY9A11vSEy1Se9eDpilKu2168GB4pAIa9R7mrAFdBmFSzu9yL","date":"May 21, 2025","link":"https://finance.yahoo.com/news/urogen-announces-outcome-oncologic-drugs-161700762.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA review","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd., a biotech company focused on urothelial and specialty cancers, announced the outcome of the FDAs Oncologic Drugs Advisory Committee (ODAC) meeting regarding their investigational drug UGN-102 for recurrent LG-IR-NMIBC. The ODAC narrowly voted against the drugs benefit/risk profile, which is a setback for UroGen as they await the FDAs final decision. Despite the vote, UroGen remains committed to the drugs development, citing high unmet needs in treating this type of cancer. The NDA for UGN-102 is under FDA review with a PDUFA date set for June 13, 2025.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["FDA review","clinical trial","drug application","cancer treatment","advisory committee"],"date_of_event":"May 21, 2025","product_stage":"Phase 3","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"nr9OtN9S2OYN8h1ILTLAcxfL9CkNHZA2RDeuGoc9D1D1v11fBUaT8s","news_summary":"UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"4r4xF4XD5cckOMFZitq0wRZk0IrUNjJ6iJEaZ8CxJY8h1gbuAIPNvk","date":"May 20, 2025","link":"https://finance.yahoo.com/news/biotech-alert-searches-spiking-stocks-145514529.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"biotech","round":null,"company":"Inozyme Pharma","layoffs":null,"summary":"Inozyme Pharma, a clinical-stage biopharmaceutical company, is experiencing a significant surge in interest, with a 1,125% increase in search activity. The company is focused on developing innovative therapeutics targeting the PPi-Adenosine Pathway, crucial for bone health and blood vessel function. Its lead therapy, INZ-701, is in late-stage clinical development for ENPP1 Deficiency and has potential applications for other conditions like ABCC6 Deficiency and calciphylaxis. This surge in interest reflects a growth-positive impact on the company, highlighting its promising therapeutic developments in the biotech sector.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["biopharmaceutical","clinical-stage","therapeutics","enzyme replacement","pathway deficiencies"],"date_of_event":null,"product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"qOdXTk3KOPwdq9Zbfy2bSjIT7xIG4Fu84nqGrszhwZMltGDLcV6Uqy","news_summary":"Biotech Alert: Searches spiking for these stocks today","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"PWs2gzZ1eBUN4rrYQe1biylOKE7pvsrwectqi4KxtkH7YfG21Wp8hG","date":"May 15, 2025","link":"https://finance.yahoo.com/news/urogen-pharma-ltd-nasdaq-urgn-102219940.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"earnings report","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. recently released its quarterly results, which fell short of analyst expectations. The company reported a revenue of $20 million, which was 11% below forecasts, and a statutory loss of $0.92 per share, 18% greater than expected. Analysts have updated their earnings models, predicting a 30% revenue increase to $119.7 million in 2025, but also a slight increase in forecasted losses per share to $2.87. The average price target for UroGen Pharma has decreased by 6.4% to $32.63, reflecting concerns over growing losses. Despite these challenges, UroGen Pharma is expected to grow faster than the broader industry, with a forecasted annual revenue growth of 42% by 2025.","partners":null,"customers":null,"eventType":null,"investors":[],"confidence":9,"key_topics":["earnings","revenue","losses","forecasts","analysts"],"date_of_event":"May 15th 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"Q3xJ4cGJ1ZpEZ0yXWZTVY5mtvauTM0bP16vEYAy0McPPvrdeFd60Wo","news_summary":"UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported Earnings, And Analysts Cut Their Target Price","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"4cGVYwjFvf2hCDj25CpCQjkC2TqgP7YhDkyLe7T3StpPPx3Q00axKw","date":"May 13, 2025","link":"https://finance.yahoo.com/news/urogen-pharma-ltd-urgn-q1-070554766.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA approval","round":null,"company":"UroGen Pharma Ltd","layoffs":null,"summary":"UroGen Pharma Ltd reported a strong performance in Q1 2025, with Jelmyto sales reaching $20.3 million, marking an 8% year-over-year growth. The company is in the final stages of FDA review for UGN-102, with a PDUFA target date set for June 13, 2025. UGN-102 is expected to be a significant growth driver, with a market opportunity exceeding $5 billion. UroGen is expanding its sales force in anticipation of UGN-102s launch. Despite a net loss of $43.8 million, the company maintains a robust balance sheet with over $200 million in cash equivalents. The ENVISION trial for UGN-102 showed promising results, although concerns remain about its single-arm study design.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["FDA approval","Sales growth","R&D expenses","Net loss","Market opportunity"],"date_of_event":"May 12, 2025","product_stage":"final stages of FDA review","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Expand"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"OBdwVazQiiKhqnJy2xdhqWTbjevveIRYa0aJcdO4UIpofTfZmEZqGI","news_summary":"UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"b907l8ibVCl4F7lOwo4qpJqbpsFTRbGKJ7eNWHPofjMHzeb7kCsx7s","date":"May 12, 2025","link":"https://finance.yahoo.com/news/urogen-pharma-urgn-reports-q1-131505629.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"earnings","round":null,"company":"Urogen Pharma","layoffs":null,"summary":"Urogen Pharma reported a quarterly loss of $0.92 per share, missing the Zacks Consensus Estimate of a loss of $0.83. This represents an earnings surprise of -10.84%. The companys revenues for the quarter were $20.25 million, which also missed the consensus estimate by 3.67%. Over the last four quarters, Urogen Pharma has surpassed consensus EPS estimates only once. The companys shares have lost about 2.5% since the beginning of the year, outperforming the S&P 500s decline of -3.8%. The earnings outlook remains mixed, with a Zacks Rank of #3 (Hold), indicating that the shares are expected to perform in line with the market in the near future.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["earnings","revenue","stock","estimates","performance"],"date_of_event":"March 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"33wcweW7nPjDmAUlPR1JdZe7vLXj9A07yIfPyKJ7edolzOoHGP0y3T","news_summary":"Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"mi2PQxEfOeAXxqwbqSnGCxqKjAwvlrG84uW7z3vPfgO8oMrO4xHfW4","date":"May 12, 2025","link":"https://finance.yahoo.com/news/urogen-pharma-reports-first-quarter-120000405.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA approval","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd., a biotech company focused on urothelial and specialty cancers, announced its financial results for Q1 2025 and provided updates on its lead product, UGN-102. The New Drug Application (NDA) for UGN-102, intended for treating recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, is under review by the FDA. The FDA has set a target action date of June 13, 2025, with an advisory committee meeting scheduled for May 21, 2025. Assuming approval, UroGen plans to launch the product commercially in July 2025. The company reported net sales of $20.3 million for JELMYTO® in Q1 2025, reflecting a 12% demand growth. UroGen is well-positioned financially with $200.4 million in cash and marketable securities, aiming to transform uro-oncology treatment and deliver shareholder value.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["FDA approval","UGN-102","financial results","commercial launch","oncology"],"date_of_event":"May 12, 2025","product_stage":"pending approval","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"1oUJ0kVzsA1BY6GSaonfZC71b8HZ9MFKCWa3MAiqZR5xY028xnjPiF","news_summary":"UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"7gwu4daQs5f5VlToImIQFc0WOOK5wxucKghsic5j99vUt4C9wdanQW","date":"May 7, 2025","link":"https://finance.yahoo.com/news/urogen-announces-fda-advisory-committee-125700485.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA review","round":null,"company":"UroGen","layoffs":null,"summary":"UroGen, a biotech company, announced that the FDA has scheduled an Oncologic Drugs Advisory Committee (ODAC) meeting on May 21, 2025, to review the new drug application (NDA) for UGN-102, an investigational treatment for recurrent LG-IR-NMIBC. The NDA is supported by positive results from the Phase 3 ENVISION trial, showing a high complete response rate. The FDA aims to complete its review by the PDUFA target action date of June 13, 2025. UGN-102, utilizing UroGens RTGel technology, offers a non-surgical treatment option for bladder cancer. The company is optimistic about the potential approval and its impact on patients.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["FDA","UGN-102","bladder cancer","Phase 3","ODAC meeting"],"date_of_event":"May 21, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"6Vij08RnEj5V6paEykw18S6jEL7MUpnilCuxfVWL8KsZ7YjszclUcg","news_summary":"UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"r7W4Oo1rmHM1txfVRMhYyc6IZbuajJ4QQgK6N1X43BBvK0LqP6xVMu","date":"May 1, 2025","link":"https://www.businesswire.com/news/home/20250501171249/en/","source":"www.businesswire.com","visible":1,"analysis":{"tags":"financial results","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd., a biotech company focused on developing treatments for urothelial and specialty cancers, announced it will report its first quarter 2025 financial results on May 12, 2025. The announcement will be followed by a live audio webcast and conference call. UroGen has developed RTGel® reverse-thermal hydrogel, a platform technology designed to improve the therapeutic profiles of existing drugs. Their products aim to treat low-grade upper tract urothelial carcinoma (LG-UTUC) and recurrent low-grade non-muscle invasive bladder cancer using non-surgical methods. The company is headquartered in Princeton, NJ, with operations in Israel.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["conference call","financial results","webcast","biotech","cancer treatment"],"date_of_event":"May 12, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"fyQukSti5gibLLfh2evKUpvRkqDeddkwzvTaAGef1hAeALXHojAqhU","news_summary":"UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"4XktGddotBtDLVZqVLkcFY9vnirt3Y9ePwyRCUj2gmy1JMIM8OCKOA","date":"Apr 29, 2025","link":"https://finance.yahoo.com/news/urogen-pharma-urgn-moves-14-091600911.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"stock performance","round":null,"company":"Urogen Pharma","layoffs":null,"summary":"Urogen Pharmas stock rose by 14.1% to $11.26 following the presentation of data on its pipeline candidates at the American Urological Association 2025 meeting. The company is expected to report a quarterly loss of $0.83 per share, a 14.4% improvement year-over-year, with revenues projected at $21.03 million, up 12% from the previous year. Despite the positive stock movement, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Urogen Pharma is part of the Zacks Medical - Biomedical and Genetics industry and currently holds a Zacks Rank #3 (Hold).","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["stock price","earnings","revenue","cancer research","Zacks Rank"],"date_of_event":"2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"lupOmpwAjjBilpsEAp1NvE4s9C0lejqE8vB1ApKjWKbzKrClgB564u","news_summary":"Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"Ns7qh4OMESfPC3I3jhQwutilZ1C2YWjEiOZ4K05suAzSKHYR6IGUWE","date":"Apr 27, 2025","link":"https://finance.yahoo.com/news/long-term-data-optima-ii-163000202.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. presented new data from their OPTIMA II Phase 2b study at the American Urological Association 2025 Annual Meeting. The study focuses on UGN-102, a sustained-release formulation of mitomycin for treating recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The data shows a median duration of response of 24.2 months, highlighting the treatments durability. UroGen completed the submission of a rolling new drug application for UGN-102 to the FDA in August 2024, with a PDUFA goal date set for June 13, 2025. These results emphasize the potential of UGN-102 to provide meaningful and sustained responses for patients with limited treatment options.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["UGN-102","Phase 2b study","bladder cancer","FDA submission","treatment durability"],"date_of_event":"April 27, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"1qBzYHUaviK4rPt5EDHKpTpMair1O58agBNLBpRljJUi7fewX6bR7d","news_summary":"New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"89s8fBLbdns0Yr8qOo2FxmmTLj2p97yRuPNhM7J8iTmVE2vPrkjVKh","date":"Apr 27, 2025","link":"https://finance.yahoo.com/news/patient-reported-outcomes-ugn-102-170000688.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. presented new analysis of patient-reported outcomes from the OPTIMA II, ATLAS, and ENVISION studies of their investigational drug UGN-102 at the AUA 2025 Annual Meeting. The data showed that UGN-102 achieved robust and durable complete response rates in patients with low-grade intermediate-risk non-muscle invasive bladder cancer without negatively impacting their quality of life. The findings suggest that UGN-102 is a promising alternative intravesical treatment for these patients. The company emphasized the importance of advancing treatment options that improve patient outcomes and quality of life.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["UGN-102","clinical trials","quality of life","bladder cancer","patient outcomes"],"date_of_event":"April 27, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"fA83i4449gs9QtUoa2xBkiJdxQYHSO54W5W4j6LRasPMeDlqFVCq4y","news_summary":"New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"7XEKxPBUdNxTWewXyf4a2K1JwodyrO7wG9CQ3S7hLsY8ay1iTQzkcM","date":"Apr 27, 2025","link":"https://finance.yahoo.com/news/olympus-long-term-study-reports-200000840.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. presented data at the 2025 American Urological Association Annual Meeting highlighting the long-term effectiveness of JELMYTO, an FDA-approved treatment for low-grade upper tract urothelial cancer (LG-UTUC). The study showed a median duration of response of nearly four years among patients who achieved a complete response after primary chemoablation with JELMYTO. The findings underscore the treatments durability and its potential to significantly reduce recurrence rates in both new-onset and recurrent LG-UTUC patients. The studys limitations include its post-hoc nature and potential selection bias. UroGen plans to further evaluate JELMYTOs potential through the ongoing uTRACT Registry.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["JELMYTO","LG-UTUC","clinical trial","FDA approval","durability"],"date_of_event":"April 27, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"TdaynbMewq4cmTMFap52OdFxJiOOEDuuSe3oryDeckitd5ANHVV5h6","news_summary":"OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"da9FLjjyc9p4QuvLsZLCIuDV2mpiQNunzGbgd8IDcddjEZrPRZiey9","date":"Apr 26, 2025","link":"https://finance.yahoo.com/news/urogen-announces-updated-18-month-223000021.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. announced promising results from its Phase 3 ENVISION trial for UGN-102, an investigational treatment for recurrent low-grade non-muscle invasive bladder cancer (LG-IR-NMIBC). The trial demonstrated an 18-month duration of response (DOR) of 80.6% in patients who achieved a complete response at three months. The data was presented at the American Urological Association 2025 Annual Meeting. UGN-102 aims to provide a non-surgical treatment option for elderly patients who face the burden of repeated surgeries. If approved, UGN-102 could significantly impact the treatment landscape by reducing recurrence rates and extending treatment-free intervals.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["clinical trial","cancer treatment","patient response","medical data","treatment innovation"],"date_of_event":"April 26, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"aa1g62wLezsF18I4D0VCWCISXDtjJKRKZTHF8YryrAxqLrVIw25Zgl","news_summary":"UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"LyibNX8AHIqKxdDKjbDPzkwgD3GlXstjXty8hNnQcWJvpURVSUAeGA","date":"Apr 26, 2025","link":"https://finance.yahoo.com/news/urogen-pharma-announces-encouraging-results-140000307.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. announced positive safety data from its Phase 1 dose-escalation study for UGN-301, an investigational drug for recurrent non-muscle invasive bladder cancer. The study, presented at the 2025 American Urological Association Annual Meeting, showed that UGN-301 was well-tolerated across all dose levels with no dose-limiting toxicities. The drug, formulated in a reverse thermal gel, allowed sustained exposure in the bladder, reducing systemic immune-related toxicities. Clinical activity was observed, with a significant percentage of patients achieving a complete response or remaining recurrence-free. These promising results support further investigation into UGN-301s efficacy.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["UGN-301","bladder cancer","clinical trial","safety data","immune modulation"],"date_of_event":"April 26, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"6p9aeOpCbccjc8XxxMCLyx9WvKwcFLGxN39sSTquHwNsw9ig8LBIZz","news_summary":"UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"8VTSfPr08kPiToXWyM90S37XIpAE3GfgNcmnftob7jchnB6NZcXffN","date":"Apr 14, 2025","link":"https://finance.yahoo.com/news/urogen-announces-data-presentations-american-120000466.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical data","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd., a biotech company focused on developing treatments for urothelial and specialty cancers, announced the presentation of new data at the American Urological Association (AUA) 2025 Annual Meeting. The data includes 18-month duration of response (DOR) from the ENVISION trial for UGN-102, long-term outcomes from the OPTIMA II study, and results from a Phase 1 study for UGN-301. These findings highlight the potential of UroGens portfolio in advancing the treatment of urothelial cancers. The company is also participating in the AUA Innovation Nexus Conference, showcasing its involvement in innovative urology solutions.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["clinical trials","urothelial cancer","drug development","AUA conference","patient outcomes"],"date_of_event":"April 14, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Public Trading"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage  #Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Cb40IMJEXtZNmaa7dgl9UPAV0zWMliTmAZOdlGLDQvo54jvcD8maUZ","news_summary":"UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"U5yQVpR9N1f8fLakze3Z0ZScwFnPD24aQtygAAhfg7hFjQ4xSkWi7g","date":"Apr 8, 2025","link":"https://finance.yahoo.com/news/high-growth-tech-stocks-us-170824848.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"growth","round":null,"company":"Organogenesis Holdings Inc.","layoffs":null,"summary":"Organogenesis Holdings Inc., a regenerative medicine company, has demonstrated significant growth potential in the biotech sector. The company focuses on advanced wound care and surgical products, generating substantial revenue from its regenerative medicine segment. In Q4, Organogenesis reported a notable increase in sales to $126.66 million, up from $99.65 million the previous year, and achieved a net income of $7.67 million, reversing a previous net loss. The companys annual sales rose to $482.04 million, marking a steady growth rate of 9.2% per year, surpassing the US market average. Despite current unprofitability and share price volatility, Organogenesis is projected to achieve profitability within three years, with expected earnings growth of 71.83% annually, indicating strong future prospects.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["revenue growth","earnings growth","biotech sector","financial health","future prospects"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":"$490.82 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"z7KTHejxImbMWF0GiaomBgDfCUPwTqVHvIklpi0oZM5UENaqm7vcZj","news_summary":"High Growth Tech Stocks In The US To Watch April 2025","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"kwQm14q5FtSASHahTOsw8fH9Y6OB5PPsiZpW368Mf5iRKmpurtDpS3","date":"Mar 12, 2025","link":"https://finance.yahoo.com/news/urogen-pharma-ltd-urgn-q4-190031847.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"drug approval","round":null,"company":"UroGen Pharma Ltd","layoffs":null,"summary":"UroGen Pharma Ltd has submitted a new drug application for UGN 102, with FDA review underway and a target date set for June 13th. The Envision phase 3 trial showed promising results, and the company is expanding its sales force in anticipation of the drugs launch. Despite reporting a net loss for 2024, UroGen Pharma has a strong balance sheet and a 12% increase in sales for its existing product, Jelmyto. The company faces potential challenges with market access and reimbursement due to a generic J code but remains optimistic about UGN 102s revenue potential. The company is also considering pricing strategies and further clinical work.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["FDA review","clinical trials","sales growth","market access","reimbursement"],"date_of_event":"March 10, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Expand"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"pDEsZk2EUl4oTAZ3NCN2U9gJ3L14fR8sOLbZM8vGzFfHJIJSr7fL8K","news_summary":"UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ZnNrvL5YA6GvS8NGSD1Tj3sUrQjoy1exQ2ZgepzFbTrlQBNuKUMUzP","date":"Mar 10, 2025","link":"https://finance.yahoo.com/news/urogen-pharma-urgn-reports-q4-131020796.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"earnings","round":null,"company":"Urogen Pharma","layoffs":null,"summary":"Urogen Pharma reported a quarterly loss of $0.80 per share, missing the Zacks Consensus Estimate of a $0.74 loss. This represents an earnings surprise of -8.11%. The company posted revenues of $24.57 million, also missing the consensus estimate by 6.08%. Over the last four quarters, Urogen Pharma has surpassed consensus EPS estimates only once. The companys shares have declined by about 7.8% since the beginning of the year, underperforming the S&P 500s decline of -1.9%. The companys earnings outlook remains mixed, with a Zacks Rank of #3 (Hold), indicating expected performance in line with the market. Future stock movements will depend on managements commentary and earnings estimate revisions.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["earnings","revenue","stock performance","estimates","Zacks Rank"],"date_of_event":"December 2024","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"8im99xc95s9k1MzuXlXUjqq3jiiTAFSaR4T2wDIMeCfDT86qG221I2","news_summary":"Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"J8QwIsLda6hLV2nX1y1zBBYGMFf4UFAedojjJsD0a9SHmdRCcobalA","date":"Mar 10, 2025","link":"https://finance.yahoo.com/news/urogen-pharma-reports-fourth-quarter-120000884.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA review","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. announced significant progress in 2024, including the submission of a New Drug Application (NDA) for UGN-102, which is under FDA review with a PDUFA target action date set for June 13, 2025. The company reported promising 18-month duration of response (DOR) data from the Phase 3 ENVISION trial for UGN-102, a treatment for low-grade intermediate-risk non-muscle invasive bladder cancer. UroGen also acquired ICVB-1042, an investigational oncolytic virus therapy, and achieved revenue growth with its product JELMYTO®. The company is well-positioned for future growth with a strong pipeline and strategic acquisitions.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["FDA review","clinical trial","acquisition","financial results","market opportunity"],"date_of_event":"March 10, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":"ICVB-1042","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Acquisition"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ckesJY9dlJIYtPSMw64yqto8oBtqR9s5OtDLfDNMYpuPQddw0IQk3a","news_summary":"UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"4uHMKMKAQtH5DI2fNYrdDSuJJ7xnDuis3zD58xJ0QeyhvkRxKohJCL","date":"Mar 7, 2025","link":"https://finance.yahoo.com/news/exploring-high-growth-tech-stocks-170822327.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA approval","round":null,"company":"ARS Pharmaceuticals, Inc.","layoffs":null,"summary":"ARS Pharmaceuticals, Inc., a biopharmaceutical company, has received FDA approval for its innovative product, neffy 1 mg, an epinephrine nasal spray designed for children with severe allergies. This approval marks a significant milestone for the company, diversifying its product line and enhancing its competitive position in the allergy treatment market. Neffy’s needle-free design addresses a critical need for a user-friendly alternative to traditional injectable methods. The products inclusion in national formularies, such as those of Cigna Healthcare and Navitus Health Systems, significantly broadens its potential user base. Supported by robust clinical trials, neffy is poised to be a pivotal addition to ARS’s offerings, aligning with its strategy to innovate within the tech-driven pharmaceutical landscape.","partners":null,"customers":["Cigna Healthcare","Navitus Health Systems"],"eventType":null,"investors":null,"confidence":10,"key_topics":["FDA approval","allergy treatment","nasal spray","market expansion","clinical trials"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":"$1.06 billion","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["FDA approved/pending approval","Customers","Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"using","structuredIssuesShow":"#FDA approved/pending approval  #Customers  #Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ejgNAESIZk03nOvUHRdEbKndHkJP5LoVsN4XG8yE0YbzUqAbIORSS9","news_summary":"Exploring High Growth Tech Stocks in the US Market","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"mJaKMknmkdDp93NU0YpZHQDsh4GIXKXq6SwTGzvgOfjHXFvULmRVkz","date":"Mar 7, 2025","link":"https://www.businesswire.com/news/home/20250307402285/en/","source":"www.businesswire.com","visible":1,"analysis":{"tags":"employee expansion","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd., a biotech company focused on urothelial and specialty cancers, announced the grant of inducement restricted stock units (RSUs) to seven new employees. These employees will aid in the commercialization of Jelmyto®, UroGens first approved product, and the development of its pipeline. The RSUs, part of UroGens 2019 Inducement Plan, will vest over three years, contingent on continued employment. UroGen is known for its RTGel® technology, which enhances drug exposure in the urinary tract. The company is headquartered in Princeton, New Jersey, with operations in Israel.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["RSUs","commercialization","cancer treatment","hydrogel","employment"],"date_of_event":"March 07, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Expand"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"kWw6cCjhU4HGowIxQGIxaCCjl4RhiByKTZyoShTlfnK64lTHlw11yE","news_summary":"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ckFV2P1Ul3ZbJopmgw0vDTejDqNKu0xTAqhuVzvBogepysptOcL6qh","date":"Feb 27, 2025","link":"https://www.businesswire.com/news/home/20250227186280/en/","source":"www.businesswire.com","visible":1,"analysis":{"tags":"financial results","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd., a biotech company focused on developing treatments for urothelial and specialty cancers, announced it will report its fourth quarter and full-year 2024 financial results on March 10, 2025. The announcement will be followed by a live webcast and conference call. UroGen is known for its proprietary RTGel® reverse-thermal hydrogel technology, which enhances the therapeutic profiles of existing drugs by enabling longer exposure of urinary tract tissues to medications. The company offers Jelmyto® for pyelocaliceal solution and is investigating UGN-102 for intravesical solution, both aimed at non-surgical tumor ablation. UroGen is headquartered in Princeton, NJ, with operations in Israel.","partners":null,"customers":null,"eventType":null,"investors":[],"confidence":10,"key_topics":["financial results","conference call","webcast","cancer treatment","hydrogel technology"],"date_of_event":"February 27, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"4fJwbGHMwXR3imWIK99EDQVxETTUgJhyWkjMRXPEdcJfMXIM8B5fbS","news_summary":"UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"QpMoBEHzecKSrOyRRTmHkpEWjHf2INjPsGpzh3CIviCvVqbQAk2HAX","date":"Feb 25, 2025","link":"https://finance.yahoo.com/news/urogen-pharma-ltd-urgn-best-173049310.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"small-cap stocks","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"The article discusses the potential of small-cap stocks, specifically UroGen Pharma Ltd., as attractive investment opportunities due to their ability to deliver higher earnings growth compared to large-cap stocks. Nick Sheridan from Janus Henderson highlights the challenges small caps face in gaining visibility amidst the dominance of mega-cap tech stocks. However, with expected decreases in interest rates, small caps are poised to benefit, offering diversification and exposure to structural trends like de-globalization. Despite being under-researched and undervalued, small caps present opportunities for investors willing to conduct thorough research. The article emphasizes the persistent merger and acquisition activity involving small-cap targets, supporting the case for investing in them.","partners":null,"customers":null,"eventType":null,"investors":["Janus Henderson"],"confidence":9,"key_topics":["small-cap stocks","growth","diversification","market trends","investment opportunities"],"date_of_event":"November 4, 2024","product_stage":"released","investment_date":"November 4, 2024","acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"PAH8tl4qfSB2ZpA9QBFwY4S80kwyuBAlkDoKA7wUKSIsekFofC7yxS","news_summary":"Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"U8TV3iQ0BquYVyUTiuol9Vc0pKv57UZX9EF6HYYQHjmpYTMts9vqpH","date":"Feb 24, 2025","link":"https://www.businesswire.com/news/home/20250224504690/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"LnjrHv1UQmQ9PcGan0ob5o924hIO2r7PUWRmL7AxUqWCheGSqZNo82","news_summary":"UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"7nPk4X0fcboN4RDxxtx7cOBe1lDpyuNXoHZY8ulSos3m7xfdSu9dNn","date":"Feb 21, 2025","link":"https://www.pharmaceutical-technology.com/news/urogen-iconovir-oncolytic-virus/","source":"www.pharmaceutical-technology.com","visible":1,"analysis":{"tags":"acquisition","round":null,"company":"UroGen Pharma","layoffs":null,"summary":"UroGen Pharma has expanded its oncology pipeline by acquiring assets related to the oncolytic virus ICVB-1042 from IconOVir Bio. The acquisition involves issuing $4 million in ordinary shares and a potential $15 million cash payment upon reaching sales milestones. UroGen will also pay royalties on net sales of ICVB products. This acquisition aligns with UroGens strategy to advance its uro-oncology pipeline and develop novel cancer therapies. The company is also exploring research partnerships to enhance its RTGel technology, which aims to improve the efficacy of immunotherapies. UroGen, headquartered in the US and operating in Israel, recently received FDA NDA acceptance for UGN-102 to treat bladder cancer.","partners":"IconOVir Bio","customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["Oncology","Acquisition","Innovation","Partnerships","RTGel"],"date_of_event":"February 21, 2025","product_stage":"R&D","investment_date":null,"acquired_company":"IconOVir Bio","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition","Partners"],"acquisition_amount":"$4m in shares and $15m cash","FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Acquisition  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"kGtu5EWLESnwiGhgyatfH1YDObvdk0q5sp0EdEIsNkwENZZ7OCiZpw","news_summary":"UroGen acquires IconOVir’s oncolytic virus assets","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"JJ28B8bFtAkm6s4XADVGeDcOkA97uac2dKo7FGuyKFQHVxUiqSTBLe","date":"Feb 20, 2025","link":"https://finance.yahoo.com/news/urogen-advances-long-term-growth-130000739.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"acquisition","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd., a biotech company specializing in urothelial and specialty cancers, has expanded its oncology pipeline by acquiring assets related to the oncolytic virus ICVB-1042 from IconOVir Bio, Inc. This acquisition is part of UroGens strategy to develop novel therapies for bladder and other specialty cancers. Additionally, UroGen has entered into strategic research collaborations to explore the potential of its RTGel technology in enhancing the effectiveness of immunotherapies. The company aims to advance its uro-oncology pipeline and drive innovation in cancer treatment, marking a significant milestone in its growth strategy.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["oncology","acquisition","collaboration","immunotherapy","innovation"],"date_of_event":"February 20, 2025","product_stage":"R&D","investment_date":null,"acquired_company":"IconOVir Bio, Inc.","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Acquisition  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"SIFYUwKN0q7MWpEksiEDxWeNZAjlBaKIT3cOoWvcmvWzNcMecyLsaj","news_summary":"UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"GfFP4RcDE8XRmEmDl6jDeZ2lvM3zVxPggsR0QGvXGgM1OihaQ6q6Yo","date":"Feb 14, 2025","link":"https://finance.yahoo.com/news/urogen-announces-results-subgroup-analyses-193000736.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. presented promising results from the ENVISION study at the ASCO GU 2025 symposium, showcasing the efficacy of UGN-102 in treating recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The study demonstrated high complete response (CR) rates across various subgroups, with 82.8% CR for patients with tumor burden ≤3 cm and 73.2% for those with larger tumors. The treatment maintained its effectiveness over 12 months, indicating UGN-102s potential as a durable treatment option. The study involved 240 patients, with 95% completing the treatment regimen. These findings highlight UGN-102s potential to become a significant therapeutic option for LG-IR-NMIBC.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["clinical trial","bladder cancer","UGN-102","tumor burden","treatment response"],"date_of_event":"February 14, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"D7UDUVUW9Z5LrKGFN4L9teMhrkwoKealYhWyXoNusACGf6oHp7KCYK","news_summary":"UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"3TMb9Xmv5b7bbtm9nL5SCM3xOMbFecVhDN1x0C0o0Th90ZtI1nCOxt","date":"Feb 12, 2025","link":"https://finance.yahoo.com/news/data-long-term-study-olympus-130000625.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"study results","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. announced positive results from a long-term follow-up study of JELMYTO, an FDA-approved treatment for low-grade upper tract urothelial cancer (LG-UTUC). The study, published in The Journal of Urology, showed a median duration of response of 47.8 months among patients who achieved a complete response after primary chemoablation with JELMYTO. These findings underscore the treatments potential for sustained disease control. The company is also enrolling participants in the JELMYTO uTRACT Registry to collect real-world usage data. The studys positive results are expected to reinforce JELMYTOs value as a treatment option for LG-UTUC.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["JELMYTO","LG-UTUC","study results","FDA approval","treatment"],"date_of_event":"February 12, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"HfmBfcb72ssPANlOpLwQ8w4uDKtMAAUOprlmUG55ZonSWxC0pokPpV","news_summary":"Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"JhhchdFZVg92IOH3KzVceoW6ILNrLThW5v7OIbAq5JbVpVmUB2CV9w","date":"Jan 30, 2025","link":"https://www.businesswire.com/news/home/20250130241788/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"Je9qwDk2ZyVL1LWX5FhwB9fH21hdKJ0HyJsrxYkzTcvPTisbvy6MrE","news_summary":"UroGen Pharma to Present at Upcoming Investor Conferences","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"6Ne20Nzip0ceh0jrtp6RsC2tP1AAhfFcGzaCmR6t0DtqjVABmj7IsV","date":"Jan 22, 2025","link":"https://finance.yahoo.com/news/real-world-durability-response-data-130000987.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"study results","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. has released promising results from a long-term study on JELMYTO, a treatment for low-grade upper tract urothelial cancer. The study, involving 56 patients, demonstrated a 68% recurrence-free survival rate at three years, regardless of tumor size, location, or administration route. Maintenance therapy was linked to higher recurrence-free survival, though further research is needed. These findings highlight JELMYTOs potential in providing long-term disease control, supporting its broad applicability and reinforcing UroGens commitment to advancing therapies for complex urological conditions.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["JELMYTO","urothelial cancer","study results","recurrence-free survival","maintenance therapy"],"date_of_event":"January 22, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"not mentioned","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"mW89AijRAYHAC6CA0RScz5ggM4NT2SCIQBPqfujMjFCYpJ4FtwVIhy","news_summary":"New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"GTwEoUklDwy4EEiwCFSwbBOcMiJDDpaqtBBMaeuKfkjBpaSeU4fzed","date":"Jan 15, 2025","link":"https://finance.yahoo.com/news/envision-trial-results-published-february-130000391.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. announced positive results from its Phase 3 ENVISION study of the investigational drug UGN-102 for treating low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC). The study reported a 79.6% complete response rate at three months and an 82.3% duration of response at 12 months. These results highlight UGN-102s potential as a non-surgical treatment option, offering durable responses and potentially reducing recurrence rates for patients, particularly the elderly, who face repeated surgeries. The findings, published in The Journal of Urology, suggest that UGN-102 could significantly advance the management of LG-IR-NMIBC if approved.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["clinical trial","bladder cancer","treatment","response rate","durability"],"date_of_event":"January 15, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"RGJF64M7UGpMe1oW2b83fKZllJK9mCa8TIeeanlBvtf8OjcKQC7TgZ","news_summary":"ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"QcKl03bMdr7AAMslKiNJreGbmhbi6jW36rtEI8tYkyxsyimHlV0O5o","date":"Dec 31, 2024","link":"https://finance.yahoo.com/news/breakeven-horizon-urogen-pharma-ltd-120645545.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"profitability","company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd., a biotechnology company specializing in urothelial and specialty cancers, is projected to reach profitability by 2026 according to industry analysts. Despite a current market cap of $454 million and significant losses in recent years, analysts expect the company to achieve a 67% annual growth rate to meet its breakeven target. However, the companys high debt-to-equity ratio poses a risk, necessitating careful capital management. The article emphasizes the importance of understanding UroGen Pharmas financial fundamentals and growth potential, while also highlighting the need for further research into its valuation and management team.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["profitability","growth","debt","biotechnology","analysts"],"date_of_event":"2026","valuation_amount":"454 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"N7Ab653iJ0gJ98SEgvX0CHiCh7Kkv8Kzm8oOpJAwOmZdVxQe4a0Ara","news_summary":"Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN)","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"M4aRiEq0dWogroF0wBRgHky1CNAuQHa5tPZpQztzVkUXVgmyO3EEcx","date":"Dec 6, 2024","link":"https://www.businesswire.com/news/home/20241206579709/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"Of5mX5KHDGvKjXPzmNtThrBZE3QQvNuHqTFIxq5YUm80pSrSlypAuH","news_summary":"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"Byc7HpyD7o4PtKOTkEKzRyZVih01LhS9LviuIdcuD7cW230JyjP1Q0","date":"Dec 5, 2024","link":"https://finance.yahoo.com/news/ugn-102-showed-promising-long-201500253.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. announced promising results from its Phase 3 ENVISION trial for UGN-102, a treatment for recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC). The trial demonstrated an 82.3% duration of response at 12 months and a 79.6% complete response rate at 3 months. These results, presented at the Society of Urologic Oncology annual meeting, suggest UGN-102 as a viable treatment option, addressing a significant unmet need for patients with recurrent low-grade bladder cancer. The safety profile was consistent with previous trials, and the company has secured a PDUFA goal date of June 13, 2025, from the FDA. This development is seen as a positive step towards improving patient outcomes by reducing the need for multiple surgeries.","partners":null,"customers":null,"investors":null,"confidence":10,"key_topics":["clinical trial","bladder cancer","treatment option","FDA approval","patient outcomes"],"date_of_event":"December 05, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"pJSIDpmMjPzpkoiqRQ1N2i1MSJHJBVb3b95NmqYJ1EWI5b86kXx8uk","news_summary":"UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"c0jRvY2L7bbPDGFo94chBjsNNOIVM8MuutuoGIqUbOuHVGcr3oP2kt","date":"Dec 5, 2024","link":"https://finance.yahoo.com/news/long-term-study-olympus-trial-203000597.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"treatment efficacy","company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. has released favorable long-term data for JELMYTO, a treatment for low-grade upper tract urothelial cancer (LG-UTUC). The data, presented at the Society for Urologic Oncology annual meeting and published in the Journal of Urology, shows a median duration of response of 47.8 months among patients who achieved a complete response in the OLYMPUS trial. This suggests that JELMYTO provides robust long-term control of LG-UTUC, potentially improving patients quality of life by reducing the need for invasive treatments. The study highlights JELMYTOs efficacy as a primary treatment option, although it notes limitations such as post-hoc analysis and selection bias.","partners":null,"customers":null,"investors":null,"confidence":10,"key_topics":["JELMYTO","cancer treatment","clinical trial","FDA approval","long-term data"],"date_of_event":"December 05, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"sNbUSR6TLMcySBMb0kCT1UCYr3ztEnuvwToBz1yG2C1vSM9Nz1ggcm","news_summary":"Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"5fRDtIdg2yVA8q1mI4Nmg2liwaUmaf92rdNCcgd2CmhIt75T9oFDgg","date":"Dec 2, 2024","link":"https://finance.yahoo.com/news/urogen-announces-data-presentations-society-130000218.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trials","company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd., a biotech company focused on developing treatments for urothelial and specialty cancers, announced that new data on its products UGN-102, JELMYTO, and UGN-301 will be presented at the Society of Urologic Oncology (SUO) 2024 annual meeting in Dallas, Texas. The presentations will highlight the potential of UGN-102 for treating low-grade, intermediate-risk non-muscle-invasive bladder cancer and the ongoing clinical value of JELMYTO for low-grade upper tract urothelial carcinoma. The company emphasizes its commitment to addressing unmet needs in urothelial cancer treatment and improving patient outcomes and quality of life. The event will take place from December 4 to 6, 2024.","partners":null,"customers":null,"investors":null,"confidence":10,"key_topics":["urothelial cancer","clinical trials","innovative treatments","bladder cancer","SUO meeting"],"date_of_event":"December 4, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"sQIVzNJ7BSCmpBpb2ocaR9R4SwOcTJTY9Dctbd2Um6097xhNtxpEkm","news_summary":"UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"zL5Z7BewCQBRZsHzIrTdPvFUS6bmlvAMThXuWnJ6tD24FsqruxNp74","date":"Dec 2, 2024","link":"https://finance.yahoo.com/news/wall-street-analysts-believe-urogen-224437472.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"stock analysis","company":"Urogen Pharma","layoffs":null,"summary":"Urogen Pharma (URGN) has seen a 4.1% increase in its stock price over the past four weeks, closing at $12.70. Wall Street analysts have set a mean price target of $39.36, indicating a potential upside of 209.9%. The price targets range from $18 to $64, with a standard deviation of $15.76, suggesting variability in analyst opinions. Despite skepticism about the reliability of price targets, a strong consensus among analysts about Urogen Pharmas potential for better-than-expected earnings supports a positive outlook. The article highlights the potential for growth in Urogen Pharmas stock, driven by analyst agreement and positive earnings estimate revisions.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["stock price","analyst targets","earnings","investment","price variability"],"date_of_event":"not specified","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"bhoH0VioHxl65Nm9vo44mfPrU4vxblIh4xBow6bi1t7YqUI7lDcnxi","news_summary":"Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"el4Td8CzhcAiwaa18Tnm0GwNzz2bvNSYiaEtAx98MGwj2Alvq0pHCw","date":"Nov 28, 2024","link":"https://www.clinicaltrialsarena.com/news/urogen-jelmyto-lg-utuc/","source":"www.clinicaltrialsarena.com","visible":1,"analysis":{"tags":"clinical trial","company":"UroGen Pharma","layoffs":null,"summary":"UroGen Pharma has reported positive outcomes from a long-term follow-up study of JELMYTO (mitomycin) for treating low-grade, upper tract urothelial cancer (LG-UTUC) in adults. Among 71 subjects, 41 achieved a complete response with a median duration of 47.8 months. The study, despite some limitations, shows promising long-term durability of JELMYTO as a primary treatment. The JELMYTO uTRACT Registry is enrolling subjects to gather real-world data. UroGen Pharmas chief medical officer, Mark Schoenberg, emphasized the importance of managing relapse and preserving organ function in LG-UTUC treatment. The company is also conducting a Phase III trial for UGN-103 to treat low-grade intermediate-risk non-muscle invasive bladder cancer.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["JELMYTO","cancer treatment","clinical trial","patient response","long-term study"],"date_of_event":"November 28, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"v8VFaLDzKhQb0kyCYBRTLFLmUm0QnM0btoJcpMeZprKDZ3XLuEsDhs","news_summary":"UroGen reports long-term data from study of JELMYTO for LG-UTUC treatment","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"vZbIZpTghakq4OD7IlCl3IHKbDOhh4EfpbUqX4PeYBvUnzly3S2Evs","date":"Nov 26, 2024","link":"https://finance.yahoo.com/news/data-long-term-study-olympus-130000060.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical study","company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. has published results from a long-term follow-up study of JELMYTO, an FDA-approved treatment for low-grade upper tract urothelial cancer (LG-UTUC). The study, published in the Journal of Urology, highlights a median duration of response of 47.8 months among patients who achieved a complete response after primary chemoablation with JELMYTO. This evidence suggests robust durability in maintaining control of LG-UTUC over an extended period. The studys findings are encouraging for the use of JELMYTO as a primary treatment, with ongoing research in the JELMYTO uTRACT Registry to gather real-world data. The studys limitations include its post-hoc nature and selection bias.","partners":null,"customers":null,"investors":null,"confidence":10,"key_topics":["JELMYTO","UTUC","durability","treatment","study"],"date_of_event":"November 26, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"zleYlUrGo2JdvPI9RMH2WCQkApMMoSYX4ul7UribBWL2S583FCXLJA","news_summary":"New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"aJFUSsPFzThdNwQOvIRQBXSz0m5xsPGaoAXOXV4NLpvgfIQhS4FtU7","date":"Nov 9, 2024","link":"https://finance.yahoo.com/news/urogen-pharma-ltd-nasdaq-urgn-142657750.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"earnings report","company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. recently released its quarterly results, showcasing strong performance with revenues of US$25 million, surpassing estimates by 4.1%. The companys losses per share were also better than expected, at US$0.55. Analysts have adjusted their forecasts, predicting a 49% revenue increase to US$133.4 million by 2025, with losses narrowing to US$2.46 per share. Despite a dip in revenue estimates, analysts are optimistic about reduced losses. The consensus price target fell by 7.4% to US$39.93, reflecting mixed sentiments. However, UroGen Pharma is expected to grow faster than its industry peers, with a 38% annualized revenue growth forecasted, compared to the industrys 21%.","partners":null,"customers":null,"investors":null,"confidence":10,"key_topics":["revenue","losses","analysts","forecasts","growth"],"date_of_event":"2025","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"G6KcACscXxuHdcM5MndAGtUxbjUPFhnfkUcl8y3HpfLTu3H7w5Gjes","news_summary":"UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported, And Analysts Assigned A US$39.93 Price Target","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"Ut9fbFbhMdeDSRAQezFKR0aS9MHk4myKTY40JsZeRg7X5vZvljL5iC","date":"Nov 7, 2024","link":"https://finance.yahoo.com/news/urogen-pharma-ltd-urgn-q3-071641959.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA approval","company":"UroGen Pharma Ltd","layoffs":null,"summary":"UroGen Pharma Ltd reported a 21% year-over-year increase in net product revenue for Q3 2024, driven by strong patient demand. The company submitted a new drug application for UGN 102, which, if approved, will be the first FDA-approved treatment for low-grade intermediate-risk non-muscle invasive bladder cancer. This represents a significant market opportunity with over 80,000 addressable patients annually in the US, translating to a market of over $5 billion. Despite facing challenges with gross-to-net discounting and ongoing litigation related to intellectual property, UroGen remains optimistic about its robust pipeline and life cycle management strategy. The FDA has set a PDUFA target date of June 13, 2025, for UGN 102. The company expects full-year gel Mito revenues to fall below previous guidance due to these challenges.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["FDA approval","Revenue growth","Market opportunity","Clinical trials","Intellectual property"],"date_of_event":"November 06, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"oixfxrbVn7iZOU3QHB3ErXnikUFakTknzHPagJJxU7LSNSu4n9Zgvm","news_summary":"UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"E1R2mf9NqdbqL4CPooJ0gqLaQdDWZQyyPxh6rznh5Z5KbpKQRW55wt","date":"Nov 6, 2024","link":"https://finance.yahoo.com/news/urogen-pharma-urgn-reports-q3-141506562.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"earnings report","company":"Urogen Pharma","layoffs":null,"summary":"Urogen Pharma reported a quarterly loss of $0.55 per share, which was better than the Zacks Consensus Estimate of a $0.84 loss, marking an earnings surprise of 34.52%. The company also reported revenues of $25.2 million, surpassing the consensus estimate by 4.06%. Despite these positive surprises, Urogen Pharmas stock has underperformed the market, losing about 18.6% since the beginning of the year compared to the S&P 500s gain of 21.2%. The companys earnings outlook remains unfavorable, with a Zacks Rank of #4 (Sell), indicating expected underperformance in the near future. Investors are advised to monitor earnings estimate revisions closely as they can significantly impact stock movements.","partners":null,"customers":null,"investors":null,"confidence":10,"key_topics":["earnings","revenue","stock performance","estimates","Zacks Rank"],"date_of_event":"September 2024","valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"NwmMPImk2wBnOpe6i878D8LCesnd2gsiYVjkfmMXuxdVcUw9gPlSZ6","news_summary":"Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"w4Ln2gHihu3ZwhnVmJcLz6pId09cMXk0GwmDPyKZNFvSHMYbnwh60X","date":"Nov 6, 2024","link":"https://finance.yahoo.com/news/urogen-pharma-reports-2024-third-130000824.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA approval","company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. announced that the FDA has accepted its New Drug Application for UGN-102, a treatment for low-grade intermediate-risk non-muscle invasive bladder cancer. The company anticipates a potential FDA approval by June 13, 2025. UGN-102 has shown promising results in clinical trials, with a high complete response rate and duration of response. UroGen reported net product sales of $25.2 million for JELMYTO® in Q3 2024, an increase from the previous year. The company holds $254.2 million in cash and equivalents as of September 30, 2024. UroGen is preparing for a commercial launch of UGN-102, which could address a market opportunity exceeding $5 billion.","partners":null,"customers":null,"investors":null,"confidence":10,"key_topics":["FDA approval","clinical trials","drug application","market opportunity","financial results"],"date_of_event":"November 06, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"FIfaNV6Ei9XECdCPDaFX712uR5dJKY7cszY6qDfj1bHTzPqxCvK7tC","news_summary":"UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"Vm9I32LPYgk3nKsDkoAS6OPcZXwFxWMjzKSJPXXHJrng14gW97EES4","date":"Nov 5, 2024","link":"https://www.businesswire.com/news/home/20241105753655/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"9OPlop48CPR5XVYPrMOcYSO4SAzGCxR8oUiyAIVgT8LOEnKJLBKLI8","news_summary":"UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"GGDWYjVG61DmWL9P0hkvZBb7PniYCUMU4EPEKq5P5SqxRxfOl3YLiK","date":"Oct 30, 2024","link":"https://www.businesswire.com/news/home/20241030832940/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"hTPMRiLem8qJGB5E4ZRb4DcRnE10hI38BK8xxVbC6Mge5orwNmCwId","news_summary":"UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"KmeDtTleHXoF4SUb7NjXvvyYbXO3BhXP1teiR04lr3tnBcXRQgYcnW","date":"Oct 28, 2024","link":"https://finance.yahoo.com/news/envision-trial-results-published-journal-120000949.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. announced promising results from the Phase 3 ENVISION study of their investigational drug UGN-102 for treating low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC). The study demonstrated an 82.3% 12-month duration of response (DOR) for patients who achieved a complete response at three months. The drug showed a 79.6% complete response rate at three months, indicating its potential as a valuable treatment option. UroGen has submitted a New Drug Application (NDA) to the FDA, with a PDUFA goal date set for June 13, 2025. The results highlight UGN-102s potential to improve patient outcomes by reducing the need for repeated surgeries, which are common in treating LG-IR-NMIBC.","partners":null,"customers":null,"investors":null,"confidence":10,"key_topics":["clinical trial","drug efficacy","FDA submission","bladder cancer","treatment option"],"date_of_event":"October 28, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"C7bZaDoRoujYcLLmDJpJ9A9Nt254g1WhhzA96mC9WOu5O8GL1aFH80","news_summary":"ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"cFd0ebXxOWN9ESs4zk7Om4Le3dseax00lhk2tl99k1aOrxqUuemETG","date":"Oct 19, 2024","link":"https://finance.yahoo.com/news/investors-urogen-pharma-nasdaq-urgn-143258569.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"stock performance","company":"UroGen Pharma Ltd.","layoffs":null,"summary":"The article discusses the performance of UroGen Pharma Ltd. over the past five years, highlighting a 42% decline in share price. Despite a 50% annual increase in revenue, shareholders have experienced a 7% annual loss over the same period. The companys stock has underperformed compared to the market average, although it has seen a 7.1% increase in the past year. The article suggests that the business may be stabilizing, but emphasizes the importance of considering other factors, such as risks, when evaluating the companys financial health.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["shareholders","revenue growth","stock performance","financial health","market returns"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"UIfAMAlK0RjcylMXOBTQe2dC3aAXnvoGVKHwkjZxtPcuxGryYuVGLI","news_summary":"Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"FTDwc0QMZYZsRm5LKacVDQ1NYynIODOPL0lI4c0zwzIZ90hog9A0K0","date":"Oct 16, 2024","link":"https://www.pharmaceutical-technology.com/news/fda-urogens-ugn-102-bladder-cancer/","source":"www.pharmaceutical-technology.com","visible":1,"analysis":{"tags":"FDA approval","company":"UroGen Pharma","layoffs":null,"summary":"UroGen Pharma has received acceptance from the US FDA for its new drug application (NDA) for UGN-102, a treatment for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The drug, which uses UroGens RTGel technology, is designed to prolong exposure of bladder tissue to mitomycin, offering a non-surgical treatment option. The NDA is supported by data from the Phase III ENVISION study, which showed a 79.6% complete response rate three months after the first instillation and an 82.3% 12-month duration of response. The FDA has set a Prescription Drug User Fee Act (PDUFA) date of June 13, 2025, for a decision on the NDA. This development is seen as a pivotal moment for UroGen Pharma, potentially expanding treatment options for bladder cancer.","partners":null,"customers":null,"investors":null,"confidence":10,"key_topics":["NDA acceptance","bladder cancer","UGN-102","FDA review","clinical trials"],"date_of_event":"October 16, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"6AWFjG4nfCyTxtZJ5zmnBCOk242yDE5F49qOKPNAoi1zsKjt8XpfpP","news_summary":"FDA accepts UroGen’s UGN-102 NDA for bladder cancer treatment","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"PuAaEwnQGAKHI10aNdPnA6OBVN9QIdLLPu02AoHdWBeFWAipVuBsDK","date":"Oct 15, 2024","link":"https://www.businesswire.com/news/home/20241015921667/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"jpTYw9ES3lwRSyx8BW6XCGz1WIQXmelmDGrlwkCpDeHUvqLopvmobu","news_summary":"UroGen Announces FDA Acceptance of its New Drug Application for UGN-102","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"R4PH7gLGxZxDOSSU5jl2GVIMZ6JqIhxb41eYlulhzKmsWPRaWslqEq","date":"Oct 9, 2024","link":"https://www.businesswire.com/news/home/20241009626123/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"6aEj9GgMvwPYz9uTYpeokB37FlkRq7g2KgtfUHRK5WNcj6JaKtZkSy","news_summary":"UroGen Appoints Chris Degnan as Chief Financial Officer","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"i0WV9NB2g98MI3sLQpY85gvZevdtfRy5ZOz1lpZknrJnUnp1FZmgNw","date":"Oct 9, 2024","link":"https://finance.yahoo.com/news/urogen-pharma-ltd-urgn-q2-221830902.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"earnings report","company":"UroGen Pharma Ltd","layoffs":null,"summary":"UroGen Pharma Ltd reported its financial results for Q2 2024, highlighting a net product revenue of $21.8 million for JELMYTO, marking a 16% sequential growth. Despite a net loss of $33.4 million, the company successfully raised approximately $116.2 million through a public offering. UroGen is preparing for the NDA submission of UGN-102, with a potential FDA approval decision in early 2025. The company faces challenges with JELMYTOs revenue growth due to headwinds and increased expenses. However, the positive data from the ENVISION study for UGN-102 and the significant market opportunity estimated at over $5 billion are promising. UroGen plans to expand its sales force by adding 10 to 15 sales reps to support UGN-102s launch.","partners":[],"customers":[],"investors":[],"confidence":9,"key_topics":["JELMYTO","UGN-102","revenue","expenses","FDA approval"],"date_of_event":"August 13, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"116.2 million","structured_issues":["Public Trading","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"EgEdslbXJOD4rB5mUeWr9t9X17AePRwB9cT1J3Wx6Ud7NItxOldrcl","news_summary":"UroGen Pharma Ltd (URGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"J1poogZDAAn2dHwqmeZRbmKZ0l1ZEJ3M7hH5jQI1baVqpvsgVtdUwT","date":"Oct 3, 2024","link":"https://www.clinicaltrialsarena.com/news/urogen-trial-bladder-cancer-2/","source":"www.clinicaltrialsarena.com","visible":1,"analysis":{"tags":"clinical trial","company":"UroGen Pharma","layoffs":null,"summary":"UroGen Pharma has commenced the Phase III UTOPIA clinical trial for its investigational drug UGN-103, aimed at treating low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The trial will enroll 87 subjects, each receiving a 75mg dose of UGN-103 weekly for six weeks. The efficacy will be evaluated based on the complete response rate at the three-month mark. UGN-103 utilizes UroGens RTGel platform technology, enhancing therapeutic profiles through sustained release. The FDA accepted the investigational new drug application for UGN-103 in April, allowing its use in adults with LG-IR-NMIBC. UroGens CEO, Liz Barrett, emphasized the significance of this milestone in advancing patient care. The trials initiation marks a positive step in the companys innovative treatment development.","partners":null,"customers":null,"investors":null,"confidence":10,"key_topics":["clinical trial","bladder cancer","UGN-103","FDA approval","RTGel technology"],"date_of_event":"October 3, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"DV9Z4JQyhyufji7AJKmY3FWIUsIDmAx3qeZJ6cbfgWIpjSjajftqD1","news_summary":"UroGen begins subject dosing in Phase III bladder cancer drug trial","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"fI1UcNx4AGffeQDKFpG5ZsVeWqLgxSuMtfq8cjQJgVw4y8zsvnvsYh","date":"Oct 2, 2024","link":"https://www.businesswire.com/news/home/20241002363009/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"UKOCAlu1rRFjY4vuEo3W6YZeC62ncszLqUBbzVJkaVM1KHqpeXEMe3","news_summary":"First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"0C5XYgZ966mUl93xqgQneoxFDCv5JboN7E24Giq5G2PbKGksz77vBz","date":"Sep 23, 2024","link":"https://finance.yahoo.com/news/urogen-pharma-urgn-short-seller-075801297.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"ADR stocks","company":"UroGen Pharma","layoffs":null,"summary":"UroGen Pharma, an Israeli biopharmaceutical company listed on NASDAQ, is focused on developing non-surgical treatments for uro-oncology diseases, particularly bladder cancer. Despite being ranked as one of the worst ADR stocks to buy according to short sellers, the company has shown promising clinical outcomes with its products like JELMYTO and UGN-102. UGN-102 is currently under FDA submission and targets a $5 billion market. The company has attracted investment from 25 hedge funds, with Adage Capital Management being the largest shareholder. Analysts maintain a consensus Buy rating for the stock, with significant upside potential.","partners":null,"customers":null,"investors":["Adage Capital Management"],"confidence":10,"key_topics":["ADR","short sellers","hedge funds","biopharmaceutical","oncology"],"date_of_event":"September 18, 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$329.33 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"7hBnPUs1ahbQ9kMuTHfUUdxGRdz0xIWmu5D0HAbYrzpTFYlb1GvnJC","news_summary":"UroGen Pharma (URGN): Short Seller Sentiment is Bearish On This ADR Stock","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"4nJpLQKLwnHnlrXsmkZIojYoyCj1vlYO5YeSceOVPZ3xCpWhJhSTs7","date":"Sep 23, 2024","link":"https://finance.yahoo.com/news/urogen-pharma-urgn-among-worst-095041773.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"biopharmaceutical, innovation","company":"UroGen Pharma","layoffs":null,"summary":"UroGen Pharma (NASDAQ:URGN), an Israeli biopharmaceutical company, is noted for its innovative treatments for urothelial and specialty cancers. The company has developed RTGel, a reverse-thermal hydrogel, and JELMYTO, which has shown a 58% complete response rate for low-grade upper tract urothelial cancer. UGN-102, targeting a $5 billion market for low-grade intermediate-risk non-muscle invasive bladder cancer, is under FDA review with potential approval in Q1 2025. Despite 16.87% of shares being shorted, 25 hedge funds, including Adage Capital Management, hold a bullish sentiment with stakes worth $329.33 million. The article ranks URGN as the 3rd worst Middle East and Africa stock to buy according to short sellers.","partners":null,"customers":null,"investors":["Adage Capital Management"],"confidence":10,"key_topics":["short interest","hedge funds","FDA review","bladder cancer","investment"],"date_of_event":"April 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"B6Qi8WTeO2djvjvZFGMEN2YzBeQKMMFJ7NTEB6Si2zIme5WwGgeKZu","news_summary":"UroGen Pharma (URGN): Among the Worst Middle East and Africa Stocks to Buy Now","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"xBngdqgwMxDbrJ53aNzr4xXDecqn7QRNrUoaD2KckuU7mANPmMOVqy","date":"Sep 16, 2024","link":"https://www.businesswire.com/news/home/20240916912176/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"nU51b0sLQEtmKJRkga2xwnwRMcwD9QQUiLmGzreMnaeLQlIhL6Rtm5","news_summary":"UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"ffdtIThGYP3OxxHbGXFuPlyvEkkeijZsefoOApIx3MHuwL0dqiMBnk","date":"Sep 5, 2024","link":"https://www.businesswire.com/news/home/20240905237247/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"n3DWZ75UfDC7XRanpCBM2nou4dgpaob5SeGMuq8klnDWlYsllc2PfY","news_summary":"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"F6LTLWJKmbClV6C9q2TPxrbRU1wCWPutriwNqwc28tY9jLUl6IUZSk","date":"Aug 29, 2024","link":"https://www.businesswire.com/news/home/20240829971223/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"c6VAeE8SP0k6v6VH3avcgS5JS1MvPqJUijUCgc1DrXVKG2USw3S4vq","news_summary":"UroGen Pharma to Present at Upcoming Investor Conferences","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"OcATdFlPZ8EFdCzh7XIc8nW0UfHmShk9b0fKUtvAleejkqvd1HnlHQ","date":"Aug 16, 2024","link":"https://finance.yahoo.com/news/urogen-pharma-ltd-nasdaq-urgn-113452578.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Earnings, Forecast","company":"UroGen Pharma Ltd.","layoffs":"N/A","summary":"UroGen Pharma Ltd. has released its Q2 report, revealing revenues of $22m, below expectations, and a larger than forecast loss per share of $0.91. Analysts have adjusted their forecasts for the company, predicting revenues of $94.2m in 2024, an 11% improvement on the last 12 months. However, per-share losses are expected to increase to $3.49. Despite this, analysts have increased their price target for the company by 15% to $43.88. The companys revenue growth is expected to slow, but remain in line with the industry average.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":8,"key_topics":["Revenue Miss","Loss Increase","Analyst Forecasts","Price Target","Industry Growth"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-negative","investment_amount":"N/A","structured_issues":["Investment"],"acquisition_amount":"N/A","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"bRSnpoPVsx65BTwRSZKHg5rBKuZ12rDg3lylW68bYKEKGB4n6hlK6K","news_summary":"UroGen Pharma Ltd. (NASDAQ:URGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$43.88","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"7iJEMHWtBOr0osudA6hY3cCTlIJCVWdrRBuO1WV16YMG0enI0V6MoN","date":"Aug 14, 2024","link":"https://www.businesswire.com/news/home/20240814480495/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"2Pn2lVMBzYgveluQBisseXMMrrTpHZ6tZ6tySbPlpSqoSz7RdBhXIz","news_summary":"UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"hlB0ztPcG3mcJEhHpAjf34vhx9p8QNK0S0wxXUxEjbwCFaZNHL4yt0","date":"Aug 13, 2024","link":"https://finance.yahoo.com/news/urogen-pharma-urgn-reports-q2-131503880.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Earnings Report","company":"Urogen Pharma","layoffs":"Not mentioned","summary":"Urogen Pharma reported a quarterly loss of $0.91 per share, which is worse than the Zacks Consensus Estimate of a loss of $0.82. This is also a larger loss compared to $1.03 per share a year ago. The companys revenues for the quarter ended June 2024 were $21.85 million, missing the Zacks Consensus Estimate by 7.76%. This is slightly higher compared to year-ago revenues of $21.14 million. Urogen Pharmas shares have lost about 3.3% since the beginning of the year. The companys future performance will depend on managements commentary on the earnings call.","partners":"Not mentioned","customers":"Not mentioned","investors":"Zacks Investment Research","confidence":8,"key_topics":["Earnings Report","Stock Performance","Revenue","Industry Outlook","Future Expectations"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-negative","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"vvdDPvkPGeMwtug7t1GMyVjuNdw1Hbakysj9kSeVk70efmfl06UB8j","news_summary":"Urogen Pharma (URGN) Reports Q2 Loss, Misses Revenue Estimates","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"4QdZwsqUiOyuAGH3T5kUQxE87ietQqJqXjx8hso0T0xpgCYeVgj847","date":"Aug 13, 2024","link":"https://www.businesswire.com/news/home/20240813598782/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"C5MTKsTAyavbpbNvtSYtPcs1KMoEsqLCbXdJwKoIHvrNFENLVr71Ko","news_summary":"UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"7Y20NLSzH5kTICYUTZM4MyTwi5XloHA7T5FNbOGB7ThWxBhqnO88UA","date":"Aug 7, 2024","link":"https://finance.yahoo.com/news/earnings-preview-precigen-inc-pgen-140017998.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Earnings Report, Stock Performance","company":"Precigen, Inc.","layoffs":"Not mentioned","summary":"Precigen, Inc. is expected to report a year-over-year decline in earnings and lower revenues for the quarter ended June 2024. The earnings report might impact the companys stock price depending on whether the key numbers are better or worse than expectations. The company is expected to post a quarterly loss of $0.09 per share, representing a year-over-year change of -12.5%. Revenues are expected to be $1.28 million, down 27.7% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 12.5% lower over the last 30 days.","partners":"Not mentioned","customers":"Not mentioned","investors":"Zacks Investment Research","confidence":8,"key_topics":"Earnings Report, Stock Performance, Revenue Decline, Earnings Expectations, Earnings Surprise","date_of_event":"Not specified","valuation_amount":"Not mentioned","impact_on_company":"growth-negative","investment_amount":"Not mentioned","structured_issues":"Investment, Management Changes","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment, Management Changes","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"MIZRL8DTBCaVlPAsugNqy96fY9R9s7uCJLSPaoHmmtabvsJPDfjON7","news_summary":"Earnings Preview: Precigen, Inc. (PGEN) Q2 Earnings Expected to Decline","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"c7CplsaIcRwVwqmZRHBmK0Gil2r8Qui5LpJq5JuVvVy5NDgFzwu2TS","date":"Aug 5, 2024","link":"https://www.businesswire.com/news/home/20240805414962/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"nUqhW7kviQV02yuHsEswTbkhyC971OoK6okAwX8mTCw5qRg8USIuY1","news_summary":"UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"d2tqBV3GAAMJkKtvDj7NTyRks5tpWYHF5PQzLY5kHMASUlTra6MLR7","date":"Aug 2, 2024","link":"https://finance.yahoo.com/news/does-urogen-pharma-urgn-potential-135506257.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Stocks, Investment, Price Targets","company":"Urogen Pharma","layoffs":"Not mentioned","summary":"Shares of Urogen Pharma (URGN) have seen a 5.4% increase over the past four weeks, closing the last trading session at $15.82. However, Wall Street analysts predict a potential upside of 171.1%, with a mean estimate of $42.88. This estimate comprises four short-term price targets ranging from $18 to $60. Analysts also agree that the company will report better earnings than previously estimated. Despite the potential for misleading investors, price targets are still highly sought after. URGN currently has a Zacks Rank #2 (Buy), indicating potential for further growth.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":"Stock Price, Price Targets, Earnings Estimates, Analysts Opinions, Investment","date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"SnAIfENWq3HPlgkxNJBf1UxqzIY9nWi5L7yfVEiCe0ZSf4O9bO7uwo","news_summary":"Does Urogen Pharma (URGN) Have the Potential to Rally 171.05% as Wall Street Analysts Expect?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"T4Dpejh7xrvMESj6gF1Tte1QyM5i4cBhvMDsVHOmJtlE2B47wQQmyG","date":"Aug 1, 2024","link":"https://finance.yahoo.com/news/urogen-pharma-urgn-expected-beat-140129664.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Earnings Report, Stock Performance","company":"Urogen Pharma","layoffs":"Not mentioned","summary":"Urogen Pharma is expected to post a year-over-year increase in earnings on higher revenues for the quarter ended June 2024. The companys earnings report could potentially impact its near-term stock price. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. The companys Earnings ESP is +4.66%, indicating that Urogen Pharma will most likely beat the consensus EPS estimate. However, investors are advised to pay attention to other factors too before making investment decisions.","partners":"Not mentioned","customers":"Not mentioned","investors":"Zacks Investment Research","confidence":8,"key_topics":["Earnings Report","Stock Performance","Revenue Increase","EPS Surprise","Zacks Rank"],"date_of_event":"Not specified","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"uaGrNwhBdnvyGB34ZdCPz1cPvOTrd5bbdeyQyOT3cwu90G3eTd2juL","news_summary":"Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"KrJ9fZuMWCixzRG0bJ2zjPoVVgJMKq6wbFrEVYHfnXoc1ZyHzQUwQP","date":"Jul 17, 2024","link":"https://finance.yahoo.com/news/wall-street-analysts-see-149-135509661.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Stock Analysis","company":"Urogen Pharma","layoffs":"N/A","summary":"Urogen Pharmas stock closed at $17.22 in the last trading session, marking a 2.1% gain over the past four weeks. Wall Street analysts have set short-term price targets for the stock, with a mean price target of $42.88, indicating a 149% upside potential. The targets range from $18 to $60. Analysts also predict the company will report better earnings than previously estimated. However, the article cautions against relying solely on these targets for investment decisions, as they can often be misleading. Urogen Pharma currently has a Zacks Rank #2 (Buy), indicating potential upside in the near term.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":8,"key_topics":["Stock Price","Analyst Predictions","Earnings Prospects","Investment Research","Price Targets"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Public Trading","acquisition_amount":"N/A","structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"9ZkvYvmw1zpaLnHqlzFiA71VA2BDSlsxTjZ6B7qLh7ZE7M0Ta4Znna","news_summary":"Wall Street Analysts See a 149.01% Upside in Urogen Pharma (URGN): Can the Stock Really Move This High?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"yYSxIldPVHBer6Dj7ALxohgrlybSoBv4hQ2lGnlDoq91jnO4WR4hhz","date":"Jun 27, 2024","link":"https://finance.yahoo.com/m/6ccb8047-2fa9-329b-8736-2f5eb3617bef/urogen-pharma-stock-earns-91.html","source":"finance.yahoo.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"OQeL4btnYL1FyuyPd876lwgZ3gKGsniOD22LH8P7a5RBwK2DQiNbw2","news_summary":"UroGen Pharma Stock Earns 91 RS Rating","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"cSHMFgLbPeHrdcVs4NqNz5WUxPgEXbBpV8AtdWw8TfY65SyOQQMSJy","date":"Jun 18, 2024","link":"https://www.businesswire.com/news/home/20240617926085/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"VAELHDoArsI5nwNLWFqPDf9Fj5HjtUI5skjbCbzcLYrqWthj5YN5W2","news_summary":"UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"6wydIPwpXvCamIJo0sgj11PfTWnrM0L2WMoIghSjodPRbn8e6t4XeC","date":"Jun 17, 2024","link":"https://www.businesswire.com/news/home/20240617926085/en/UroGen-Pharma-Announces-Pricing-of-Public-Offering-of-Ordinary-Shares-and-Pre-Funded-Warrants","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"U22lYRBIjh0AFYXuf3Cpbp4UEXmq8Q0SPEINuTCLpUrteqNlqVXmdg","news_summary":"UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"ybKXF2mX0LKjKjTcqOfdjPNb1GeJJ8A4YsFNFlktCY2PvkT7oN9tSy","date":"Jun 17, 2024","link":"https://finance.yahoo.com/news/urogen-pharma-urgn-surges-9-090000178.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Stock Performance, Clinical Trials","company":"Urogen Pharma","layoffs":"N/A","summary":"Urogen Pharmas shares rose by 9.7% in the last trading session, closing at $19.20. This increase was supported by a higher than usual volume of shares being traded. The company recently announced data from the phase III ENVISION study, which is evaluating UGN-102 as a potential non-surgical treatment for patients with low-grade intermediate-risk non-muscle invasive bladder cancer. The data showed an 82.3% 12-month duration of response in patients who achieved complete response at three months after the first instillation of UGN-102.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":8,"key_topics":["Stock Rise","Clinical Trial","UGN-102","Non-surgical Treatment","Bladder Cancer"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Investment"],"acquisition_amount":"N/A","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"nwRGSvHUWY04TQIOqDKIOcIgWnni9r17OMjgcQwrXAxv1Sq5BDQNNL","news_summary":"Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"M1DKiyd5h9PC5Tl8CIkFaeFamW93mEir3VdtNdr4c3EBEDtEaXS9Az","date":"Jun 17, 2024","link":"https://finance.yahoo.com/news/urogen-pharma-announces-commencement-public-204600136.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Public Trading, Investment","company":"UroGen Pharma Ltd.","layoffs":"N/A","summary":"UroGen Pharma Ltd. has announced the commencement of an underwritten public offering to issue and sell its ordinary shares and pre-funded warrants. The biotech company, which focuses on developing and commercializing solutions for urothelial and specialty cancers, will also grant underwriters a 30-day option to purchase up to an additional 15% of the total number of ordinary shares offered in the public offering. The offering is subject to market and other conditions, and there is no assurance as to when or if the offering will be completed.","partners":"TD Cowen, Guggenheim Securities, Oppenheimer & Co., Ladenburg Thalmann","customers":"N/A","investors":["TD Cowen","Guggenheim Securities","Oppenheimer & Co.","Ladenburg Thalmann"],"confidence":9,"key_topics":["Public Offering","Biotech","Cancer Treatment","Investment","Securities"],"date_of_event":"June 17, 2024","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Public Trading","Investment"],"acquisition_amount":"N/A","structuredIssuesShow":"#Public Trading  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"78VozhZ3NzdbmPSRJTWOX61yu1nbIEtKrC9RuKXNZh0iMVeOMhrmQr","news_summary":"UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"yrvmq9KbHcf4OXo5cTuNro200ABlCQJmRrMKN2DNrlQ7E1BEyLSLxH","date":"Jun 13, 2024","link":"https://www.businesswire.com/news/home/20240613476477/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"pjVHeGg9kD33PUay3XYRAw5khPR7USaZC6XPtWtfy7tYBBh7kBS3Q7","news_summary":"UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"oquIWXuwGZStr148wIBDE2Yj82BINlUodUU2NO3B30t1xXcGpJVvqP","date":"Jun 13, 2024","link":"https://finance.yahoo.com/m/ee43f3f9-46ff-3b36-b7f8-fcb3c31e23ee/urogen-catapults-on.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Drug Development","company":"UroGen","layoffs":"Not mentioned","summary":"UroGens stock value increased significantly due to unprecedented test results for its bladder cancer treatment. The drug, which is gel-based, provides an alternative to surgery.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":["Cancer Drug","Test Results"],"date_of_event":"Thu, Jun 13, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"8EBN024iBDAOXKNzPbx3gRWPtTmg8d6zpBVZb2uuhMTXbQhBtrQEaA","news_summary":"UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9TANuChEomhddcl0ot6SBlXFkOTUvAQQYv1yB9GAs1EydTJNAWEKfu","date":"Jun 7, 2024","link":"https://www.businesswire.com/news/home/20240607623862/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"qPtqGts0P4NcLD2n36ozQsCQujZqgPHLNm7NpPUxGM5zZL3ZaoOGP5","news_summary":"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"csDG5go1k0Cu2XfOEjODn7hRWAArpgrzsvnMbsYTEissImaQjUbV4i","date":"Jun 6, 2024","link":"https://www.businesswire.com/news/home/20240606674853/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"w3RNenpxowixl5JRbIXl8C3lIP3Q5dGytx9jHb1nxEpIT1DlKT85Lx","news_summary":"UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"6gXqX59h0SOlQuauuk2slBHTIqeObqbIrESdD6O3KXfpfvLglxlCZB","date":"Jun 5, 2024","link":"https://www.businesswire.com/news/home/20240605807048/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"qeC5lb98qLyHDAiHiEIqSleuRvunXOfEtgi1KzBZPfcgmWAc4omdjq","news_summary":"UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"hbOtt3Tsj4HulwnO62cQAF2dl0d9u4UpMjTwdzg7IcjmB1LRgc7adP","date":"Jun 3, 2024","link":"https://www.businesswire.com/news/home/20240603331264/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"8plsAWrc4M9fhOiNbBHrBbi2PAjS4FPFDDyiszzXvmMECe9UmOO8Ms","news_summary":"UroGen Pharma Appoints David Lin as New Chief Commercial Officer","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"VDj30RA5nRfIGKWHpytXiABPW3WzkOApn3ZUBBSgcaVOTwDtJ7kAyQ","date":"May 22, 2024","link":"https://www.businesswire.com/news/home/20240522560591/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"cNDk0Aks0felOi16ZJlvdJLjld4o9iqUu7snGHJPXeKlF3GmXGKiDN","news_summary":"UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"9jK4SJMaAh1tTg9A8czadk3tHk8sVLPULveiKElRY8nC7PMnwKmFEG","date":"May 14, 2024","link":"https://finance.yahoo.com/news/urogen-pharma-first-quarter-2024-103121845.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Results, Revenue Miss","company":"UroGen Pharma","layoffs":"NA","summary":"UroGen Pharma reported its Q1 2024 results, with revenue of $18.8m, up 9.2% from Q1 2023, and a net loss of $32.3m, a widening of 6.9% from Q1 2023. However, the companys revenue and earnings per share (EPS) missed analyst estimates by 12% and 9.3% respectively. Looking ahead, the companys revenue is forecast to grow 35% p.a. on average over the next three years, compared to an 18% growth forecast for the US biotech industry. The companys shares are down 5.6% from a week ago.","partners":"NA","customers":"NA","investors":"NA","confidence":9,"key_topics":["Revenue","Net Loss","EPS","Growth Forecast","Risk Analysis"],"date_of_event":"First Quarter 2024","valuation_amount":"NA","impact_on_company":"Growth-Negative","investment_amount":"NA","structured_issues":["Customers"],"acquisition_amount":"NA","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"Growth-Negative","analysisId":"7nwjdYNyP2v7nO5FsZBheJlX3uDvhYWSCdxYh7wRvmsbtUjz2449QW","news_summary":"UroGen Pharma First Quarter 2024 Earnings: Misses Expectations","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"j5dK7VwPJx78jqcAGsbb6YB2aATq2kZkC4CtxBXW1dn8iEEgoV4U4f","date":"May 13, 2024","link":"https://www.businesswire.com/news/home/20240513271801/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"CPLcQalUaLqxLMUgzUJIknugKBjnNRWsWUkPiAqOPsmmkF5IGNjQgK","news_summary":"UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"hWm4NTVta4uHFJnOnqAOjpgZusm4HVLRzxbqvMvO48i0wY10MygwU7","date":"May 13, 2024","link":"https://finance.yahoo.com/news/urogen-pharma-ltd-urgn-q1-133213252.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Report, Biotech","company":"UroGen Pharma Ltd","layoffs":"Not mentioned","summary":"UroGen Pharma Ltd reported Q1 2024 revenue of $18.8 million, up from $17.2 million in Q1 2023, but fell short of the estimated $21.38 million. The net loss increased to $32.3 million from $30.2 million, exceeding the estimated net loss of $30.26 million. R&D expenses rose to $15.5 million from $12.5 million, reflecting ongoing investment in product development. The company reiterated full-year revenue guidance for JELMYTO between $95 million and $102 million. UroGen is preparing for the potential launch of UGN-102, targeting a market opportunity exceeding $3 billion.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Q1 2024 Earnings","Revenue","Net Loss","R&D Expenses","Financial Guidance"],"date_of_event":"May 13, 2024","valuation_amount":"Not mentioned","impact_on_company":"Growth-Negative","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"Growth-Negative","analysisId":"Xn5whbOzeU0EAMiliipozzK37DLWmEvC7l7qZbpMuoBWi0RXa4QPgF","news_summary":"UroGen Pharma Ltd (URGN) Q1 2024 Earnings: Misses EPS Estimates, Revenue Slightly Above Expectations","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"EpDT1kDd4RghmPlKeX2alj0PN5Y3azkchMTviyz1x6fPgSaYoFxE1u","date":"May 12, 2024","link":"https://finance.yahoo.com/news/shareholders-urogen-pharma-nasdaq-urgn-133814307.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Stock Performance, Revenue Growth","company":"UroGen Pharma Ltd.","layoffs":"Not mentioned","summary":"UroGen Pharma Ltd.s share price has dropped 67% in the last five years, with a 34% drop in the last three months alone. Despite this, the company has seen its revenue grow at 58% per year over the same period, a rate well above most other pre-profit companies. However, the share price has averaged a loss of 11% per year. Despite a total return of 5.7% during the last year, this falls short of the market average. The company is not currently profitable.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":["Share Price Drop","Revenue Growth","Investment Risk","Market Conditions","Business Performance"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"Growth-Negative","investment_amount":"Not mentioned","structured_issues":["Customers"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"Growth-Negative","analysisId":"2l6II5c4Fhc40SlnqhjZPFN8uB7V4BrBg6wgBppBBocGs9FcnyXDt0","news_summary":"Shareholders in UroGen Pharma (NASDAQ:URGN) have lost 67%, as stock drops 11% this past week","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ojGUBy7AlMBwfCFo3qxxtsXZvZUIQDWJHNAIjtkPA4xSSkVvWD5hkL","date":"May 7, 2024","link":"https://www.businesswire.com/news/home/20240507449972/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"RzlzTQZyIe6VBRwRiVf3KeURG5XMJv9VC5PIBdYDXkwHyF8WFazxkO","news_summary":"UroGen Pharma to Participate at Upcoming Investor Conferences","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"paplp3x1NJI9Hw3S7ymDLqaIYddgJFHLuZ2LNlrAiRzd6BBZjudYDr","date":"May 5, 2024","link":"https://www.businesswire.com/news/home/20240505867534/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"jyWMAd96RQDNOQJTWZfUXb4M0RS17Rv222xww6yXbOVMO6SgQdqP71","news_summary":"New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"HUgMjnBqlBL84DtIbym7PSFz81CY7r3loMGjkY8dBXADIQEwbVG7nJ","date":"May 4, 2024","link":"https://www.businesswire.com/news/home/20240504905017/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"IhZbJbZTax28lXC5rXiRnBULDjIBbmFygMauPgHsxuNGeWiypaNRph","news_summary":"New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"Unc4thlW7CT1hpoAgupv9AnUlmFOdD9NWX88LblmSRT1tv7G1GmlSq","date":"May 4, 2024","link":"https://www.businesswire.com/news/home/20240504411697/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"z7KA5mvJMHX1TCqNNDgLnzC8mKOhkvNNlpcJK1NQxD545LXVDrZobH","news_summary":"UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"OHO0Fa10QaYuIu8V63Pzzwl1CiZ9YDygrfZdRWfWtDxYCEhn0H1bZH","date":"May 3, 2024","link":"https://www.businesswire.com/news/home/20240503850056/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"OoBAyxfKrJiQYt3NjPW1AEUw03TBialtRlNspQQD0QIKDHqtwiQCa9","news_summary":"UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"P4SSr86njVQp2XFUv5reWiTZm92TsU24ajJIBFUK9I6FW4bwN0rcSY","date":"Apr 22, 2024","link":"https://finance.yahoo.com/news/pharming-group-phar-surges-7-092900543.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Stock Performance, Earnings Expectations","company":"Pharming Group N.V. Sponsored ADR","layoffs":"N/A","summary":"Pharming Group N.V. Sponsored ADRs shares rose by 7.2% at the end of the last trading session, a significant increase compared to the stocks 15.2% loss over the past four weeks. This rise is attributed to positive investor expectations for the companys approved products in the upcoming Q1 2024 earnings release. The company is also expanding the eligible patient population for its product, Joenja. The company is expected to post quarterly earnings of $0.01 per share, a year-over-year change of +105.9%, and revenues of $68.43 million, up 60.9% from the year-ago quarter.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":8,"key_topics":["Stock Jump","Earnings Release","Product Expansion","Earnings Estimate","Industry Comparison"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"3aC43odydFaB2S6JjIqoZb5Sf7sShgXylHgzoNpdbBL4jtpRIz1Syt","news_summary":"Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"0vFTu5kRh1Zy7bEEPf97gzPaYLZehEDPr1WLXOJBBeeXd2iG2Yxsbf","date":"Apr 17, 2024","link":"https://www.businesswire.com/news/home/20240417923260/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"YuNkAeDlLVi58f1Renn1upMFm0swTBlAxXOH6hL5WgyetDNrQupEfS","news_summary":"UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"mwqXylY6C3Gj3rulRM0xwglqXE8TTxRP60EUvXfEfrF5AiCb2bQI0h","date":"Apr 15, 2024","link":"https://www.businesswire.com/news/home/20240415706532/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"gE5XWI5nrSwjhAg14qcqv2PDfC4TVVXXWArAFGaO1wmMlfcSE0slh2","news_summary":"UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"wnD6IOHog5XXJNMZf0JBBhWk1ltZ5BGKXITmphKp2m814X4HOrh6Lo","date":"Apr 14, 2024","link":"https://finance.yahoo.com/news/urogen-pharma-ltd-nasdaq-urgn-142612147.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Institutional Ownership, Stock Price","company":"UroGen Pharma","layoffs":"Not mentioned","summary":"Institutions hold a significant stake in UroGen Pharma, with the top 9 shareholders owning 50% of the company. This has a substantial influence on the companys share price. Recently, the companys stock price gained 11%, benefiting these institutional investors. However, insiders have been selling lately. The largest shareholder is RA Capital Management, L.P. with 9.0% of shares, followed by Great Point Partners, LLC and Menora Mivtachim Pensions & Gemel Ltd. The companys CEO, Elizabeth Barrett, directly holds 1.0% of the total shares. Private equity firms hold a 17% stake in UroGen Pharma.","partners":"Not mentioned","customers":"Not mentioned","investors":["RA Capital Management, L.P.","Great Point Partners, LLC","Menora Mivtachim Pensions & Gemel Ltd."],"confidence":8,"key_topics":["Institutional Ownership","Stock Price Increase","Insider Selling","Private Equity Ownership","Shareholder Influence"],"date_of_event":"Not specified","valuation_amount":"US$515m","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"O54ChxvShWDEW0KKAVP4uEJiQtOnEayAMJQkeI7oamvFBTU8kXKwRW","news_summary":"UroGen Pharma Ltd.'s (NASDAQ:URGN) high institutional ownership speaks for itself as stock continues to impress, up 11% over last week","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"I32uhy6JagDPQJvv7DL3Zacv5K59n4fHxRaLArEy4JvjWYWF4kv4pA","date":"Apr 3, 2024","link":"https://www.businesswire.com/news/home/20240403581964/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"BwYfhSbBY4Xb1FLVPnOKdl4Xh2kY8MwDzmpLlyD2y5D2KuP8r5AIWv","news_summary":"UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"5qCyK64ZG6cJuAx7cFcaWb25KGtWTCuAlyg1mnCuveozO2yl9fnpIE","date":"Mar 17, 2024","link":"https://finance.yahoo.com/news/urogen-pharma-full-2023-earnings-125548919.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Results, Revenue Growth","company":"UroGen Pharma","layoffs":"Not mentioned","summary":"UroGen Pharma has reported its full year 2023 results, with a revenue of US$82.7m, up 28% from FY 2022. The companys net loss narrowed by 6.9% to US$102.2m, and loss per share improved from US$4.81 in FY 2022 to US$3.55. The companys revenue exceeded analyst estimates by 1.2%, and its EPS was mostly in line with estimates. The companys shares are down 20% from a week ago. Looking ahead, revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":"Revenue, Net Loss, EPS, Biotechnology, Risk Analysis","date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":"Customers","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"SPUAl67KiIUYyXLZVq3Gcf940EKCjehqeFIrMzXA6FBeikpFG3no1E","news_summary":"UroGen Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"gKEqsbAJLNIz7ZAB5NCsMZhDdqjf1VLw6Sk0UFN4UKfqIU0nr99GDf","date":"Mar 15, 2024","link":"https://finance.yahoo.com/news/urogen-pharma-ltd-nasdaq-urgn-143021200.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Earnings Call, Financial Results, Product Development","company":"UroGen Pharma Ltd.","layoffs":"Not mentioned","summary":"UroGen Pharma Ltd. reported its Q4 2023 earnings, highlighting a successful year with progress and growth. The companys lead development candidate, UGN-102, met its primary endpoints in the Phase III ATLAS and ENVISION trials. UroGens existing commercial product, JELMYTO, continues to see double-digit growth. The company also announced an expanded partnership with Pharmakon Advisors, providing additional funding of up to $100 million. UroGen expects to have the capital to execute a comprehensive launch for UGN-102, if approved, and fund potential new clinical studies.","partners":"Pharmakon Advisors, medac","customers":"Not mentioned","investors":"Pharmakon Advisors","confidence":9,"key_topics":["Earnings Call","UGN-102","JELMYTO","Financial Results","Product Development"],"date_of_event":"March 14, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$100 million","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"GIyblonxqOK9ZAwZnCWxKoGGBpPvRjuQIiNQvTJMQmg10QQkSBCxCK","news_summary":"UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call Transcript","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"b7TUo67OFGRcnDh5sIlJjbfiKDm0g8vjit8dBVayTbJP4wATPBvhnG","date":"Mar 14, 2024","link":"https://finance.yahoo.com/news/urogen-pharma-ltd-urgn-reports-133209722.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Performance","company":"UroGen Pharma Ltd","layoffs":"Not mentioned","summary":"UroGen Pharma Ltd reported a significant growth in its JELMYTO product revenues for Q4 2023, reaching $23.5 million, up from $18.1 million in the same period last year. The companys full year 2023 net revenues also increased to $82.7 million, a rise from $64.4 million in 2022. Despite this growth, the company faced challenges with higher than expected 340B chargebacks and estimated Medicare refunds for discarded drugs. The companys net loss narrowed to $26.0 million in Q4 2023, compared to a net loss of $28.9 million in Q4 2022. As of December 31, 2023, the companys liquidity position remains strong, with cash, cash equivalents, and marketable securities totaling $141.5 million.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Revenue Growth","Net Loss Improvement","Research and Development","Liquidity Position","Financial Challenges"],"date_of_event":"March 14, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"vE0eYbNTRnVFCHWz4SycAbz5Ljj7rxmEv96Z6OtC5ufcaJeLvSmlxh","news_summary":"UroGen Pharma Ltd (URGN) Reports Solid JELMYTO Growth Amidst Financial Challenges","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"AB2tiC4Jsd92M1N9EEhCRl6ewcEklzzK2CD3bveOtL74bsQoQhMqJ7","date":"Mar 14, 2024","link":"https://finance.yahoo.com/news/urogen-pharma-urgn-reports-q4-131002410.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Earnings Report, Stock Performance","company":"Urogen Pharma","layoffs":"Not mentioned","summary":"Urogen Pharma reported a quarterly loss of $0.72 per share, which is higher than the expected loss of $0.67 per share. However, the companys revenues for the quarter ending December 2023 were $23.53 million, surpassing the Zacks Consensus Estimate by 5.52%. This is an increase from the previous years revenues of $18.09 million. Despite the loss, Urogen Pharmas shares have increased by about 16.5% since the beginning of the year. The companys future performance will depend on managements commentary on the earnings call and the companys earnings outlook.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":"Quarterly Loss, Stock Performance, Earnings Surprise, Revenue Increase, Future Expectations","date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"Growth-Negative","investment_amount":"Not mentioned","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"Growth-Negative","analysisId":"apBkTdxMXCZLvEORQekURw7508jkilrzzoHC0urc4VVqDcwb0yregm","news_summary":"Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"DQDwCBNukiEGuKMZojNSau1xfVStcWHTaEJUlU2kjactdpFaPt6W4x","date":"Mar 14, 2024","link":"https://www.businesswire.com/news/home/20240314112098/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"jXamD7OADwwqD6FDhGcvsHjFGHDWbYxyvcL1kvnFZsrbNwsdcPVCCV","news_summary":"UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"iCCOr4KlkMMHt5AUp4JxIZ8i7DBCay6k6yGWFJJ5gKSpK8pDo1Fdft","date":"Mar 8, 2024","link":"https://www.businesswire.com/news/home/20240308154847/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"KjOhFa4Zlzyw8lojrNUtVspBnAAzU02owAKN5UvSPeDDRdpYi8nIim","news_summary":"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"qlZIrBeDgEW7tyVeAUep5MQp9vIdUeKQi6nPEY8YkWE1x0HGp3hrUN","date":"Mar 4, 2024","link":"https://www.businesswire.com/news/home/20240304990376/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"XaluWfX4fXLzmCoheeKd8IwcAm40zs72a179tYMVBMNOeQljpcKP0l","news_summary":"UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"ZNtX7imq0DLm5ukXZPkj5i109sBpytIx7bsMJBrVvaJAxSA3Z9uXXp","date":"Feb 26, 2024","link":"https://www.businesswire.com/news/home/20240226631566/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"W4XqwjCGF5cR0Qp67lKqNanWbHZ1CBkXRzbALtFbYf1Y9xkOhRGC4B","news_summary":"UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"JAlc4t1qwPnUofkEhPzC9UH8WxNytQltOxhadodc5KPNkh9he65Lol","date":"Feb 23, 2024","link":"https://finance.yahoo.com/news/nurix-therapeutics-inc-nrix-surges-112000670.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Stock Performance, Earnings Forecast","company":"Nurix Therapeutics, Inc.","layoffs":"Not mentioned","summary":"Shares of Nurix Therapeutics, Inc. (NRIX) rose by 5.1% in the last trading session, with a higher-than-average number of shares changing hands. This follows a 29.2% gain over the past four weeks. The rally is driven by growing optimism over the drug biotech sector in 2024. The company is expected to post a quarterly loss of $0.83 per share in its upcoming report, a year-over-year change of -10.7%. However, revenues are expected to be $14.28 million, up 12.5% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 2.2% higher over the last 30 days.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":["Stock Rally","Earnings Estimate","Revenue Growth","Biotech Sector","Zacks Rank"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"aFFu2KeId8F1IEa3cDgLk34Zl519Qwn6BcDap1PfvoeshTqHFT9oRj","news_summary":"Nurix Therapeutics, Inc. (NRIX) Surges 5.1%: Is This an Indication of Further Gains?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"0Q6dqK1MXbZioVjr8DToEa6wJX3hWNkwyiAMVqtfxJx2aXR7AUD5wB","date":"Feb 1, 2024","link":"https://www.businesswire.com/news/home/20240201163986/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"BRGAoCZ8nsyTC3v4CqLoVkCQmWSF3Pgy7uCLUPEErKPt0ADTHoZnRT","news_summary":"UroGen Pharma to Participate at Upcoming Investor Conferences","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"me4tOcN9qDR8cBzs1LD07EUsLTIx1DINEUoatMUA6hFmhb1gM8ZSXH","date":"Jan 24, 2024","link":"https://www.businesswire.com/news/home/20240124917135/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"IgBVJ3vXHV2rroaHpgF7p7bQFGM7ID5fZzzdhld8ApNtbqrownZsfb","news_summary":"UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"TztxufqnfIxMIvscT3tf9LaYPrnsDtX1GKOT7zTVrj829fOEkm8xu0","date":"Jan 17, 2024","link":"https://www.businesswire.com/news/home/20240117582883/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"CpoqOdg7V05iTeTBsUPw2CHNjHzf3BhYpJLt2D4QMtmxUo8xp93kau","news_summary":"UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"lZ3cm3hsBfc4m0HCLvDfrgrqqKeCXEALSWPIqE4HtMiScA0OxrpJzs","date":"Jan 11, 2024","link":"https://www.businesswire.com/news/home/20240111451437/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"MBSdoqpBcGvZcpNnZUkh5rGzw2UHmqGHqe5nArTkO9mXa9jas0euP9","news_summary":"UroGen Pharma to Participate in the B. Riley Healthcare Conference","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"A5Hd06q5m0ssOSFhYFLKucsrgn24fXB09BfSjMUl4PN82dMafayxsj","date":"Dec 8, 2023","link":"https://www.businesswire.com/news/home/20231208128226/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"MfzlNyv4LXLgb8NtggQB94sg52LOvT2SDVilKFN75NJsHUuN1FhImt","news_summary":"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"4R7ArFdbJUjXc9XhNBEGTipjwb8cx84j5gvAm6SjbDEHYpoSUyHWX3","date":"Nov 27, 2023","link":"https://finance.yahoo.com/news/shareholders-urogen-pharma-nasdaq-urgn-124256306.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Stock Performance","company":"UroGen Pharma Ltd.","layoffs":"N/A","summary":"UroGen Pharma Ltd.s share price has risen by 17% in the last month, however, it is still down by 73% over the last five years. Despite this, the company has seen its revenue grow by 62% per year over the same period. This growth is significantly higher than most other pre-profit companies. The recent increase in share price could indicate a positive turning point for the business, but potential investors are advised to look closely at the companys balance sheet strength.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":8,"key_topics":["Share Price","Revenue Growth","Balance Sheet","Total Shareholder Return","Warning Signs"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Public Trading","acquisition_amount":"N/A","structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"HVraQyiGlgruaDT5M8QQuCe8WsHbQCDziubKzA29O6kZ30CERr5OSl","news_summary":"Shareholders in UroGen Pharma (NASDAQ:URGN) are in the red if they invested five years ago","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"e3RukAQ9vsJQVN5UtkfHnVAQbHpZbnfTnKCZkmPitdEAsRHU26XhDJ","date":"Nov 15, 2023","link":"https://finance.yahoo.com/news/urogen-pharma-ltd-nasdaq-urgn-185043158.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Earnings Call, Financial Results","company":"UroGen Pharma Ltd.","layoffs":"Not mentioned","summary":"UroGen Pharma Ltd. held its Q3 2023 earnings call, reporting strong financial results and significant progress in its clinical trials. The company reported $20.9 million in JELMYTO net revenues, a 30% increase year-over-year. UroGen also closed a $120 million private placement during the quarter, significantly strengthening its balance sheet. The companys UGN-102, a potential treatment for low-grade intermediate-risk nonmuscle-invasive bladder cancer, showed promising results in Phase III clinical trials. If approved, UGN-102 could become a major growth driver for UroGen, with a potential market in the U.S. exceeding $3 billion.","partners":"Not mentioned","customers":"Not mentioned","investors":"RTW Investments, Pharmakon Advisors","confidence":9,"key_topics":["UGN-102","JELMYTO","Earnings","Investment","Clinical Trials"],"date_of_event":"November 14, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$120 million","structured_issues":["Customers","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"MenH3UO3nIsUidu9Gp1raHEq9myy2xqsbZuEveIEkNsikBpNBexKe9","news_summary":"UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2023 Earnings Call Transcript","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Qoxm3HFsJVjqD7bk7Xs3I5NfYK1FUQOYvNbZlEKRRJhS9gEWVpBI6t","date":"Nov 14, 2023","link":"https://www.businesswire.com/news/home/20231114806402/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"sLF0i3KMthA8z6IcwERTAIbarEtHCiDcZRYnG5PSs9mrPxbUlbydbH","news_summary":"UroGen Pharma Reports Third Quarter 2023 Financial Results","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"cjv6o8JGP3UYvy2AasSa8sZnA0H1fNnkJEaiHN3qSCIIhrNI3i2koW","date":"Nov 14, 2023","link":"https://finance.yahoo.com/news/urogen-pharma-ltd-urgn-reports-171930638.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Results, Clinical Trials","company":"UroGen Pharma Ltd","layoffs":"Not mentioned","summary":"UroGen Pharma Ltd has reported a 29.8% increase in net product revenue from JELMYTO in Q3 2023 compared to Q3 2022. The companys net loss improved to $21.9 million in Q3 2023, down from $25.8 million in Q3 2022. UroGen also highlighted significant milestones in its clinical development, particularly the positive results from the ENVISION and ATLAS Phase 3 trials of UGN-102 for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer. The company reiterated its full-year 2023 guidance, expecting net product revenues from JELMYTO to be in the range of $76 to $86 million.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Revenue Increase","Net Loss Improvement","Clinical Trial Progress","Financial Guidance","Product Approvals"],"date_of_event":"November 14, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Dv9DZxYO7ykpRMg8DJ2wUSf5inl28ugAYBbLAKVq842gqt98rTIw9M","news_summary":"UroGen Pharma Ltd (URGN) Reports Growth in Q3 Revenue and Progress in Clinical Trials","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"K9EO9hMD9f0S3sSxZHF1rdddTRnlteaUj0IjeRc20Tr1rhTozSU1hF","date":"Nov 13, 2023","link":"https://www.businesswire.com/news/home/20231113669672/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"CQzdsHw5LmO6ARhDyFLVyAbUu31io1WE5lY9xFnypaWMVWmrlk3iLl","news_summary":"UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"kidgr38dppXbeDbCfj8shv15hxKzKcpBg1sYfA1xYqjIAEE6hUjQea","date":"Nov 7, 2023","link":"https://www.businesswire.com/news/home/20231107012900/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"zTxFZDD3psJBKn1Q31GExXgFZhCHuuXCXzaVbmx8U8amj2FZoOyzRz","news_summary":"UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"FANgTa3HbzhoprEdkEsNyj3RW1cCVJFSRNXPR68yd0ORgwhECTcojL","date":"Oct 30, 2023","link":"https://finance.yahoo.com/news/institutional-investors-own-significant-stake-111238004.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Ownership Structure, Institutional Investment","company":"UroGen Pharma Ltd.","layoffs":"Not mentioned","summary":"Institutions hold a significant stake in UroGen Pharma Ltd., with the top 13 shareholders controlling 51% of the business. The largest shareholder is Menora Mivtachim Pensions & Gemel Ltd., owning 8.2% of the shares. The companys CEO, Elizabeth Barrett, owns 1.1% of the shares. Private equity firms hold a 13% stake in UroGen Pharma. The general public, primarily individual investors, hold a 30% stake in the company. The substantial institutional ownership suggests credibility among professional investors.","partners":"Not mentioned","customers":"Not mentioned","investors":"Menora Mivtachim Pensions & Gemel Ltd.","confidence":9,"key_topics":["Institutional Ownership","Shareholder Structure","Investment","Private Equity","Insider Ownership"],"date_of_event":"Not specified","valuation_amount":"US$341m","impact_on_company":"Neutral","investment_amount":"Not mentioned","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"none;"},"sentiment":"Neutral","analysisId":"bPLQ9iIXDK963NXjRvzM60O3dWjIOXTNMfEtDjjtq5rDRBIAKys4oU","news_summary":"Institutional investors own a significant stake of 50% in UroGen Pharma Ltd. (NASDAQ:URGN)","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"n8FY1zQwuPbfkcmZJT335exxYLKhePaXUdOeUDLf1lQuSCFWZbd6h6","date":"Oct 3, 2023","link":"https://www.businesswire.com/news/home/20231003915532/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"yQAAZtNBdoPRajH3spCzSpHQllzgtp8CQ0DNGxj6LWHLcJFXJvmWAt","news_summary":"Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"9wR75PL0JYw0B6xx9vc23m8PC6GJXEaLWyRWShtZAK8WZoEJ8LZEa5","date":"Sep 8, 2023","link":"https://www.businesswire.com/news/home/20230908931196/en/","source":"www.businesswire.com","visible":1,"analysis":{"tags":"Employee Inducement, Stock Options","company":"UroGen Pharma Ltd.","layoffs":"N/A","summary":"UroGen Pharma Ltd., a biotech company focused on urothelial and specialty cancers, has announced the grant of inducement restricted stock units (RSUs) to 11 new employees and options to one new employee. These new team members will support the commercial launch of Jelmyto, UroGens first approved product, and the continued development of the companys pipeline. The RSUs and options will vest equally over three years, subject to the employees continued service with UroGen. The companys sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, potentially making local therapy a more effective treatment option.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["New Employees","Stock Options","Product Launch","Pipeline Development","Company Growth"],"date_of_event":"September 08, 2023","valuation_amount":"N/A","impact_on_company":"Growth-Positive","investment_amount":"N/A","structured_issues":["Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"4ayTMjEUGQT0x3gSDCQTftfIPu6ViRxWv3wbYs5oF1dLZ9OlgLAM0d","news_summary":"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"k1MOdBBpZEFE0r0x99VwnAZKD1fYnAsyEwMEOQCbTCvSAkwW1VgbGu","date":"Aug 31, 2023","link":"https://www.businesswire.com/news/home/20230831174677/en/","source":"www.businesswire.com","visible":1,"analysis":{"tags":"investor conferences","company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. will be presenting at two investor conferences in September. The company is dedicated to developing and commercializing solutions for urothelial and specialty cancers. They have developed a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGens products include JELMYTO® for pyelocalyceal solution and investigational treatment UGN-102 for intravesical solution for patients with low-grade non-muscle invasive bladder cancer. The investor conferences will be available via webcast on UroGens website.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["investor conferences","biotech company","novel solutions","urothelial and specialty cancers","webcasts"],"date_of_event":"August 31, 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cBosrZHXGzuhRQGdzTwoOeaSQO1P5GSmeW6RKzM3akDawqU3SfBs6g","news_summary":"UroGen Pharma to Present at Upcoming Investor Conferences","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"LfCVm8rEPDBrHhRVyVVVjrudJLSt1ktlJDERPllJAWuhSEFuCnckz8","date":"Aug 18, 2023","link":"https://finance.yahoo.com/news/urogen-pharma-urgn-stock-surges-174000057.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial results","company":"UroGen Pharma","layoffs":null,"summary":"UroGen Pharmas stock has surged 89.2% in the past month following positive data from two phase III studies evaluating UGN-102, a treatment for bladder cancer. The studies met their primary endpoints, showing the superiority of UGN-102 over the current standard of care. UroGen plans to file a new drug application with the FDA in 2024. If approved, UGN-102 will be the companys second marketed product. UroGen recently completed a private placement of shares and warrants to fund its operations.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["UGN-102","ATLAS study","ENVISION study","FDA approval","non-surgical treatment"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$120 million","structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ZQxA3TVdh6LovmGlkVlRug5b6Lsj79fuw5Qb9RaLUHrqq663OjDtCK","news_summary":"UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"JhZFeaLkphrux7YLZGAcPYQntQHaFgKoSZEskP01Ec5F6I5LMrDoKX","date":"Aug 17, 2023","link":"https://finance.yahoo.com/m/c0742d54-e448-32cd-970b-9451541ae848/new-treatment-for-bladder.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"new treatment, bladder cancer","company":"UroGen Pharma","layoffs":null,"summary":"UroGen Pharma, a biotech company, is seeking investor interest after its first approved drug faced commercial challenges. The company recently announced positive results from trials of its reformulated chemotherapy drug for bladder cancer patients. The drug outperformed the standard treatment in a specific patient subset. UroGen Pharma plans to gather more data on the drugs durability of response and submit it for FDA approval next year.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["UroGen Pharma","bladder cancer","drug reformulation","late-stage trials","FDA approval"],"date_of_event":"July","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"1AdBMQofeF5cnsl5ihhC0fajQoBeVCWSC8BPA2Zt8zMCMtc45rylAW","news_summary":"New Treatment for Bladder Cancer Offers This Biotech a Second Chance","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"bpDUdCe6w4p5tIlxeJoHhKmZFZJvyqFRY5wFDYbUOq147P0m1BDhjM","date":"Aug 12, 2023","link":"https://finance.yahoo.com/news/urogen-pharma-ltd-nasdaq-urgn-131835358.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Earnings Call, Clinical Trials, Financial Results","company":"UroGen Pharma Ltd.","layoffs":"Not mentioned","summary":"UroGen Pharma Ltd. reported its Q2 2023 earnings, beating expectations with a reported EPS of $-1.03 against expectations of $-1.13. The company also announced positive results from two Phase 3 clinical trials for UGN-102, a treatment for low grade intermediate risk non-muscle invasive bladder cancer. UroGen also reported record net revenues of $21.1 million for JELMYTO, a 27% increase from the same quarter the previous year. The company recently raised $120 million in a private placement of ordinary shares.","partners":"Not mentioned","customers":"Not mentioned","investors":"High quality biotech investors","confidence":9,"key_topics":["Earnings Report","Clinical Trials","Investment","Expansion","Financial Results"],"date_of_event":"August 10, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$120 million","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"KycQWOOlBOxloBeLNBzpz4d9hv4QboEUgpYujSS9hN4JcJZGuXfifK","news_summary":"UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2023 Earnings Call Transcript","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"d2WVI8d8IWoL76LGMSRVqdz0MpxIWO2tslwk4JitV9T70w3nwhkGOE","date":"Aug 10, 2023","link":"https://www.businesswire.com/news/home/20230810124339/en/","source":"www.businesswire.com","visible":1,"analysis":{"tags":"Clinical Trials, Financial Results","company":"UroGen Pharma Ltd.","layoffs":"Not mentioned","summary":"UroGen Pharma Ltd. has announced positive results from its ENVISION and ATLAS Phase 3 trials of UGN-102 in treating low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC). The company also reported record JELMYTO net product revenues in Q2 2023 of $21.1 million, a 27% increase from the same period last year. UroGen has also strengthened its balance sheet with a $120 million private placement of ordinary shares and pre-funded warrants. The company anticipates submitting a New Drug Application (NDA) for UGN-102 in 2024.","partners":"Not mentioned","customers":"Not mentioned","investors":"select group of biotech investors","confidence":9,"key_topics":["Clinical Trials","Financial Results","Investment","Expansion","Product Launch"],"date_of_event":"August 10, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$120 million","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"OwdBXJSL0GY9tg89W8GOvUg3d4s5y90SPVaWMDu8a6MrPkbnPmNG37","news_summary":"UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"dOfm1ffuprmkRFBvvJUqFfxgJ3FMaKq8oZRnUfctfnCAQ8wTgHE4FC","date":"Aug 10, 2023","link":"https://finance.yahoo.com/news/urogen-pharma-urgn-reports-q2-131507984.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Earnings Report, Stock Performance","company":"Urogen Pharma","layoffs":"Not mentioned","summary":"Urogen Pharma reported a quarterly loss of $1.03 per share, which is better than the Zacks Consensus Estimate of a loss of $1.13. This is also an improvement from a loss of $1.18 per share a year ago. The company posted revenues of $21.14 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 6.23%. This is an increase from year-ago revenues of $16.6 million. Urogen Pharma shares have added about 133.4% since the beginning of the year. The companys future performance will depend on managements commentary on the earnings call.","partners":"Not mentioned","customers":"Not mentioned","investors":"Zacks Investment Research","confidence":9,"key_topics":["Earnings Surprise","Revenue Increase","Stock Performance","Future Expectations","Industry Outlook"],"date_of_event":"Not specified","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"FymUnXUSbARe88dHzlcLl41PvRoYTMqUMvV0xbIutt0xx0BVdJmeEO","news_summary":"Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"iep6t7qiasjGLVtNkVgsM5miRjRpkh2BY1urdpxdS8DwgNYVsWynXD","date":"Aug 10, 2023","link":"https://finance.yahoo.com/news/wall-street-analysts-think-urogen-135522763.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Stock Growth","company":"Urogen Pharma","layoffs":"Not mentioned","summary":"Shares of Urogen Pharma have increased by 115.6% over the past four weeks, closing the last trading session at $20.70. Wall Street analysts predict further growth, with a mean estimate of $39.25, indicating a potential upside of 89.6%. The company is also expected to report better earnings than previously estimated. However, the article warns against relying solely on these predictions for investment decisions, as they can often be misleading. Instead, it suggests considering other factors such as earnings estimate revisions and the companys Zacks Rank. Urogen Pharma currently has a Zacks Rank #2 (Buy), indicating potential for further growth.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Stock Price","Analyst Predictions","Earnings Estimates","Investment Decision","Zacks Rank"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ibYVhB9xzSjsRwfyOfk1oMJbKdifWLMvzrrKzszOy43GqTGgiqPUeT","news_summary":"Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 89.61%: Read This Before Placing a Bet","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"s7xaLevrjXpPcBSRGMlLwWtfBAYl9m7J58nQa1nPa8QUi16gN201N6","date":"Aug 8, 2023","link":"https://www.businesswire.com/news/home/20230808428206/en/","source":"www.businesswire.com","visible":1,"analysis":{"tags":"Clinical Trials, Cancer Treatment","company":"UroGen Pharma Ltd.","layoffs":"Not mentioned","summary":"UroGen Pharma Ltd. has announced that The Journal of Urology has published data from the Phase 3 ATLAS trial for investigational agent UGN-102 (mitomycin) for intravesical solution in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The trial demonstrated superiority to transurethral resection of bladder tumor surgery (TURBT) with a 55% reduction of risk for recurrence, progression, or death in patients who received UGN-102. The company hopes that UGN-102 could provide an effective, non-surgical therapy option beyond TURBT for this large patient population. A New Drug Application (NDA) is anticipated to be submitted to the U.S. Food and Drug Administration (FDA) in 2024.","partners":"Not mentioned","customers":"Patients with low-grade, intermediate-risk non-muscle invasive bladder cancer","investors":"Not mentioned","confidence":9,"key_topics":"Clinical Trial, Cancer Treatment, UGN-102, ATLAS Trial, FDA Approval","date_of_event":"August 08, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment, Expand","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"prmqKs1RuWnVJABZVF9bTVtlniirWKPX8DwsiMhPa7B4FgZ32zbybs","news_summary":"The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"oZIUPUCj0DxEsQNNcLS5QclEiAKmzLZTFxwdBdiPh5HkYsmtfZ3qFY","date":"Aug 2, 2023","link":"https://www.businesswire.com/news/home/20230802943779/en/","source":"www.businesswire.com","visible":1,"analysis":{"tags":"Financial Results, Biotech","company":"UroGen Pharma Ltd.","layoffs":"Not mentioned","summary":"UroGen Pharma Ltd., a biotech company focused on developing and commercializing solutions for urothelial and specialty cancers, has announced that it will report its second quarter 2023 financial results on Thursday, August 10, 2023. The announcement will be followed by a live audio webcast and conference call. UroGen has developed a proprietary sustained release, hydrogel-based platform technology that aims to improve the therapeutic profiles of existing drugs. The companys first commercial product is Jelmyto, a solution for patients with low-grade non-muscle invasive bladder cancer.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Financial Results","Conference Call","Webcast","Cancer Treatment","Biotech"],"date_of_event":"August 10, 2023","valuation_amount":"Not mentioned","impact_on_company":"Neutral","investment_amount":"Not mentioned","structured_issues":["Public Trading"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"none;"},"sentiment":"Neutral","analysisId":"9RtCBgjoRJAY0ALGlTAeRKwQDqxBA9uKplL2drRWOyDi4MnCzDf2gg","news_summary":"UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"3FOXkrSQlbhagKUXLY4AnWQyPpG5F4wtU4XbFeuqvEYx4PraUn1AS8","date":"Aug 1, 2023","link":"https://finance.yahoo.com/news/opportunities-outweigh-risks-oppenheimer-sees-140518406.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Stock Market, Investment, Battery Technology, Biotech","company":"Enovix Corporation, UroGen Pharma","layoffs":"Not mentioned","summary":"Oppenheimers Chief Investment Strategist, John Stoltzfus, predicts a continued bull market, creating more opportunities for investors. Among Oppenheimers top picks are Enovix Corporation and UroGen Pharma. Enovix, a developer and manufacturer of high-capacity lithium-ion batteries, has exceeded production targets and secured $70 million in non-dilutive local funding from YBS International Berhad. UroGen Pharma, a biotech company, has seen success with its FDA-approved treatment, Jelmyto, and is planning to submit a marketing application for another treatment, UGN-102, next year.","partners":"Not mentioned","customers":"U.S. Army","investors":"Oppenheimer, YBS International Berhad","confidence":8,"key_topics":"Stock Market, Battery Technology, Biotech, Investment, Revenue Growth","date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$70 million","structured_issues":"Investment, Customers","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment, Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"bhiZDcB9qM1rDiXwhkdiqZ1HpAP7wi8WiA6RP8BDQZ0Xpa4TJlHane","news_summary":"‘Opportunities Outweigh Risks’: Oppenheimer Sees at Least 60% Gains in These 2 Stocks","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"72RWz2kQcY5hn2tRcqhKTZtg8et9EUDKoKOyOm1XPHMSolq96VjmGo","date":"Jul 31, 2023","link":"https://www.businesswire.com/news/home/20230731957828/en/","source":"www.businesswire.com","visible":1,"analysis":{"tags":"Management Changes, Public Trading","company":"UroGen Pharma Ltd.","layoffs":"N/A","summary":"UroGen Pharma Ltd., a biotech company focused on urothelial and specialty cancers, has announced the hiring of Michael Louie as SVP Medical Affairs & Clinical Development. As part of his employment package, Louie has been granted inducement restricted stock units (RSUs) and options. Up to 30,000 ordinary shares of UroGen are issuable upon the vesting and settlement of the RSUs and up to 20,000 ordinary shares are issuable upon the vesting and exercise of the Options. The RSUs and Options will vest over three years, subject to Louies continued service with UroGen.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["New Hire","Stock Options","Medical Affairs","Clinical Development","Biotech"],"date_of_event":"July 31, 2023","valuation_amount":"N/A","impact_on_company":"Growth-Positive","investment_amount":"N/A","structured_issues":["Management Changes"],"acquisition_amount":"N/A","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"4wMgKK8dEOVBnzQM94nIWZi5FfSR1FiUaNbdFQvxEQifnR9bnjf84e","news_summary":"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"cN0p3Qs3mINFbQDeIZTZFmNiUowQbDbkWLee5Dg1O2lHdDsMpXQdGM","date":"Jul 31, 2023","link":"https://nocamels.com/2023/07/biotech-firm-to-raise-120m-after-promising-cancer-drug-trials/","source":"nocamels.com","visible":1,"analysis":{"tags":"Investment, Clinical Trials","company":"UroGen Pharma","layoffs":"Not mentioned","summary":"UroGen Pharma, an Israeli-founded biotech company, has announced plans to raise $120 million following positive results from clinical trials of its bladder cancer drug, UGN-102. The funding will come from investors including Capital, Green Point Ventures, Acorn Bioventures, Monograph Capital, and Horton Capital Partners Fund, LP. UGN-102 is designed for patients with bladder cancer that can be treated by surgery but has a high recurrence rate. The companys research found that 64.8% of patients with low-grade bladder cancer who were administered the drug had no detectable disease three months after starting treatment.","partners":"Not mentioned","customers":"Not mentioned","investors":["Capital","Green Point Ventures","Acorn Bioventures","Monograph Capital","Horton Capital Partners Fund, LP"],"confidence":9,"key_topics":["Investment","Bladder Cancer","Clinical Trials","UGN-102","Urologic Cancer Treatment"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$120 million","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Ylu7riiuk0pkDrwuVTMlmkN7zghqKePzw2tVG1JFTCqabL2EAeb61u","news_summary":"Biotech Firm To Raise $120M After Promising Cancer Drug Trials","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"gOPCO9ti9TixyMvVV6QmKKSU8v84LbXx6d2tCXJINBHXISBKLHRh4P","date":"Jul 28, 2023","link":"https://finance.yahoo.com/m/6cfa41ee-6878-3275-8691-40d36bc57f01/why-shares-of-urogen-pharma.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Biotech, Cancer Therapy","company":"UroGen Pharma","layoffs":"Not mentioned","summary":"Shares of UroGen Pharma were up by over 25% following the announcement of positive top-line data from two phase 3 trials for UGN-102, a bladder cancer therapy. The intravesical solution is designed to treat patients with low-grade, intermediate-risk non-muscle-invasive bladder cancer.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Phase 3 trial","Bladder cancer therapy","UGN-102","Stock jump","Biotech"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"IwpPcLwR0cyrGYZyP1Ga7aInVvnkljANP28XCIpLTjGRynZlyIqw71","news_summary":"Why Shares of UroGen Pharma Jumped Friday","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ggZXrhQCXw7RZYwDPxlWeRq0c1LFDZbxkuwSeH82VjBBB73pb3wF6Z","date":"Jul 27, 2023","link":"https://www.businesswire.com/news/home/20230727005666/en/","source":"www.businesswire.com","visible":1,"analysis":{"tags":"Clinical Trials, Cancer Treatment","company":"UroGen Pharma Ltd.","layoffs":"Not mentioned","summary":"UroGen Pharma Ltd. has announced positive topline data from its Phase 3 trials ATLAS and ENVISION studying UGN-102 for intravesical solution in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). Both trials met their primary endpoints, with UGN-102 demonstrating a 55% reduction of risk for recurrence, progression, or death in the ATLAS trial and a 79.2% complete response rate at 3-months in the ENVISION trial. The company anticipates submitting a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in 2024.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Clinical Trials","Cancer Treatment","UGN-102","Bladder Cancer","FDA Approval"],"date_of_event":"July 27, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cOXW1TX5k1leV5fwde84AJVt9iLfJDuhNJP0ekfcJOoJ8al90i2P85","news_summary":"UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"h4yJDMoAu6vzaFVlojTfeSVzywpjSi8S4eTRC9RHmgG7USLjAxXwzj","date":"Jul 27, 2023","link":"https://www.businesswire.com/news/home/20230727406893/en/","source":"www.businesswire.com","visible":1,"analysis":{"tags":"Investment, Private Placement","company":"UroGen Pharma Ltd.","layoffs":"Not mentioned","summary":"UroGen Pharma Ltd. has announced a definitive securities purchase agreement in connection with a private placement to selected institutional and accredited investors. The private placement was led by RA Capital Management L.P. and Great Point Partners LLC, and also included Acorn Bioventures, Monograph Capital, and Horton Capital Partners Fund, LP. UroGen expects to receive gross proceeds of approximately $120 million. The net proceeds will be used for non-clinical and clinical development activities for its product candidates, commercialization expense, and general corporate purposes. The private placement is expected to close on July 28, 2023.","partners":["BofA Securities","H.C. Wainwright & Co.","Ladenburg Thalmann & Co. Inc."],"customers":"Not mentioned","investors":["RA Capital Management L.P.","Great Point Partners LLC","Acorn Bioventures","Monograph Capital","Horton Capital Partners Fund, LP"],"confidence":10,"key_topics":["Private Placement","Securities Purchase","Clinical Development","Commercialization Expense","Corporate Purposes"],"date_of_event":"July 27, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$120 million","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2iM9N31i7FIdQa8A41IxOVyjt8P8y62EkdzQc1xg4C2BbSyn2xUJ7N","news_summary":"UroGen Announces $120 Million Private Placement of Ordinary Shares","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"W28biK3RsqBQNplTlzNOd9iINbBrkxfZpHxz2xScfu06lXFs3C3wT6","date":"Jul 25, 2023","link":"https://www.businesswire.com/news/home/20230725242491/en/","source":"www.businesswire.com","visible":1,"analysis":{"tags":"Management Changes, Expand","company":"UroGen Pharma Ltd.","layoffs":"N/A","summary":"UroGen Pharma Ltd., a biotech company specializing in urothelial and specialty cancers, has announced the appointment of James Robinson to its Board of Directors. Robinson, the former President and CEO of Urovant Sciences, brings over 30 years of experience in the biopharmaceutical industry. His appointment is expected to provide valuable guidance as UroGen seeks to expand access to JELMYTO and advance its lead clinical development program, UGN-102, for low-grade intermediate risk bladder cancer. Robinsons background aligns well with the current Board members, and his leadership is anticipated to be beneficial for the company.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Board Appointment","Company Expansion","Clinical Development","Leadership","Urothelial Cancer Treatment"],"date_of_event":"July 25, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Management Changes","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Management Changes  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"y21NfhXSIwwuzLjOF07xRkUo4zDSbJeb5gCNFZXFrxMNZGsVmtorRQ","news_summary":"UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"27QcUJDuUa9uY2dIbLLjFES1bkYo0eimcZHPFHyvGZV2QWEwyOZ5KB","date":"Jul 10, 2023","link":"https://www.businesswire.com/news/home/20230710759851/en/","source":"www.businesswire.com","visible":1,"analysis":{"tags":"biotech, cancer treatment","company":"UroGen Pharma Ltd.","layoffs":"N/A","summary":"UroGen Pharma Ltd. has highlighted the results of a sub-analysis from the first post-commercial utilization review of JELMYTO for pyelocalyceal solution. The study assessed the efficacy of JELMYTO in managing patients with larger volume disease where initial tumor burden may not be amenable to complete mechanical ablation or renal preservation. The study found no significant differences in the rates of rendered disease free among those who underwent complete ablation, partial ablation, or biopsy only during the initial URS procedure. The findings provide evidence in support of a new treatment strategy utilizing JELMYTO for reducing the volume of larger low-grade tumors to help spare the kidney.","partners":"N/A","customers":"Patients with larger volume disease","investors":"N/A","confidence":9,"key_topics":["JELMYTO","cancer treatment","study results","kidney preservation","tumor ablation"],"date_of_event":"July 10, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"L6KAIZNILJ7ozYA75KwNJp90p3hSPYIJzWzPsllSCgZetR5tSofSWo","news_summary":"Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"MkTOUJBdWxcvUdK6RUgXqkVQ2dMNIoOFkzMzBqZKsHfCkvujwwMqyh","date":"Jun 20, 2023","link":"https://www.businesswire.com/news/home/20230620105493/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"ZLVtHPb3g1V10ge9G2G9JymWq123UDi69SarcVjkTbTvvIp7Sdyk5j","news_summary":"Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"oUARJAaB57cdn351pkUhGlqlKF2A4h6IvKAEY4cHRbz0bfsXgagLya","date":"Jun 9, 2023","link":"https://www.businesswire.com/news/home/20230609005029/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"VUEAfsf8MneHFEepp22wv0kx77FEeVaRGdOGKVpM0GoEN13BqPSicF","news_summary":"UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"REqDMp4iuzula4NxU4XeGJE5xTy9HqaFtUQ0Ov3eqyd8eZ8VUUchuT","date":"Jun 2, 2023","link":"https://www.businesswire.com/news/home/20230602005026/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"cQzBrgayXJlmMW0kRIwnj009eCq0sRMCoaTGX3Rr4gSMMPKP1MMDWS","news_summary":"UroGen Pharma to Present at Upcoming Investor Conferences","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"1TJFVr1g7p4uCqqSAEo6R8gx4uPTj6kGLMKv9ouhZqh9YzkVZCgiNm","date":"May 22, 2023","link":"https://finance.yahoo.com/news/58-institutional-ownership-urogen-pharma-171810768.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":["ownership structure","institutional investors","analyst forecasts","share price","earnings history"],"company":"UroGen Pharma Ltd.","layoffs":null,"summary":"The article discusses the ownership structure of UroGen Pharma Ltd. and the influence of institutional investors on the companys share price. Institutional investors hold a majority stake of 58% in the company, indicating their confidence in its future. The top 11 shareholders control 51% of the ownership, with no single shareholder having a majority interest. The largest shareholder is Menora Mivtachim Pensions & Gemel Ltd. The article also mentions the insider ownership, with insiders collectively owning US$27m worth of shares. The general public holds a 26% stake, while private equity firms hold a 6.3% stake. The article highlights the importance of considering other information and risks when analyzing the company. The event described in the article is ongoing and does not have a specific date.","partners":null,"customers":null,"investors":["Menora Mivtachim Pensions & Gemel Ltd.","Pontifax Venture Capital","Moshe Arkin"],"confidence":8,"key_topics":["ownership structure","institutional investors","analyst forecasts","share price","earnings history"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"gyaWyJKFUXklftg4Ng6HukE4B3ofZFCY3Q0Y5zXfhVxJ391elSdy1H","news_summary":"With 58% institutional ownership, UroGen Pharma Ltd. (NASDAQ:URGN) is a favorite amongst the big guns","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"kxamgRGtxPuxci8wUwcH9mAoVNJ4xKOHEE6ni12uNmbbkHgW8NRJrr","date":"May 16, 2023","link":"https://finance.yahoo.com/news/urogen-pharma-ltd-nasdaq-urgn-161311577.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Earnings Report, Financial Results","company":"UroGen Pharma Ltd.","layoffs":"N/A","summary":"UroGen Pharma Ltd. reported its Q1 2023 earnings, beating expectations with a reported EPS of $-1.3 against expectations of $-1.33. The company reported net revenues of $17.2 million for the quarter, a 27% increase from the same quarter the previous year. The companys product JELMYTO continues to see growth in adoption. The company also highlighted its development strategy focus on UGN-102, with top line data from Phase III studies expected to be provided in the summer. The company also addressed its balance sheet, emphasizing fiscal prudence and prioritizing cash spend on advancing core value drivers.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Earnings Call","Financial Results","JELMYTO","UGN-102","UGN-301"],"date_of_event":"May 11, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers","Management Changes"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"BFzPxZX6VztS92ggUooSHXTtyI91YNL3iXK0MSs9n7wm2hPlxgmBsr","news_summary":"UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2023 Earnings Call Transcript","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ClkLDuh3HX1HAt8BApUiAlipAfoKtJwUFlH8Ky04FBMHi2XqlxPKF6","date":"May 11, 2023","link":"https://www.businesswire.com/news/home/20230511005168/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"o56GQUyuMrLTJDpKV6yYmEddYVlZKevY9TQ6R8SbPY44Mni0yEXMF9","news_summary":"UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"BTHtFkCZFLBS3Ci1NSXWgJrLlzl0bVi07Zt5DK38YhCgmebjU58CUN","date":"May 11, 2023","link":"https://finance.yahoo.com/news/urogen-pharma-urgn-reports-q1-131501450.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"omsIwDXMWaREiN3ibY2GtIUzDy2IQfShI6cwV02ujhqVitMkMlQml2","news_summary":"Urogen Pharma (URGN) Reports Q1 Loss, Tops Revenue Estimates","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"D0kPOJso10I7SJ0jMASpgfYpkDFRPdAPSmYjsDO2EwCoXKXYvn6TQJ","date":"May 4, 2023","link":"https://www.businesswire.com/news/home/20230504005293/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"eR65pFbC9x5PJuWBt7or2QWL5Q6VFW0EOWu5D2QEf0jMejT4Nr4UB8","news_summary":"UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"QGDRBwRsb3qM7hv0pRt5C46hXyXVbYl4auHWaRe9aOVudfeYg5obCO","date":"May 2, 2023","link":"https://finance.yahoo.com/news/earnings-preview-urogen-pharma-urgn-140202637.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"cDW2L8U0eZBfJQ2juFgNq5fjV9L2dCNfUxnnG4psa8cpSMupz6WyOm","news_summary":"Earnings Preview: Urogen Pharma (URGN) Q1 Earnings Expected to Decline","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"pPO7r4WKnvRXVtdu0HFrs0NS57YJCBVI7xxNVHvj2UNK5sbBL2gmBy","date":"May 1, 2023","link":"https://www.businesswire.com/news/home/20230501005228/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"6HqAmZ5aXHsgU3tDRLXqGmwKQoRc2J1QXIu8DynA9b8JWaI10feU9O","news_summary":"First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"aLbpIIGI81UJdJMmvBFFJIslL0oBKvBnsqLgS6HpDvYxdaxdushtXj","date":"Apr 30, 2023","link":"https://www.businesswire.com/news/home/20230430005010/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"vXF7A9SPv9HPPkylPhvIlnOJz71nIUY3PRDCNwWZk3KKEGnXVktEZa","news_summary":"New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"afdpuEHHPZtzs6ybqAazOnV6sQuPfcsVqgfZIbc3fjYACLMM7i8wfY","date":"Apr 25, 2023","link":"https://www.businesswire.com/news/home/20230425005188/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"4RHysz23RsekqsejV124ZEV2mhlP2SOVYIqOgCytLBJORss1t6zM5t","news_summary":"UroGen Pharma to Present at H.C. Wainwright BioConnect Conference","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"ms368oD0pvWdpT9jRCpE6yQ2homQEUm8wwWCIFIrXQY1rIhn28DtnP","date":"Apr 18, 2023","link":"https://finance.yahoo.com/news/urogen-pharma-ltd-nasdaq-urgn-161632170.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"EsdC9f9T71cGqsKBh9xHkkV5zI4459ngy0qGYe3nA2ZfIkUctgn2TN","news_summary":"UroGen Pharma Ltd.'s (NASDAQ:URGN) Prospects Need A Boost To Lift Shares","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"5wzVT67D15Bv8ropxbEpTFJDxUbrVvR1zLSKNcMViThiY2t37Jxn4s","date":"Mar 18, 2023","link":"https://finance.yahoo.com/news/urogen-pharma-ltd-nasdaq-urgn-060630061.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Earnings Call, Financial Results","company":"UroGen Pharma Ltd.","layoffs":"Not mentioned","summary":"UroGen Pharma Ltd. reported its Q4 2022 earnings, highlighting a 34% increase in net product revenues from 2021, ending the year with $64.4 million. The companys product JELMYTO had its strongest quarter ever, and the company is optimistic about the potential of UGN-102, a non-surgical treatment for low-grade intermediate risk non-muscle invasive bladder cancer. UroGen expects to provide top line data from Phase 3 studies of UGN-102 midyear, and if results are positive, it plans to submit to the FDA in 2024. The company ended the year with $100 million in cash and expects revenue growth in 2023 to reflect growth of 20% to 30% over 2022.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Earnings Call","Financial Results","UGN-102","JELMYTO","Clinical Trials"],"date_of_event":"March 16, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"0xxtD2tMXu3uCj538K7MZaHNPgPO0ElMgmLNdzlfQIOYxRqXRVQMbK","news_summary":"UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2022 Earnings Call Transcript","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"RaZvkxt8WLWlSMNsVlYI4ZeN5OqMOSuFfT1oC2Y0nd5GbAfFdo1iBg","date":"Mar 16, 2023","link":"https://www.businesswire.com/news/home/20230316005328/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"RyUfGa318cZHJw23WCK6u5g4wiAt5f1Uj2FEfzpz5YMeaJrNPWP4ah","news_summary":"UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"uxHxnp9dC5E1WjxswgFjYjS1lRyp6P9xRz9Eiht4JpihQj1FNQEE8o","date":"Mar 16, 2023","link":"https://finance.yahoo.com/news/urogen-pharma-urgn-reports-q4-131501472.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"j4LVNlTZXymRxyjzn4eEDUMxEmf4xjP1iStDAPf21XTkKtqNVBGitp","news_summary":"Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"nzEvWyoKXq6Pig0lUIdcJyHYuKV7XqS1NrJvfK2SYMBy4knfFFUCuS","date":"Mar 9, 2023","link":"https://www.businesswire.com/news/home/20230309005742/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"n0XZJqw3Bnkrcg8xNK30d9fbvspH3AfSym4YkaBDejaTSHg6PptSft","news_summary":"UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"4XpoSYGn6nMNJYePHQJ0XhmRKL7Bc6a5zbeJ0Tkjs0x1AW7thsT8pg","date":"Mar 6, 2023","link":"https://www.businesswire.com/news/home/20230306005090/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"DZ47QddPPrbUUtAHVLUx91ciHmDY5Yis2nUsyHdz4hmjxlfrsR2WVE","news_summary":"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"iUw38N3OdbUpDC2xaqquhTiGw03qOvUlZPobwTVipTyvpETnnzregk","date":"Feb 27, 2023","link":"https://finance.yahoo.com/news/axsome-therapeutics-axsm-reports-q4-131501865.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"4GmlZVKYuNpNCHqml2epUrbK2Q6YyQZRN2Crwo7AhPqQ0yRcHQFICA","news_summary":"Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"45QURYNHKlqS0n8Th96h4Lb1p6lTOUdqS5OH2ghlhDADC4VMRrWpb0","date":"Feb 15, 2023","link":"https://www.businesswire.com/news/home/20230215005534/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"wo4DAmyDH4u2TBNGrcGsBOCI0ZdQj21h9slMD97RL3sVGEeDCROvLp","news_summary":"Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"oDn3TCkdnW7faOMpyCak7lJbJdLdjvZu2rMJ5GsFeJCONkS1YbPH2r","date":"Feb 6, 2023","link":"https://finance.yahoo.com/news/urogen-pharma-ltd-nasdaq-urgn-103339110.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"4RycyGlln51fIuaYfxQ2SW2yQUmRvTRxoscAOhmdn9pCkKORekDpDz","news_summary":"UroGen Pharma Ltd. (NASDAQ:URGN) Is Expected To Breakeven In The Near Future","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"OYzYSUspjh5yHslGmIDbRkHDzvv8YSnvwc0rTSwZufhhiP5TUGTgbm","date":"Oct 11, 2022","link":"https://www.businesswire.com/news/home/20221011005425/en/UroGen-Pharma-to-Host-Thought-Leader-Webinar-on-UGN-102-and-Non-Muscle-Invasive-Bladder-Cancers","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"MaTA93xk4POGFNLy9bYx39iuyIuWwxedl1aMwSB31aToVHIVewJncY","news_summary":"UroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder Cancers","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"c2V6fqvNXgYzCIr4tBFU9KuDEafeOdGUbp6VQNHj51yjYZuw2Mmkil","date":"Sep 28, 2022","link":"https://www.businesswire.com/news/home/20220928005322/en/FDA-Authorizes-an-Extension-of-the-In-Use-Period-for-UroGen-Pharma%E2%80%99s-JELMYTO%C2%AE-Admixture-to-96-Hours-Following-Reconstitution","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"7SRew282FHKqFhgLUAyiFKvEBWT8OFrfAFrjyRCwnQNhEUN6K622d4","news_summary":"FDA Authorizes an Extension of the In-Use Period for UroGen Pharma's JELMYTO® Admixture to 96 Hours Following Reconstitution","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"rxk2VVfqlsPfWydQlRpcwbSMJIty3EOU7XnP1bR1mDOVA5FZsd9Ein","date":"Sep 12, 2022","link":"https://www.citybiz.co/article/318860/urogen-pharma-appoints-dr-leana-s-wen-to-board-of-directors/","source":"www.citybiz.co","visible":1,"analysis":{"tags":"appointment","company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma has appointed Dr. Leana S. Wen to its Board of Directors. Dr. Wen is an emergency medicine physician and public health and policy expert. Her appointment is expected to bring a deep understanding of diverse stakeholders and the complex dynamics of the biopharmaceutical industry to UroGen. The company aims to transform the field of uro-oncology with therapeutic interventions. Dr. Wen has previously served on the board of directors of Glaukos Corporation and is a contributing columnist for The Washington Post. She has extensive experience in health policy and public health.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Dr. Leana S. Wen","Board of Directors","UroGen Pharma","health policy","uro-oncology"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"zliMWGnNqu0IRUuEROdWLMOaKqiAsd9oonwPrFP9uGuIFRTA7QGxDI","news_summary":"UroGen Pharma Appoints Dr. Leana S. Wen to Board of Directors | citybiz","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9aaa471c-f344-4a84-bfc1-26014794d8c0","date":"Mar 21, 2022","link":"https://www.businesswire.com/news/home/20220321005260/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"LYdSpFf1XsAHhdrFLTyi6auy9iJfquKNz0H18h5T1OqOL0Z3OH4kEh","news_summary":"UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"90ad9476-dd55-4eb3-ad02-5ac4f3aadc5c","date":"Sep 13, 2021","link":"https://www.businesswire.com/news/home/20210913005198/en/UroGen-Pharma-Presents-Data-Showcasing-Novel-Clinical-Data-at-2021-American-Urological-Association-AUA-Annual-Meeting","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"U4ONai5QQHcUzc6ZdVNCECJ8U4GwUYJgN2ukGMNgNPtZJdatPy4z9h","news_summary":"UroGen Pharma Presents Data Showcasing Novel Clinical Data at 2021 American Urological Association (AUA) Annual Meeting","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"2ffd23c9-93d2-4963-83e8-ab5f3a578695","date":"Jul 28, 2021","link":"https://www.businesswire.com/news/home/20210728005968/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"NQCrCdun4sZHFtSDo5AyscqmGTLgpI2PA89oYV3DJEwhQqVnaZQESQ","news_summary":"UroGen Pharma Announces License and Supply Agreement with Neopharm to Pursue Regulatory Approval and Commercialization for Jelmyto® in Israel","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"e4343d8d-3bf9-4e78-915c-a2b65c196044","date":"Mar 18, 2021","link":"https://www.businesswire.com/news/home/20210318005444/en/UroGen-Pharma-Announces-75-Million-of-Non-Dilutive-Funding-from-RTW-Investments","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"FywXvzPHxIY9TQgSdeCPKkVUCYOTIttkofdgZtzlVZ65M3qj54xfNn","news_summary":"UroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW Investments","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"cb26a063-5880-4536-bfad-98944ce78488","date":"Jun 5, 2020","link":"https://www.businesswire.com/news/home/20200605005046/en/UroGen-Pharma-Announces-Inducement-Grant-Nasdaq-Listing","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"QDfPmyDleeUm70OJTZNnARehIaMcPOaLYONgpf70MITcTKe3rKgcVZ","news_summary":"UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"8f018cae-243f-43eb-b125-eea3bcaf89bf","date":"May 23, 2020","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3826110,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"COVID-19, FDA approval, vaccination, cancer treatment, market valuation","company":"UroGen Pharma","layoffs":null,"summary":"The article features an interview with Arie Belldegrun, chairman of UroGen Pharma. The article discusses his experience with COVID-19, the progress of vaccine development, Israels handling of the pandemic, and UroGen Pharmas FDA approval for a gel that replaces kidney surgery. The company has raised $300 million through IPOs and is still being traded at a valuation of around $500 million. The article also mentions UroGen Pharmas major product for bladder cancer treatment, which is expected to receive FDA approval within a year. Belldegrun emphasizes that exits were never the strategy for UroGen Pharma, but if the company proves to be of interest to big companies, it would be a great outcome.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["COVID-19","Vaccination","FDA approval","Cancer treatment","Market valuation"],"date_of_event":"23.05.20","valuation_amount":"$500 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment","Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"owdA0sjTul5QlrdBaMi0bimTs5aSka6k0bY8WAhOLUpqHM7RoCNzVH","news_summary":"\"Exits are not a Strategy. I Never put up a 'For Sale' Sign\"","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"05c8d4b7-71b3-4fbc-bca7-256d9303c36b","date":"Apr 16, 2020","link":"https://en.globes.co.il/en/article-fda-approves-urogens-urothelial-cancer-drug-1001325536","source":"en.globes.co.il","visible":1,"analysis":{"tags":"FDA acceptance, cancer treatment","company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma has received FDA acceptance for its New Drug Application (NDA) for UGN-101, a treatment for low-grade upper tract urothelial cancer. UGN-101 will be the only drug available for this type of cancer. The FDA has granted priority review for UGN-101, shortening the review period to six months. The company is on track for the potential launch of UGN-101 by mid-year 2020. UroGen Pharma has raised $320 million from investors including Mori Arkin, OurCrowd, Pontifax, and CHealth Fund.","partners":null,"customers":null,"investors":["Mori Arkin","OurCrowd","Pontifax","CHealth Fund"],"confidence":9,"key_topics":["UGN-101","FDA acceptance","cancer treatment","priority review","investors"],"date_of_event":"April 16, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"UKrsaRk5pt2CwyjmS0LGKOmfqfQH4QL67iULN24waSYR3HI5S19asX","news_summary":"FDA approves UroGen's urothelial cancer drug","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"7fdbb8fb-98f8-4233-8277-db32454af1f9","date":"Nov 13, 2019","link":"https://en.globes.co.il/en/article-urogen-buys-new-urinary-tract-cancer-drug-candidate-1001306964","source":"en.globes.co.il","visible":1,"analysis":{"tags":"acquisition","company":"Urogen Pharma Ltd.","layoffs":null,"summary":"Urogen Pharma has acquired the rights to develop a delayed-release version of a new upper urinary tract cancer drug from Agenus. The acquisition aims to combine Agenuss product with Urogens unique technology for delayed release of drugs in the urinary tract. Urogens share price increased by 13.6% following the announcement, and its market cap reached $500 million. Agenuss share price also rose by 9.3%, increasing its market cap to $535 million. Urogen will pay $10 million immediately for the rights to develop the product, with an additional $115 million if Agenuss product meets certain milestones. Urogen will assume responsibility for the development and marketing of the product.","partners":null,"customers":null,"investors":"N/A","confidence":8,"key_topics":["acquisition","drug development","immunotherapy","urinary tract cancer","market cap"],"date_of_event":"2019-11-13","valuation_amount":"$500 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"HfauhovIQkswDsNgzcPYJ14XGZGyakI9mpGfbMmYRFAGedX92sfzjK","news_summary":"Urogen buys new urinary tract cancer drug candidate","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"48f6cb3a-fb90-49ea-832b-a2e17fadaf12","date":"Sep 26, 2019","link":"https://en.globes.co.il/en/article-urogen-addresses-a-market-that-can-reach-1b-annually-1001302246","source":"en.globes.co.il","visible":1,"analysis":{"tags":"bladder cancer","company":"UroGen Pharma Ltd.","layoffs":null,"summary":"Israeli company UroGen Pharma announced the results of a trial for its second product in the treatment of bladder cancer. The trial showed that the product caused the malignant tumor to vanish in 63% of patients. UroGens leading product for the treatment of cancer in the upper urinary tract is scheduled to reach the market next year. The companys share price has dropped 36% in 2019. UroGens market cap is $682 million. The company is preparing for the launch of its leading product, including assembling a sales team and working on insurance reimbursement. UroGen aims to create a urology company and acquire rights to additional products in the future.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["bladder cancer","clinical trial","market launch","reimbursement code","future acquisitions"],"date_of_event":"September 26, 2019","valuation_amount":"$682 million","impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"wgfX10ZdU1LZmZ48sBCfhylL7jr0LYEjpRCL4CKZrhj7hFJQMD6rCU","news_summary":"Prof. Arie Belldegrun sees $1b market for UroGen drugs","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ee0cadab-132c-4845-86b8-259f0df36eee","date":"Apr 24, 2019","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3760997,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"research agreement","company":"UroGen Pharma Ltd.","layoffs":null,"summary":"UroGen Pharma Ltd. has announced a research agreement with Janssen Research & Development LLC. The two companies will collaborate on an early-stage feasibility evaluation in a therapeutic area of mutual interest. The financial terms of the agreement were not disclosed.","partners":["Janssen Research & Development LLC"],"customers":null,"investors":null,"confidence":8,"key_topics":["research agreement","therapeutic area","mutual interest","financial terms","gel for sustained release"],"date_of_event":"24.04.19","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"tJxvWuaSc0A8oahSLCCvMFDYnoFa6Zdb9p1967frWkCbP5lW3O1d1Z","news_summary":"Johnson & Johnson Subsidiary Janssen Partners With Sustained Drug Release Company UroGen","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5993b61a-78a7-4d90-a851-2f1531e339b4","date":"Jan 23, 2019","link":"https://en.globes.co.il/en/article-cancer-co-urogen-to-raise-150m-in-nasdaq-offering-1001270101","source":"en.globes.co.il","visible":1,"analysis":{"tags":"cancer treatment","company":"Urogen Pharma","layoffs":null,"summary":"Urogen Pharma plans to raise $150 million through a shelf prospectus on Nasdaq. The company recently appointed a new president and CEO, Liz Barrett, and published positive results for its urinary tract cancer treatment. The market responded positively to the announcement, with Urogens share price rising 5%. The funds raised will be used to launch the upper urinary tract cancer treatment and expedite clinical trials for other urinary cancer drugs. Urogens chairperson, Arie Belldegrun, has played a significant role in the companys growth. Urogen was founded in 2004 and had a successful IPO in 2017.","partners":["Allergan"],"customers":null,"investors":["Goldman Sachs","JP Morgan","Jeffries","Oppenheimer"],"confidence":9,"key_topics":["urinary tract cancer treatment","financing round","clinical trials","IPO","chairperson"],"date_of_event":"January 23, 2019","valuation_amount":"$864 million","impact_on_company":"growth-positive","investment_amount":"$150 million","structured_issues":["Investment","Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"3Pr6Ok8DhyicMlba33w6ZZjuncNdwCEo2sAkjfvPdf0w5LUc71DghQ","news_summary":"Cancer co Urogen to raise $150m in Nasdaq offering","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"6998b6e2-a9a4-4670-b6ac-5bf82b3750ad","date":"Jan 8, 2019","link":"https://en.globes.co.il/en/article-urogen-reports-positive-phase-iii-urinary-tract-cancer-drug-results-1001268175","source":"en.globes.co.il","visible":1,"analysis":{"tags":"drug approval","company":"Urogen Pharma","layoffs":null,"summary":"Israeli company Urogen Pharma expects FDA approval and plans to launch its drug this year. In a Phase III trial, 58% of patients responded fully to treatment, with no cancer found after treatment. The trial was conducted on 60 patients without a control group. Urogen submitted the results for FDA approval on a rolling submission track and expects approval in 2019. The company appointed Elizabeth Barrett as CEO, who has connections with Urogens chairperson and a background in the cancer sector. Urogens market cap before the trial results was $878 million. The companys product is a polymer that becomes a gel at body temperature, allowing for delayed drug release. Urogen plans to prepare production facilities before approval is granted.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Phase III trial","FDA approval","drug alternative","rolling submission track","new CEO"],"date_of_event":"January 8, 2019","valuation_amount":"$878 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"FbATCkPC5wJK6fylcs5PgftHIqrwvlvi0sQb1h84fZkssRb20a05Om","news_summary":"Urogen reports positive Phase III urinary tract cancer drug results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5575a1bd-255c-43e1-a5cb-3425ba401857","date":"Jan 21, 2018","link":"http://www.globes.co.il/en/article-urogen-pharma-raises-60m-in-nasdaq-offering-1001220496","source":"www.globes.co.il","visible":1,"analysis":{"tags":"drug delivery","company":"UroGen Pharma","layoffs":null,"summary":"UroGen Pharma, a drug delivery developer, has seen a 230% increase in its share price since its IPO in April 2017. The company recently raised $60 million in a secondary issue on Nasdaq, bringing its total raised amount to nearly $120 million. UroGen has developed a unique system for delivering drugs to the bladder and is also working on a Botox-based product for relieving overactive bladder syndrome in partnership with Allergan. The companys independent product is set to enter Phase IIb clinical trials in mid-2018. The successful financing round and planned IPOs by other medical companies indicate a positive start for the offerings market in 2018.","partners":["Allergan"],"customers":null,"investors":null,"confidence":9,"key_topics":["IPO","secondary issue","drug delivery","partnership","clinical trials"],"date_of_event":"January 21, 2018","valuation_amount":"$567 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"DPjsLReDAv0tm7ovDAseok6o3vh8aZnrDklBimVobvuiTmSIRvthaU","news_summary":"UroGen Pharma raises $60m in Nasdaq offering","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"3b241160-8719-4365-9bca-7e4d9a47e9f6","date":"May 7, 2017","link":"http://www.globes.co.il/en/article-urogen-pharma-raises-582m-in-nasdaq-ipo-1001187475","source":"www.globes.co.il","visible":1,"analysis":{"tags":"IPO","company":"UroGen Pharma","layoffs":null,"summary":"UroGen Pharma, an Israeli urological cancer treatment developer, raised $58.2 million in its Nasdaq IPO, exceeding the planned amount by 20%. The company offered 4,473,373 shares at $13 per share, resulting in a valuation of $150 million. Jefferies LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. UroGen Pharmas main shareholders include Arkin Holdings, Pontifax fund, ProQuest Investments, Telormedix, and Tatham Investments. The company is led by CEO Ron Bentsur and Chairman Prof. Arie Belldegrun. The offering is expected to close on or about May 9, 2017.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["UroGen Pharma","IPO","Nasdaq","investment","valuation"],"date_of_event":"May 7, 2017","valuation_amount":"$150 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"viRYSg9L6tfjSnJVzRoSOoqshPyinfd61QbHQ7UG6DTSwiHZ6o5hBl","news_summary":"UroGen Pharma raises $58.2m in Nasdaq IPO","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"89209080-6bb9-442c-9366-772afa1e7469","date":"May 3, 2017","link":"http://www.globes.co.il/en/article-urogen-pharma-sets-terms-for-45m-nasdaq-ipo-1001186924","source":"www.globes.co.il","visible":1,"analysis":{"tags":"IPO","company":"UroGen Pharma","layoffs":null,"summary":"UroGen Pharma, an Israeli urological cancer treatment developer, plans to raise $45 million through an IPO on Nasdaq. The company will offer 3.5 million shares at a price range of $12 to $14, giving UroGen a valuation of $166 million. Insiders will purchase $20 million worth of shares in the offering. UroGen Pharma was founded in 2004 and has major shareholders including Arkin Holdings, Pontifax fund, ProQuest Investments, Telormedix, and Tatham Investments. The IPO is expected to take place on Thursday.","partners":null,"customers":null,"investors":"Insiders","confidence":9,"key_topics":["UroGen Pharma","IPO","Nasdaq","valuation","shares"],"date_of_event":"May 3, 2017","valuation_amount":"$166 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"RCuGJjt3EmBumBiTSje26EuKUFKwQJZOERyYYuIkO9XCSkVcKDYAwR","news_summary":"UroGen Pharma sets terms for $45m Nasdaq IPO","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"691f4423-a3ce-4ed7-92b0-3219f4c64d96","date":"Apr 9, 2017","link":"http://www.globes.co.il/en/article-urogen-pharma-files-for-50m-nasdaq-ipo-1001184604","source":"www.globes.co.il","visible":1,"analysis":{"tags":"IPO","company":"UroGen Pharma","layoffs":null,"summary":"UroGen Pharma, an Israeli urological cancer treatment developer, has filed for an IPO on Nasdaq to raise up to $50 million. The company, formerly known as TheraCoat, is focused on developing novel therapies for urological pathologies. Its lead drug candidates, MitoGel and VesiGel, aim to remove tumors non-surgically. UroGen Pharma also has an additional drug candidate, Vesimune, for the treatment of high-grade non-muscle invasive bladder cancer. The company has recently licensed BotuGel to Allergan for further development. UroGen Pharmas CEO is Ron Bentsur, and its chairman is Prof. Arie Belldegrun. The largest shareholder is Mori Arkins Arkin Holdings. Other shareholders include Pontifax fund, ProQuest Investments, Telormedix, and Tatham Investments.","partners":null,"customers":null,"investors":"Mori Arkins Arkin Holdings, Pontifax fund, ProQuest Investments, Telormedix, Tatham Investments","confidence":9,"key_topics":["Urological cancer treatment","IPO","Lead drug candidates","Shareholders","Company executives"],"date_of_event":"April 9, 2017","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"XW7qDZHv9bYcrZE1ntkyhDhal5V2AkCoxm2ohUxE9FzPPuhy1oHNtr","news_summary":"UroGen Pharma files for $50m Nasdaq IPO","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"bcb92f3e-d05c-48f4-bb53-7028be008013","date":"May 21, 2013","link":"http://www.globes.co.il/en/article-1000845547","source":"www.globes.co.il","visible":1,"analysis":{"tags":"drug delivery systems","company":"TheraCoat Ltd.","layoffs":null,"summary":"TheraCoat Ltd. has raised $7 million from investors for R&D, clinical trials, and the launch of sales. The company has developed a unique platform technology for targeted drug delivery into internal cavities, including the bladder. TheraCoats system improves the therapeutic index of drugs, patient benefit, compliance, safety, and extends patent protection. They have received EU CE Mark and are preparing for clinical trials for urologic applications. The company aims to address non-muscle invasive bladder and urothelial cancer, and overactive bladder. The funds raised will support clinical trials and the marketing strategy of their lead product. TheraCoat plans to expand the development of their urological products.","partners":null,"customers":null,"investors":["Pontifax","CHealth Fund","private investors"],"confidence":9,"key_topics":["R&D","clinical trials","sales","drug delivery systems","bladder indications"],"date_of_event":"May 21, 2013","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$7 million","structured_issues":["Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Vv37648GQNLNVT2AiFDxDKod3wVQ5oOSBBDQSQiHwMo8pl9AQ5Unxq","news_summary":"Bladder treatment co TheraCoat raises $7m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"a6fc6bd4-f1e9-425d-8fe8-284fb5afd7e0","date":"Apr 15, 2013","link":"http://www.israel21c.org/health/theracoat-gel-makes-drugs-stick-to-the-bladder/","source":"www.israel21c.org","visible":1,"analysis":{"tags":["medical","drug delivery system","bladder cancer","incontinence"],"company":"Theracoat","layoffs":null,"summary":"Theracoat, an Israeli company, has developed a new drug delivery system called Intra Cavity Drug Retention (ICDR) using a unique material that becomes a sticky gel once inside the body. The gel is currently undergoing advanced clinical trials in Europe and is classified as a medical device. The company aims to provide a new and better way for delivering drugs to any cavity in the body. Theracoats material has the potential to be used in various treatments, including bladder cancer, incontinence, and other malignancies. The company is seeking strategic partnerships with pharmaceutical companies and is currently testing its material in bladder cancer chemo in Europe and Israel. The solutions for bladder cancer and incontinence are expected to be ready in 2014.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["bladder cancer","drug delivery system","Theracoat material","clinical trials","chemotherapy"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Qo9XNRUbl6f1x3BDvem9toVLgTmvtG5uuXhyqjP7JJN2KyeOI5EuMo","news_summary":"Theracoat gel makes drugs stick to the bladder","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":210,"techcommunityinvolvement":null,"mediagallery":[],"tags":["oncology","drug-delivery","sustained-release","urology","pharmaceuticals","orphan-drug","non-surgical","pharma-companies","drug-design","cancer"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If5xtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["UGN-201","Jelmyto","UGN-101","UGN-102","UGN-301","UGN-103","UGN-104"],"geomarkets":["Europe","United States","Israel"],"targetmarkets":[],"marketcapital":947026782,"marketcapitaldate":"2025-11-01T14:06:10.000Z","funding":{"investors":8,"lastfunding":"$107.5M","totalrounds":10,"fundingstage":"Public","totalfunding":"$522.2M","publicinvestors":8,"lastpublicfunding":107500000,"totalpublicrounds":10,"totalpublicfunding":522200000},"team":[{"name":"Liz  Barrett","email":"liz.barrett@urogen.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwInqpZ0KDA","bounced":false,"claimed":0,"founder":0,"urlname":"liz-barrett","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDAibHMlAoM","position":"CEO & President","last_name":"Barrett","claimtoken":"ZkksQoeSYBLnTjOtpbxg2zj4kGognupNA7jqLphugY6OuzZMFFV1uI","first_name":"Liz ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/liz-barrett/","unsubscribed":false,"is_activeuser":0,"additionalemail":"ron.bentsur@urogen.com","claimedemaildate":"2024-10-28 14:10:47.000000","initials":"LB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":" Asher  Holtzer","email":"asher@urogen.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoOXVrPAIDA","bounced":true,"claimed":0,"founder":1,"urlname":"asher-holtzer-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg9bm47wsM","position":"Founder","last_name":"Holtzer","claimtoken":"78502e2a7ee57c1372c2743581d6d0549503496c3b91ec801a5c7ab775d6dd14","first_name":" Asher ","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2020-04-21 17:56:09.000000","initials":" H","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Sheli Heksch-Agassi","email":"sheli@urogen.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoJXPvJQJDA","bounced":false,"claimed":0,"founder":0,"urlname":"sheli-heksch-agassi","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgpe_F7AkM","position":"HR Director","last_name":"Heksch-Agassi","claimtoken":"wySbabPXEVlXLUP8yzP8AfzKBEPgcEHw0o3olANCjwOcytvLn5ycoT","first_name":"Sheli","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/sheli-heksch-agassi-350b026b/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-10-28 14:10:50.000000","initials":"SH","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMGgoMMJDA","fullname":"Yanina Wainscheinker"},"biverifydate":"2020-05-24T00:00:00.000Z","crunchbaseid":"urogen-pharma","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Rebecca Mack","creator_email":"rebeccamack26@gmail.com","createdate":"2014-07-27T00:00:00.000Z","biverification":"Yanina Wainscheinker","sectorverification":"Natalia Golczar","affiliatedOrganizations":null,"timeline":[{"id":"cWgaLYEx5hnYh5bbhyoYbA7pPNGXQZ3eV9DJeCluu4xKiE7E9jH6x4","date":"Jun 2024","amount":"Undisclosed","source":"https://www.businesswire.com/news/home/20240617926085/en/UroGen-Pharma-Announces-Pricing-of-Public-Offering-of-Ordinary-Shares-and-Pre-Funded-Warrants","ticker":"URGN","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$107.5M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":107500000,"valuationnumber":null},{"id":"5jsly6AIQxRPH4aK3N6fC0KlPxOFQbwsHjrpNJMlpJ870YFoHHtpEx","date":"Jul 2023","amount":"$120M","source":"https://investors.urogen.com/news-releases/news-release-details/urogen-announces-120-million-private-placement-ordinary-shares","eventtype":"FundingRoundEvent","investment":[{"name":"Great Point Partners","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/great-point-partners","logokey":"$9H4FqY24kraRa1TfmxCBfYP4VkFdMECbTdaukFKDIkYXaZvmHMWMnw.jpeg","tagline":"financial services","urlname":"/investor_page/great-point-partners","isisraeli":null,"investorid":"BI8mbLFgK4j4l57Dfo0LoKXIOJzTzLh1Sl1aRb02b6Bl57FykNPHoh","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"klxGosBtCrvnaS04PYyMkKU0DOToeAuiXJkal32mGTc9GQAIRbk3it","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$9H4FqY24kraRa1TfmxCBfYP4VkFdMECbTdaukFKDIkYXaZvmHMWMnw.jpeg","leadcaption":"Lead&nbsp;","followupcaption":""},{"name":"RA Capital Management","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/ra-capital-management","logokey":"$pxsSJ062wtTQ8U4XrrcGgTjWSlJ7r6H4BLfokHIjyTzFBJZ9dSX4yY","tagline":"","urlname":"/investor_page/ra-capital-management","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCn2NrTCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"wSrjMnKFbTKSVUvX3ZyKh5TUe1IjajQJLyCDtfIXKW1A7xlUwNtP8v","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$pxsSJ062wtTQ8U4XrrcGgTjWSlJ7r6H4BLfokHIjyTzFBJZ9dSX4yY","leadcaption":"Lead&nbsp;","followupcaption":""},{"name":"Acorn Bioventures","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/acorn-bioventures","logokey":"$k6qstIBeEIeHwy5Gmv3zfQLyuO1RMeaqz4iYPvES6EnhCUkVLdrJk8","tagline":"","urlname":"/investor_page/acorn-bioventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCLwNGbCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"4QMomZ9MMKaxgsOTiO0R8mm7qCfXPxuoItERxGwIQ7Tgw9tS4idDbf","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$k6qstIBeEIeHwy5Gmv3zfQLyuO1RMeaqz4iYPvES6EnhCUkVLdrJk8","leadcaption":"","followupcaption":""},{"name":"Monograph Capital","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/monograph-capital","logokey":"$G4P4boQquWpXLD9hFkmazTqn4uNF6jhFXA4nYaddPFjLUt7YwcmnUT.jpeg","tagline":"VC & PE life sciences companies to transform promising science into life-changing treatments.","urlname":"/investor_page/monograph-capital","isisraeli":null,"investorid":"unAlddOpSiQKXKnuYPVuArbEqSsHHQrGG4Mv67syRUBJGc2rLg5h8s","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"8EaSO7qh9Skm8SF2gDIHyJybEUlxeYafhHzPfXWaMVmeJBeKp8jNN9","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$G4P4boQquWpXLD9hFkmazTqn4uNF6jhFXA4nYaddPFjLUt7YwcmnUT.jpeg","leadcaption":"","followupcaption":""},{"name":"The Horton Fund","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/the-horton-fund","logokey":"$8wGbC0MpKCcaOvdnLJImQ9jExvc0NLUEK639M3tWvo70O4S8mMdGHx.jpeg","tagline":"Financial Services","urlname":"/investor_page/the-horton-fund","isisraeli":null,"investorid":"onF8XrmZM6YtKjUIV5Gkg6NA84MvvVBhQWr0iZLrpOeqIYhySfH3J0","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"bBqiTNR4LX9OoBQwUGFOAbhc3p6syeOYyTlfEXhsTC6yU5AcOJyqF0","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8wGbC0MpKCcaOvdnLJImQ9jExvc0NLUEK639M3tWvo70O4S8mMdGHx.jpeg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":120000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"gcUsa19RNpcj8RD60ml1coG1kd893qTz3387nvJeLnWsfJaaf19Adf","date":"Mar 2022","amount":"$100M","source":"https://investors.urogen.com/news-releases/news-release-details/urogen-secures-100-million-non-dilutive-term-loan-financing","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":null,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"GNnWss3NujPPDuScc02u7RSoADvKHCqWgLEbNlUTS1hggFQvDMumAe","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":"Follow on&nbsp;"}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Debt Financing","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":100000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"4Czbi5vXjSxzWIrPT0n08m809emzDDf3GfMdRC6wilkY89VSF81KQ0","date":"Mar 2021","amount":"$75M","source":"https://www.biospace.com/article/releases/urogen-pharma-announces-75-million-of-non-dilutive-funding-from-rtw-investments-/","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":null,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"Qqf9QDioII1jp26XyPv3XsfFBx05MtOLRhQYjVUVuhpfvemgwGlfXp","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Debt Financing","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":75000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCe_P3ACAw","date":"Jan 2019","amount":"Undisclosed","source":"https://en.globes.co.il/en/article-cancer-co-urogen-to-raise-150m-in-nasdaq-offering-1001270101","ticker":"URGN","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$150M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":150000000,"valuationnumber":null},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODutNaSCAw","date":"Jan 2018","amount":"Undisclosed","source":"https://en.globes.co.il/en/article-urogen-pharma-raises-60m-in-nasdaq-offering-1001220496","ticker":"URGN","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$60M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":60000000,"valuationnumber":null},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODwxJDaCQw","date":"May 2017","amount":"Undisclosed","source":"","ticker":"URGN","eventtype":"POEvent","valuation":"$155.6M","investment":[],"capitalraised":"$58.2M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":58200000,"valuationnumber":155600000},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODElf_2CAw","date":"Nov 2015","amount":"$18M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Two River","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/two-river","logokey":"$fJoPCYfyo3iDmRWRElfDLpz4GoQjJFilM7Xt7sG6wyQ9uu5u9kOboQ","tagline":"","urlname":"/investor_page/two-river","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEqMGaCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"2a1a819f-40a4-4509-8346-4054910f0b9a","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$fJoPCYfyo3iDmRWRElfDLpz4GoQjJFilM7Xt7sG6wyQ9uu5u9kOboQ","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":18000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODkgvzgCgw","date":"May 2013","amount":"$7M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Pontifax","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"442596a9-1037-41dc-91f6-6d621215367c","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","leadcaption":"","followupcaption":"Follow on&nbsp;"}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":7000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODElY2aCAw","date":"Jan 2010","amount":"$1.5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Pontifax","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"e4a70ded-662d-4b42-a9c1-308678b9e297","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":1500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"4/2004","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"UroGen Pharma","logourl":"https://storage.googleapis.com/clean-finder-353810/$wVPjRd4z7vx729DcWE9IfJnzFDmkc5wlJT7WfRUQHHyWjGYsgx5hv2","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$wVPjRd4z7vx729DcWE9IfJnzFDmkc5wlJT7WfRUQHHyWjGYsgx5hv2","seoabout":"UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated. \n\nThe company ...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":3,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drug Delivery","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Consumers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Demographics & Family","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Men","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If5xtgKDA","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA>Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA>Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA>Men#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If5xtgKDA","IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drug Delivery#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drug Delivery#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA|2:>IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA/Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA|3:>IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA>Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA/Men#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If5xtgKDA|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"},{"title":"Drug Delivery","key":"0-0-0-1","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drug Delivery"}]}]}],"targetCustomer":[{"title":"Consumers","key":"0-0","path":"IndustryClassificationModel>Consumers","children":[{"title":"Demographics & Family","key":"0-0-0","path":"IndustryClassificationModel>Consumers>Demographics & Family","children":[{"title":"Men","key":"0-0-0-0","path":"IndustryClassificationModel>Consumers>Demographics & Family>Men"}]}]},{"title":"Healthcare & Life Sciences","key":"0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Patients","key":"0-1-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Patients"}]},{"title":"Life Sciences","key":"0-1-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-1-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Cells","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Cells"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drug Delivery","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Consumers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Demographics & Family","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Men","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If5xtgKDA","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development","Drug Delivery"],"coreTechnology":["Biologicals","Cells"],"targetCustomer":["Consumers","Demographics & Family","Men","Healthcare & Life Sciences","Healthcare","Patients","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[{"id":"cWgaLYEx5hnYh5bbhyoYbA7pPNGXQZ3eV9DJeCluu4xKiE7E9jH6x4","date":"Jun 2024","amount":"Undisclosed","source":"https://www.businesswire.com/news/home/20240617926085/en/UroGen-Pharma-Announces-Pricing-of-Public-Offering-of-Ordinary-Shares-and-Pre-Funded-Warrants","ticker":"URGN","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$107.5M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":107500000,"valuationnumber":null},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCe_P3ACAw","date":"Jan 2019","amount":"Undisclosed","source":"https://en.globes.co.il/en/article-cancer-co-urogen-to-raise-150m-in-nasdaq-offering-1001270101","ticker":"URGN","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$150M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":150000000,"valuationnumber":null},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODutNaSCAw","date":"Jan 2018","amount":"Undisclosed","source":"https://en.globes.co.il/en/article-urogen-pharma-raises-60m-in-nasdaq-offering-1001220496","ticker":"URGN","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$60M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":60000000,"valuationnumber":null},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODwxJDaCQw","date":"May 2017","amount":"Undisclosed","source":"","ticker":"URGN","eventtype":"POEvent","valuation":"$155.6M","investment":[],"capitalraised":"$58.2M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":58200000,"valuationnumber":155600000}],"privateequityfunding":[{"id":"5jsly6AIQxRPH4aK3N6fC0KlPxOFQbwsHjrpNJMlpJ870YFoHHtpEx","date":"Jul 2023","amount":"$120M","source":"https://investors.urogen.com/news-releases/news-release-details/urogen-announces-120-million-private-placement-ordinary-shares","eventtype":"FundingRoundEvent","investment":[{"name":"Great Point Partners","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/great-point-partners","logokey":"$9H4FqY24kraRa1TfmxCBfYP4VkFdMECbTdaukFKDIkYXaZvmHMWMnw.jpeg","tagline":"financial services","urlname":"/investor_page/great-point-partners","isisraeli":null,"investorid":"BI8mbLFgK4j4l57Dfo0LoKXIOJzTzLh1Sl1aRb02b6Bl57FykNPHoh","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"klxGosBtCrvnaS04PYyMkKU0DOToeAuiXJkal32mGTc9GQAIRbk3it","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$9H4FqY24kraRa1TfmxCBfYP4VkFdMECbTdaukFKDIkYXaZvmHMWMnw.jpeg","leadcaption":"Lead&nbsp;","followupcaption":""},{"name":"RA Capital Management","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/ra-capital-management","logokey":"$pxsSJ062wtTQ8U4XrrcGgTjWSlJ7r6H4BLfokHIjyTzFBJZ9dSX4yY","tagline":"","urlname":"/investor_page/ra-capital-management","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCn2NrTCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"wSrjMnKFbTKSVUvX3ZyKh5TUe1IjajQJLyCDtfIXKW1A7xlUwNtP8v","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$pxsSJ062wtTQ8U4XrrcGgTjWSlJ7r6H4BLfokHIjyTzFBJZ9dSX4yY","leadcaption":"Lead&nbsp;","followupcaption":""},{"name":"Acorn Bioventures","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/acorn-bioventures","logokey":"$k6qstIBeEIeHwy5Gmv3zfQLyuO1RMeaqz4iYPvES6EnhCUkVLdrJk8","tagline":"","urlname":"/investor_page/acorn-bioventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCLwNGbCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"4QMomZ9MMKaxgsOTiO0R8mm7qCfXPxuoItERxGwIQ7Tgw9tS4idDbf","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$k6qstIBeEIeHwy5Gmv3zfQLyuO1RMeaqz4iYPvES6EnhCUkVLdrJk8","leadcaption":"","followupcaption":""},{"name":"Monograph Capital","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/monograph-capital","logokey":"$G4P4boQquWpXLD9hFkmazTqn4uNF6jhFXA4nYaddPFjLUt7YwcmnUT.jpeg","tagline":"VC & PE life sciences companies to transform promising science into life-changing treatments.","urlname":"/investor_page/monograph-capital","isisraeli":null,"investorid":"unAlddOpSiQKXKnuYPVuArbEqSsHHQrGG4Mv67syRUBJGc2rLg5h8s","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"8EaSO7qh9Skm8SF2gDIHyJybEUlxeYafhHzPfXWaMVmeJBeKp8jNN9","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$G4P4boQquWpXLD9hFkmazTqn4uNF6jhFXA4nYaddPFjLUt7YwcmnUT.jpeg","leadcaption":"","followupcaption":""},{"name":"The Horton Fund","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/the-horton-fund","logokey":"$8wGbC0MpKCcaOvdnLJImQ9jExvc0NLUEK639M3tWvo70O4S8mMdGHx.jpeg","tagline":"Financial Services","urlname":"/investor_page/the-horton-fund","isisraeli":null,"investorid":"onF8XrmZM6YtKjUIV5Gkg6NA84MvvVBhQWr0iZLrpOeqIYhySfH3J0","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"bBqiTNR4LX9OoBQwUGFOAbhc3p6syeOYyTlfEXhsTC6yU5AcOJyqF0","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8wGbC0MpKCcaOvdnLJImQ9jExvc0NLUEK639M3tWvo70O4S8mMdGHx.jpeg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":120000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"gcUsa19RNpcj8RD60ml1coG1kd893qTz3387nvJeLnWsfJaaf19Adf","date":"Mar 2022","amount":"$100M","source":"https://investors.urogen.com/news-releases/news-release-details/urogen-secures-100-million-non-dilutive-term-loan-financing","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":null,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"GNnWss3NujPPDuScc02u7RSoADvKHCqWgLEbNlUTS1hggFQvDMumAe","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":"Follow on&nbsp;"}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Debt Financing","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":100000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"4Czbi5vXjSxzWIrPT0n08m809emzDDf3GfMdRC6wilkY89VSF81KQ0","date":"Mar 2021","amount":"$75M","source":"https://www.biospace.com/article/releases/urogen-pharma-announces-75-million-of-non-dilutive-funding-from-rtw-investments-/","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":null,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"Qqf9QDioII1jp26XyPv3XsfFBx05MtOLRhQYjVUVuhpfvemgwGlfXp","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Debt Financing","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":75000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODElf_2CAw","date":"Nov 2015","amount":"$18M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Two River","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/two-river","logokey":"$fJoPCYfyo3iDmRWRElfDLpz4GoQjJFilM7Xt7sG6wyQ9uu5u9kOboQ","tagline":"","urlname":"/investor_page/two-river","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEqMGaCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"2a1a819f-40a4-4509-8346-4054910f0b9a","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$fJoPCYfyo3iDmRWRElfDLpz4GoQjJFilM7Xt7sG6wyQ9uu5u9kOboQ","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":18000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODkgvzgCgw","date":"May 2013","amount":"$7M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Pontifax","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"442596a9-1037-41dc-91f6-6d621215367c","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","leadcaption":"","followupcaption":"Follow on&nbsp;"}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":7000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODElY2aCAw","date":"Jan 2010","amount":"$1.5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Pontifax","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"e4a70ded-662d-4b42-a9c1-308678b9e297","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":1500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}